Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia
Phase: PHASE3
Conditions: Acute Schizophrenia
Sponsor: Rovi Pharmaceuticals Laboratories

COVER PAGE 
Protocol 
 
TITLE: Multicenter, Randomized, Double-Blind, Placebo-
Controlled Study to Evaluate the Efficacy and Safety of 
Intramuscular Injections of Risperidone ISM® in Patients 
with Acute Exacerbation of Schizophrenia (PRISMA-3) 
 
PROTOCOL NUMBER: ROV-RISP-2016-01 
 
NCT NUMBER: NCT03160521 
 
PROTOCOL VERSION 7.0 
DOCUMENT DATE: 22 MARCH 2018 
 
 

 
Laboratorios Farmacéuticos ROVI, S.A. 
C/ Julián Camarillo 35, 28037 Madrid, Spain 
 
CLINICAL STUDY PROTOCOL 
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 
Intramuscular Injections of Risperidone ISM® in Patients with Acute Exacerbation of Schizophrenia 
(PRISMA-3) 
PROTOCOL NUMBER 
ROV-RISP-2016-01 
VERSION 7.0 
 
EudraCT No: 2016-002206-39 
 
CLINICAL DEVELOPMENT PHASE 
III 
 
DOCUMENT DATE 
 
22 March 2018 
 
CONFIDENTIAL 
 
 
This document and its contents are the property of and confidential to Laboratorios Farmacéuticos ROVI, 
S.A.  Any unauthorized copying or use of this document is prohibited. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 2 of 114 
Synopsis 
Protocol Number: ROV-RISP-2016-01 
Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and 
Safety of Intramuscular Injections of Risperidone ISM® in Patients with Acute Exacerbation of 
Schizophrenia (PRISMA-3) 
Active Study Drug: Risperidone ISM® 
Study Sites: Multinational multicenter  
Phase: III 
Objectives: 
Primary: 
 
To evaluate the efficacy of Risperidone ISM as compared with that of placebo in the treatment of 
patients with acute exacerbation of schizophrenia 
Secondary: 
 
To characterize safety and tolerability of Risperidone ISM as compared with that of placebo in 
patients with acute exacerbation of schizophrenia 
 
To quantify healthcare resource utilization (HRU), health-related quality of life (HRQL), and 
social functioning in patients treated with Risperidone ISM versus placebo for an acute 
exacerbation of schizophrenia  
 
To explore pharmacokinetic characteristics of Risperidone ISM and associations with efficacy 
Study Design:  
This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the 
efficacy and safety of Risperidone ISM, a new long-acting injectable form of the licensed drug 
Risperidone.  The study design includes a screening period, a 12-week treatment period, a follow-up 
period, and a 12-month open-label extension period.  Eligible patients will be randomly assigned, under 
double-blind conditions, to receive Risperidone ISM (75 or 100 mg) or placebo. 
If indicated for an individual patient, prohibited medications may be washed out during the screening 
period.  Patients who have never taken Risperidone must have a brief trial of oral Risperidone (2 mg/day 
for 3 days during the screening period) in order to ensure a lack of any clinically significant 
hypersensitivity reactions before the first dose of long-acting intramuscular (IM) study drug is 
administered.  Either of these circumstances may, at the investigators’ discretion, involve admitting the 
patient to the inpatient unit during the screening period.   
An ophthalmological examination, including slit-lamp biomicroscopy examination (eyelids, conjunctiva, 
iris, crystalline lens, sclera, and cornea), best corrected visual acuity, visual field, and intraocular 
pressure, should be done at any time during the screening period. The result of the ophthalmological 
examination must be available by study day -1.  These tests need to be done again at visit 14 or at early 
termination visit.     
Patients enrolled in the double-blind segment of the study will be admitted to the study site’s inpatient 
unit sometime during the screening period (from 1 to 8 days before study day 1).  It is generally 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 3 of 114 
anticipated that patients may remain in the inpatient unit for at least 7 days after the first dose of study 
drug is administered, though inpatient duration for a given patient will be flexible.   
The IM study drug (double-blind active Risperidone ISM or placebo) will be administered in a deltoid or 
gluteal muscle for a total of 3 times, once every 4 weeks, during the 12-week treatment period (i.e., at 
study days 1, 29, and 57).  
Efficacy will be assessed by describing changes in scores on standard psychiatric assessment tools at each 
visit.  Safety assessments will also be conducted at each visit.   
Patients who complete planned double-blind study drug treatments and study evaluations may be eligible 
to participate in an optional long-term extension segment of the study, in which treatment with open-label 
Risperidone ISM 75 or 100 mg would begin immediately.  For patients who do not participate in the 
extension segment, a safety follow-up phone contact will occur approximately 2 weeks after the end-of-
treatment visit.  
In addition to patients continuing from the double-blind segment of the study (rollover patients), clinically 
stable patients not previously enrolled in the study (de novo patients) may be eligible to enter the 
long-term extension segment of the study.  These patients will be evaluated for eligibility at a screening 
visit and, if eligible, will be allocated to receive either 75 or 100 mg Risperidone ISM every 4 weeks for 
approximately 12 months. 
Number of Patients: Approximately 436 patients total randomized are planned (145 per arm) in the 
double-blind segment of the study.  Approximately 100 de novo patients are planned to be enrolled in the 
extension segment of the study, in addition to rollover patients. 
Interim Analysis: One unblinded interim analysis will be conducted when 196 (approximately 50%) 
randomized patients, for whom the blinding was not compromised, have either reached study day 85 or 
withdrawn from the study to re-estimate the sample size required for the final analysis up to 558 patients 
(186 patients per arm). 
Treatment: The active study drug is Risperidone ISM, and the comparator study drug (inactive) is 
placebo.  Eligible patients will be randomly assigned under double-blind conditions to receive the 
following study drug treatments in a 1:1:1 ratio during the double-blind treatment period: 
Risperidone ISM 75 mg, Risperidone ISM 100 mg, or placebo. 
During the treatment period of the double-blind segment of the study, treatment assignment for each 
individual patient will remain blinded for patients, investigators, and all study site staff, with the 
exception of certain identified individuals at each study site who will be unblinded in order to prepare and 
administer IM study drug for each patient at that study site.   
However, in the extension segment of the study, all participating patients will receive active Risperidone 
ISM under open-label conditions.  Patients who had been on active Risperidone ISM in the double-blind 
segment of the study will continue to receive active Risperidone ISM at the same dose (i.e., 75 or 100 mg) 
in the extension segment.  Patients who had been receiving placebo in the double-blind segment of the 
study will be randomly assigned to receive either 75 or 100 mg during the extension segment.  However, 
in order to preserve the blinding condition of the double-blind stage of the study, if a participating patient 
enters this OLE phase of the study prior to locking the database of the double-blind stage of the study, the 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 4 of 114 
allocation to either 75 or 100 mg of this patient will still be blinded at least up to locking the 
aforementioned database.   
De novo patients participating in the extension segment of the study will receive either 75 or 100 mg 
Risperidone ISM depending on their previous oral risperidone dose.  Patients on 4 mg/day of oral 
risperidone will be assigned to 75 mg Risperidone ISM every 4 weeks, and patients on more than 4 
mg/day to a maximum of 6 mg/day of oral risperidone will be assigned to 100 mg Risperidone ISM every 
4 weeks. 
Duration of Patient Participation: Approximately 12 to 15 weeks in total is planned, including a 
screening period ranging from 1 day to 2 weeks (screening > 8 days requires medical monitor approval), a 
12-week treatment period, and a 2-week follow-up period (not applicable for patients who enter into the 
long-term extension study).  For rollover patients, the optional long-term extension segment of the study 
begins immediately upon completion of the end-of-treatment visit and continues for approximately 12 
months.  For de novo patients, a screening period of up to 8-day is planned, followed by a 12-month 
open-label treatment period.  There is a 4-week follow-up period for all patients in the extension segment 
of the study. 
Study Population: Selected main inclusion criteria for the double-blind segment of the study include the 
following: 
 
Current diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition criteria (DSM-5) 
o Currently experiencing an acute exacerbation or relapse with onset < 2 months before screening 
o If inpatient at screening, has been hospitalized for < 2 weeks for the current exacerbation 
o ≥ 2 years have elapsed since initial onset of active-phase schizophrenia symptoms 
 
Has been able to achieve outpatient status for > 4 months during the past year 
 
Has previously had a clinically significant beneficial response (improvement in schizophrenia 
symptoms), as determined by the investigator, to treatment with an antipsychotic medication other 
than clozapine 
 
Agrees to discontinue prohibited medications as applicable and as clinically indicated according to 
investigator instructions 
 
Dosages of all permitted medications are considered to have been stable (with the exception of 
medication to be used on an as-needed basis) for ≥ 2 weeks prior to the baseline visit and to remain 
stable during participation in this study 
 
Positive and Negative Syndrome Scale (PANSS) results at the screening and baseline visits meets the 
following criteria: 
o Total score between 80 and 120, inclusive 
o Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale items: 
 
Item 1 (P1: delusions) 
 
Item 2 (P2: conceptual disorganization) 
 
Item 3 (P3: hallucinatory behavior) 
 
Item 6 (P6: suspiciousness/persecution) 
 
Clinical Global Impression – Severity (CGI-S) score of ≥ 4 (moderately ill or worse) 
 
Age ≥ 18 and ≤ 65 years 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 5 of 114 
 
Resides in a stable living situation and is anticipated to return to that same stable living situation after 
discharge from the inpatient study unit, in the opinion of the investigator 
 
Has an identified reliable informant who is anticipated to remain the same after the patient is 
discharged from the inpatient study unit, in the opinion of the investigator 
 
To be eligible for rollover into the extension segment of the study, a patient must meet inclusion criteria 
including the following: 
 
Has completed scheduled participation in the main part of the study, through to the end of the 
treatment period and including the end-of-treatment visit 
 
Continues to require long-term treatment with an antipsychotic medication, in the opinion of the 
investigator 
Selected main inclusion criteria for clinically stable de novo patients in the extension segment of the study 
include the following: 
 
Subject is ≥ 18 and ≤ 65 years old, inclusive, at screening 
 
Subject is on a stable dose of oral risperidone from 4 to 6 mg daily as maintenance therapy for at least 
the last 4 weeks prior/before screening/baseline and would potentially benefit from conversion to an 
extended release injectable, in the opinion of the investigator 
 
Subject has a current diagnosis of schizophrenia, according to the DSM-5 criteria that is clinically 
stable as evidenced by: 
o No hospitalizations for acute exacerbations of schizophrenia and psychiatrically stable without 
significant symptom exacerbation over the last 3 months before screening based on the 
investigator’s judgment  
 
PANSS total score < 70 at screening 
 
CGI-S score of ≤ 3 (mild) at screening 
 
Subject has previously had a clinically significant beneficial response (improvement in schizophrenia 
symptoms), as determined by the investigator, to treatment with an antipsychotic medication other 
than clozapine 
 
Subject with ≥ 2 years elapsed since initial onset of active-phase schizophrenia symptoms 
 
Subject resides in a stable living situation, in the opinion of the investigator 
 
Subject has an identified reliable informant, in the opinion of the investigator 
 
The protocol includes a more extensive set of eligibility (inclusion and exclusion) criteria. 
Variables: 
Efficacy Variables 
Endpoint is defined as study day 85 or the last post-baseline double-blind assessment.   
Primary Efficacy Variable 
 
PANSS total score mean change from baseline to endpoint 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 6 of 114 
 
Secondary Efficacy Variables 
Key Secondary Efficacy Variable 
 
CGI-S score mean change from baseline to endpoint 
 
Other Secondary Efficacy Variables 
 
Clinician Global Impression – Improvement (CGI-I) score mean at endpoint 
 
Overall response rate at endpoint 
o Overall response is defined as either of the following: 
 
PANSS total score ≥ 30% decrease (improvement of symptoms) from baseline to endpoint 
 
CGI-I score of 2 (much improved) or 1 (very much improved) at endpoint 
 
PANSS response rate at endpoint 
o PANSS response is defined as the following: 
 
PANSS total score ≥ 30% decrease (improvement of symptoms) from baseline 
 
Time to reach PANSS response 
 
PANSS total score mean change from baseline at each post-baseline assessment time point 
 
PANSS subscale score mean change from baseline at endpoint and at each post-baseline assessment 
time point for each of the positive, negative, and general psychopathology subscales 
 
Overall response rate at each post-baseline assessment time point 
 
Time to reach overall response 
 
PANSS response rate at each post-baseline assessment time point 
 
CGI-S score mean change from baseline at each post-baseline assessment time point 
 
CGI-I score mean at each post-baseline assessment time point 
 
Health Economics and Outcomes Research Variables 
Endpoint is defined as study day 85 or the last post-baseline double-blind assessment.  
 
 HRU and cost variables include the following: 
o For each item, total quantity of resources used within and outside the participating center at 
endpoint.  For each item, mean number at endpoint and rate of use per 3 months will be 
calculated 
o By-resource use category (e.g., inpatient services, outpatient services) and total direct medical 
costs (reflecting resources used within and outside the participating center) at endpoint and 
average cost per 3 months will be calculated. 
o For all resource use categories combined, total direct medical costs at endpoint and average cost 
per 3 months will be calculated. 
o Indirect costs (days absent from work due to illness) at endpoint 
 
Personal and Social Performance Scale (PSP) total score mean change from baseline at each post-
baseline assessment time point 
 
PSP domain  score mean change from baseline at each post-baseline assessment time point 
 
20-item Subjective Well-Being Under Neuroleptics Treatment Scale (SWN-20) total score mean 
change from baseline at each post-baseline assessment time point 
 
SWN-20 subscale score mean change from baseline at each post-baseline assessment time point 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 7 of 114 
 
Safety Variables 
 
Occurrence, nature, duration, intensity, and relationship to study drug of injection site reactions: 
o Injection site pain, assessed by patients using a visual analog scale (VAS) after each dose 
o Injection site evaluation of redness, swelling, and induration, evaluated by designated study site 
personnel after each injection 
 
Occurrence (incidence), nature, onset time, duration, intensity, action taken, and relationship to study 
drug of treatment-emergent adverse events 
 
Occurrence, nature, time to onset, duration, seriousness criteria, relationship to study drug, and 
outcome of treatment-emergent serious adverse events 
 
Occurrence of extrapyramidal symptoms, as assessed using the Simpson-Angus Scale, Barnes 
Akathisia Rating Scale, and Abnormal Involuntary Movement Scale 
 
Columbia-Suicide Severity Rating Scale 
 
Physical examination, vital signs, weight, body mass index, clinical laboratory test results, and 
electrocardiogram findings 
 
Time to early termination 
Pharmacokinetic Variables (Double-Blind segment only) 
 
Summary plasma concentrations of Risperidone, its active metabolite (9-OH-Risperidone), and the 
active moiety (i.e., Risperidone plus 9-OH-Risperidone) by injection site (gluteal and deltoid) and by 
study drug dose level   
 
Trough concentrations and accumulation index for steady state based on minimum concentration 
values by injection site (gluteal and deltoid) and by study drug dose level   
 
Exploratory associations of pharmacokinetic results with efficacy results   
Genotype Sampling (Double-Blind segment only) 
A blood sample will be collected for evaluation of genotypes for cytochrome P450 enzymes and/or genes 
that are potentially related to efficacy response and/or adverse effects.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 8 of 114 
 
Table of Contents 
Synopsis .............................................................................................................................................................. 2 
1 
Introduction .............................................................................................................................................. 14 
2 
Objectives ................................................................................................................................................. 17 
2.1 
Primary Objective ............................................................................................................................ 17 
2.2 
Secondary Objectives ...................................................................................................................... 17 
3 
Investigational Plan ................................................................................................................................. 17 
3.1 
Overall Study Design and Plan ....................................................................................................... 17 
3.2 
Requirements and Restrictions ....................................................................................................... 29 
3.2.1 
Contraception and Pregnancy ................................................................................................. 29 
3.2.2 
Concomitant Therapy .............................................................................................................. 29 
4 
Patients ..................................................................................................................................................... 31 
4.1 
Eligibility ......................................................................................................................................... 31 
4.1.1 
Eligibility Criteria for Enrollment into the Double-Blind Segment of the Study ................ 31 
4.1.2 
Eligibility Criteria for Entry into Optional Extension Segment of the Study (Rollover 
Patients) .................................................................................................................................... 35 
4.1.3 
Eligibility Criteria for Entry into Optional Extension Segment of the Study (De Novo 
Patients) .................................................................................................................................... 36 
4.2 
Patient Withdrawal .......................................................................................................................... 39 
5 
Study Treatment ....................................................................................................................................... 39 
5.1 
Study Drugs ..................................................................................................................................... 40 
5.1.1 
Study Drugs ............................................................................................................................. 40 
5.1.2 
Preparation and Administration of Study Drug ..................................................................... 41 
5.2 
Study Site Inpatient Unit ................................................................................................................. 42 
5.3 
Treatment Assignment and Blinding .............................................................................................. 42 
5.3.1 
Treatment Assignment ............................................................................................................ 42 
5.3.2 
Blinding ................................................................................................................................... 43 
5.4 
Study Drug Accountability, Adherence, Handling, and Disposal................................................. 44 
6 
Procedures ................................................................................................................................................ 44 
6.1 
General ............................................................................................................................................. 45 
6.1.1 
Informed Consent .................................................................................................................... 45 
6.1.2 
Demographics, Medical History, and Psychiatric History .................................................... 45 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 9 of 114 
6.1.3 
Concomitant Medication Review ........................................................................................... 45 
6.1.4 
MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders 
Studies ...................................................................................................................................... 45 
6.2 
Efficacy Assessments ...................................................................................................................... 46 
6.2.1 
Positive and Negative Syndrome Scale and Clinician Global Impression ........................... 46 
6.3 
Health Economics and Outcomes Research Assessments ............................................................. 46 
6.3.1 
Healthcare Resource Utilization ............................................................................................. 46 
6.3.2 
Health-Related Quality of Life ............................................................................................... 46 
6.3.3 
Social Functioning .................................................................................................................. 47 
6.4 
Safety Assessments ......................................................................................................................... 47 
6.4.1 
Physical Examination, Body Height, Weight ........................................................................ 47 
6.4.2 
Ophthalmological Examination .............................................................................................. 47 
6.4.3 
Vital Signs ............................................................................................................................... 48 
6.4.4 
Electrocardiogram ................................................................................................................... 49 
6.4.5 
Laboratory Assessments ......................................................................................................... 49 
6.4.6 
Injection Site Reactions .......................................................................................................... 51 
6.4.7 
Extrapyramidal Symptoms Rating Scales .............................................................................. 51 
6.4.8 
Columbia-Suicide Severity Rating Scale ............................................................................... 51 
6.4.9 
Adverse Events ........................................................................................................................ 51 
6.5 
Pharmacokinetic Sample Collection ............................................................................................... 55 
6.6 
Genotype Sample Collection .......................................................................................................... 56 
6.7 
Outcome Variables .......................................................................................................................... 56 
6.7.1 
Efficacy Variables ................................................................................................................... 56 
6.7.2 
Health Economics and Outcomes Research Variables .......................................................... 57 
6.7.3 
Safety Variables ...................................................................................................................... 57 
6.7.4 
Pharmacokinetic Variables ..................................................................................................... 58 
6.7.5 
Genotype Sampling ................................................................................................................. 58 
7 
Statistics ................................................................................................................................................... 58 
7.1 
General Considerations ................................................................................................................... 58 
7.2 
Analysis Populations ....................................................................................................................... 58 
7.3 
Planned Analyses ............................................................................................................................. 59 
7.3.1 
Patient Disposition .................................................................................................................. 59 
7.3.2 
Demographics and Baseline Data ........................................................................................... 60 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 10 of 114 
7.3.3 
Study Drug Administration ..................................................................................................... 60 
7.3.4 
Efficacy .................................................................................................................................... 60 
7.3.5 
Safety ....................................................................................................................................... 64 
7.3.6 
Pharmacokinetics .................................................................................................................... 66 
7.4 
Sample Size...................................................................................................................................... 66 
7.5 
Sample Size Re-estimation/Interim Analysis ................................................................................. 67 
8 
Data and Documentation ......................................................................................................................... 68 
8.1 
Data Handling and Record Keeping ............................................................................................... 68 
8.1.1 
Data Handling.......................................................................................................................... 68 
8.1.2 
Data Recording ........................................................................................................................ 68 
8.1.3 
Inspection of Records.............................................................................................................. 69 
8.1.4 
Retention of Records ............................................................................................................... 69 
8.1.5 
Use of Information and Publication Policy ............................................................................ 69 
8.2 
Source Materials Access ................................................................................................................. 69 
8.2.1 
Study Monitoring .................................................................................................................... 69 
8.2.2 
Institutional Review Board ..................................................................................................... 69 
8.2.3 
Audits and Inspections ............................................................................................................ 70 
9 
Quality Control and Assurance ............................................................................................................... 70 
9.1 
Data Collection ................................................................................................................................ 70 
9.2 
Confidentiality ................................................................................................................................. 70 
10 
Ethical Considerations ......................................................................................................................... 70 
10.1 
Ethics Review .................................................................................................................................. 70 
10.2 
Ethical Conduct of the Study .......................................................................................................... 71 
10.3 
Informed Consent ............................................................................................................................ 71 
10.4 
Patient Data Protection .................................................................................................................... 71 
11 
Indemnification .................................................................................................................................... 72 
12 
Further Requirements and General Information ................................................................................ 72 
12.1 
External Service Organizations....................................................................................................... 72 
12.1.1 
Interactive Voice Response System ....................................................................................... 72 
12.1.2 
Contract Research Organization ............................................................................................. 72 
12.1.3 
Central Laboratories for Laboratory Assessments ................................................................ 72 
12.1.4 
Central Facility for Other Assessments.................................................................................. 72 
12.2 
Study Committees ........................................................................................................................... 72 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 11 of 114 
12.2.1 
Data Monitoring Committee ................................................................................................... 72 
12.3 
Changes to Final Study Protocol .................................................................................................... 73 
12.4 
Ethics Committee Notification of Study Completion or Termination .......................................... 73 
12.5 
Retention of Study Data .................................................................................................................. 73 
12.6 
Study Report Signatory ................................................................................................................... 73 
References ........................................................................................................................................................ 74 
Appendix A: Study Assessments and Procedures by Study Visit ............................................................. 76 
Appendix B: Prohibited Medications ........................................................................................................ 107 
Appendix C : Rating Scale and Interview Descriptions........................................................................... 108 
Appendix D: Visual Analog Scale (VAS) ................................................................................................ 110 
Appendix E: Risperidone ISM Investigator Brochure ............................................................................. 111 
Appendix F: Contact Information ............................................................................................................. 112 
Appendix G: Protocol Signatories ............................................................................................................ 113 
Appendix H : Investigator Agreement ...................................................................................................... 114 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 12 of 114 
Abbreviations 
AE 
Adverse event 
AIMS 
Abnormal Involuntary Movement Scale 
ANCOVA 
Analysis of covariance 
AUCtau 
Area under the concentration-time curve for a dosing interval  
BARS 
Barnes Akathisia Rating Scale 
CGI-I 
Clinician Global Impression – Improvement  
CGI-S 
Clinician Global Impression – Severity  
Cmax 
Maximum concentration 
CRO 
Contract Research Organization 
C-SSRS 
Columbia-Suicide Severity Rating Scale  
Ctrough 
Trough concentration in plasma 
CHW 
Cui, Hung, Wang 
DMC 
Data Monitoring Committee 
DMSO 
Dimethyl sulfoxide 
DSM-5 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
GCP 
Good Clinical Practice 
HRQL 
Health-related quality of life 
HRU 
Healthcare resource utilization 
ICH 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals 
for Human Use 
IEC 
Independent Ethics Committee 
IM 
Intramuscular 
IOP 
Intraocular pressure 
IRB 
Institutional Review Board 
ISM 
In situ microparticle 
ITT 
Intent-to-treat 
mITT 
modified Intent-to-treat 
MMRM 
Mixed effect model with repeated measurements 
OLE 
Open-label extension 
PANSS 
Positive and Negative Syndrome Scale 
PLGA 
Poly lactic-co-glycolic acid 
PP 
Per-protocol 
mPP 
modified Per-Protocol 
PSP 
Personal and Social Performance Scale 
QTcB 
QT interval corrected for heart rate using Bazett’s formula 
QTcF 
QT interval corrected for heart rate using Fridericia’s formula 
RO 
Receptor occupancy 
SAE 
Serious adverse event 
SAS 
Simpson-Angus Scale 
SWN-20 
20-item Subjective Well-Being Under Neuroleptics Treatment Scale 
THC 
Tetrahydrocannabinol 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 13 of 114 
Tmax 
Time to maximum concentration 
VAS 
Visual analog scale 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 14 of 114 
1 Introduction 
In the outpatient clinical setting, nonadherence with prescribed oral antipsychotic medication regimens is 
prevalent in patients with schizophrenia and has been associated with relapse and worsening of long-term 
functional and mental outcomes.1,2  Long-acting formulations of antipsychotic medications, developed to 
promote treatment adherence, have helped to improve compliance and thus efficacy.3  Initially developed 
long-acting formulations include typical antipsychotic agents, which are known to be associated with a 
number of safety and tolerability concerns that limit their acceptability in current clinical practice.  Long-
acting formulations also are available for certain atypical antipsychotics, including Risperidone (Risperdal 
Consta®) and paliperidone palmitate (Xeplion® and Invega Sustenna®).  Risperdal Consta has been shown 
to be efficacious in achieving and maintaining remission status, and studies have shown an overall 
reduction in healthcare costs associated with frequent relapse and hospitalization.4    
Clinical studies have shown that intramuscular (IM) paliperidone palmitate may be clinically useful in the 
treatment of patients with acute schizophrenia who were previously unsuccessfully treated with oral 
antipsychotics.5,6  However, the number of currently available long-acting atypical antipsychotic 
medication options is limited, and thus there is a clinical need for additional long-acting atypical 
antipsychotic medication options.   
Risperidone ISM® is an injectable IM in situ microparticle (ISM) long-acting formulation of risperidone 
currently in clinical development as a treatment for schizophrenia.  Risperidone ISM is intended for IM 
administration once every 4 weeks, without any supplementation with oral risperidone.  Previous studies 
of Risperidone ISM support its further clinical development.   
Two single-dose clinical phase I studies have been conducted to characterize the pharmacokinetic 
characteristics and to evaluate the safety and tolerability of Risperidone ISM in healthy volunteers 
(n = 17) and in subjects with schizophrenia or schizoaffective disorder (n = 36), respectively.   
In the phase I study in healthy volunteers (ROV-RISP-2009-01), single Risperidone ISM doses of 
25 mg (n = 8) and 37.5 mg (n = 9) were evaluated, and all subjects completed the study.  Risperidone, 
9-OH-risperidone, and the active moiety (risperidone and 9-OH-risperidone combined) plasma 
concentration profiles showed that while plasma concentrations were higher for the 37.5 mg dose than for 
the 25 mg dose, maximum concentration (Cmax) and area under the concentration-time curve values 
increases were not dose proportional.  All subjects had at least 1 treatment-emergent adverse event (AE).  
The most frequently reported AEs were somnolence (10.1%) and injection site pain (8.1%), all of which 
were considered to be of mild or moderate intensity.  Only 2 subjects, both in the second cohort (37.5 
mg), had a serious AE (SAE).  Each of these 2 subjects had 2 SAEs; the same 2 SAEs of tachycardia and 
oromandibular dystonia were reported by both subjects.  All subjects were considered to have recovered 
by the end of the study.   
In the phase I study in subjects with schizophrenia or schizoaffective disorder (ROV-RISP-2011-01 
[PRISMA-1]), the pharmacokinetic characteristics of risperidone after single Risperidone ISM doses of 
50 mg (n = 13), 75 mg (n = 12), and 100 mg (n = 11) were delineated.  Risperidone, 9-OH-risperidone, 
and the active moiety (risperidone and 9-OH-risperidone combined) plasma concentration profiles over 
time (up to 75 days after administration of Risperidone ISM) showed the following active moiety mean 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 15 of 114 
concentrations in the 50 mg, 75 mg, and 100 mg groups, respectively (for 3 selected time points after 
injection of Risperidone ISM): 21.4 ng/mL, 24.6 ng/mL, and 29.6 ng/mL at 24 hours; 22.8 ng/mL, 
24.5 ng/mL, and 31.4 ng/mL at 48 hours; and 12.2 ng/mL, 17.3 ng/mL, and 20.0 ng/mL at 30 days).  
Estimated pharmacokinetic parameters of Risperidone ISM were in line with the results of the previous 
phase I study and with the literature on other marketed long-acting atypical antipsychotics, and overall, 
Risperidone ISM at all 3 tested dose strengths provided sustained release of risperidone and achieved 
therapeutic plasma levels within 1 day after injection.  Overall, 34 subjects (94.4%) had at least 1 
treatment-emergent AE during the study; the percentage of subjects reporting at least 1 treatment-
emergent AE was similar across the 3 dose groups (92.3%, 100%, and 90.9% in the 50 mg, 75 mg, and 
100 mg groups, respectively).   
A phase II multiple-dose study has also been conducted (ROV-RISP-2011-02 [PRISMA-2]).  Population 
pharmacokinetics modeling simulations were performed to guide the dose selection in this multicenter, 
open-label, 2-arm, parallel-design, repeat-dose clinical study to evaluate the pharmacokinetics, safety, and 
tolerability of 4 monthly IM injections of Risperidone ISM (75 mg) in subjects with schizophrenia.  
Risperidone ISM provided a sustained release of risperidone that achieved monthly therapeutic plasma 
levels within 1 day, without oral supplementation.   
The preliminary safety data of Risperidone ISM from the clinical studies mentioned above are consistent 
with the well-known safety profile of other marketed risperidone products in subjects with schizophrenia 
or schizoaffective disorder and have shown Risperidone ISM to be well tolerated in the subjects 
evaluated.   
Based on the pharmacokinetic results from the phase I study in healthy volunteers (ROV-RISP-2009-01), 
a population pharmacokinetic model was constructed to estimate plasma concentrations for therapeutic 
doses of Risperidone ISM.  For the phase I clinical study (ROV-RISP-2011-01 [PRISMA-1]), both 
overall exposures and an active moiety Cmax cutoff point of 80 ng/mL were considered in dose selection.  
A maximum dose of 100 mg was selected for use in the first part of the study, as the population 
pharmacokinetic model’s worst-case estimate was that this dose would provide an active moiety median 
Cmax value of approximately 80 ng/mL (i.e., assuming log-linear increases in bioavailability with 
ascending doses).  Data from the phase I and phase II studies were used to further refine the population 
pharmacokinetic model to support dose selection for this and other phase III clinical studies.   
Simulations and comparison of 5 multiple-dose regimens (37.5, 50, 75, 100, and 125 mg) showed that 
doses of 75 and 100 mg administered either in the gluteal or deltoid muscle resulted in predicted median 
Cmax and trough concentration in plasma (Ctrough) that stayed between thresholds of 7.5 and 80 ng/mL, 
thereby reducing the risk of extrapyramidal symptoms while maintaining plasma concentrations 
sufficiently high for efficacy. 
Plasma concentration-time profiles and steady-state pharmacokinetic parameters of the active moiety after 
4 doses (75 and 100 mg) Risperidone ISM were compared to commercially available Xeplion 
(paliperidone palmitate).  Paliperidone is the active metabolite of risperidone (i.e., 9-OH-risperdione) and 
is administered as initial doses of 150 and 100 mg, given 1 week apart, followed by a maintenance dosing 
regimen of 75 or 100 mg, given every 4 weeks.  There was a large overlap in pharmacokinetic profiles.  
In a number of patients, the predicted plasma concentrations of active moiety at the end of the 28-day 
treatment with 75 and 100 mg isperidone ISM were below the lower threshold of 7.5 ng/mL.7  Steady-

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 16 of 114 
state pharmacokinetic parameters varied between the 2 drugs with Cmax being slightly higher and Ctrough 
slightly lower after administration of Risperidone ISM. 
Furthermore, the same 2 doses (75 and 100 mg) of Risperidone ISM were compared to oral risperidone 
given daily at doses of either 4 mg/day or 6 mg/day.  Full adherence was assumed for oral risperidone.  
Compared to Risperidone ISM, 4 mg/day oral risperidone resulted in steady-state plasma concentrations 
of the active moiety above 7.5 ng/mL in almost all patients.  In addition, all simulated profiles did not 
reach the upper threshold of 80 ng/mL, which is considered to be a surrogate for safety.  For the higher 
dose of 6 mg/day, predicted plasma concentrations were higher than 80 ng/mL in a number of patients 
and over the entire dosing interval.  The 75 mg dose of Risperidone ISM resulted in similar area under the 
concentration-time curve within a dosing interval and average plasma concentration as the oral 4 mg/day 
dose.  However, it should be kept in mind that nonadherence to long-term oral medication is a well-
known therapeutic issue in schizophrenia.8,9  Hence, the simulated pharmacokinetic profiles after oral 
risperidone treatment are predicted to be higher than those that may be actually expected in patients with 
schizophrenia.  As a consequence, Ctrough values after oral treatment in patients with schizophrenia may 
well be in the same range or even lower than those predicted for Risperidone ISM. 
In an exploratory evaluation of predicted D2 receptor occupancy (RO), it was shown that after IM 
administration of a 100 mg and 125 mg dose of Risperidone ISM, median D2 RO stayed within the 65% 
to 80% window over the entire 4-week dosing interval, only slightly exceeding the upper limit in the first 
week after administration.  Comparison of Risperidone ISM with Xeplion showed that predicted median 
average RO values were comparable for both compounds after administration of a maintenance dose of 
75 or 100 mg.  However, predicted median Ctrough RO values were slightly lower and predicted median 
peak RO slightly higher after administration of Risperidone ISM.  When evaluating predicted D2 RO, it 
should be kept in mind that the correlation between D2 RO and clinical responses to an antipsychotic 
drug might be more complex and that patients might experience efficacy on much lower predicted D2 RO 
or might not experience any extrapyramidal symptoms at higher predicted D2 RO.10   
These doses are expected to produce therapeutic levels of risperidone within 24 hours of the first 
injection; these therapeutic levels will be maintained for 28 days and will provide sustained levels of 
risperidone throughout the duration of the study.  Thus, this study is designed to statistically demonstrate 
superior efficacy of Risperidone ISM to placebo. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 17 of 114 
2 Objectives 
2.1 Primary Objective 
The primary objective of this study is the following:  
 
To evaluate the efficacy of Risperidone ISM as compared with that of placebo in the treatment of 
patients with acute exacerbation of schizophrenia 
2.2 Secondary Objectives 
The secondary objectives of this study are the following:  
 
To characterize safety and tolerability of Risperidone ISM as compared with that of placebo in 
patients with acute exacerbation of schizophrenia 
 
To quantify healthcare resource utilization (HRU), health-related quality of life (HRQL), and social 
functioning in patients treated with Risperidone ISM versus placebo for an acute exacerbation of 
schizophrenia  
 
To explore pharmacokinetic characteristics of Risperidone ISM and associations with efficacy 
3 Investigational Plan 
3.1 Overall Study Design and Plan 
This is a multicenter, randomized, double-blind study designed to evaluate the efficacy and safety of 
Risperidone ISM, a new long-acting injectable form of the licensed drug risperidone.  Eligible patients 
will be randomly assigned, under double-blind conditions, to receive Risperidone ISM (75 or 100 mg) or 
placebo. 
The study design includes a screening period (planned duration 1 to 8 days) immediately preceding the 
baseline day (designated as study day 1), a treatment period (duration 12 weeks), a follow-up period 
(duration 2 weeks; not applicable for patients who enter into a long-term extension study), and an 
open-label extension period (duration 12 months).   
The screening period for a given patient generally should be as brief as is clinically feasible (e.g., target of 
3 days preferred) but may last up to 8 days (e.g., in order to safety washout any prohibited medications); 
an extension up 14 days maximum may be permitted with medical monitor approval.  Eligible patients 
should be admitted to the inpatient study unit upon completion of screening assessments at the initial 
screening visit.    
Patients will have a diagnosis of schizophrenia experiencing an acute exacerbation.  Following 
confirmation of eligibility, each patient will be randomly assigned under double-blind conditions to 
receive 1 of the following 3 study drug treatments: Risperidone ISM 75 mg, Risperidone ISM 100 mg, or 
placebo. 
The randomization scheme will ensure that an overall 1:1:1 ratio of assignments to each of these 3 study 
drug treatments is approximated.  

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 18 of 114 
Patients who have never taken risperidone must have a brief trial of oral risperidone 2 mg/day for 3 days 
during the screening period in order to ensure a lack of any clinically significant hypersensitivity 
reactions before the first dose of long-acting IM study drug is administered.  A trial of oral risperidone is 
not required for patients who have previously taken any formulation of risperidone. 
Patients enrolled in the double-blind segment of the study will be admitted to the study site’s inpatient 
unit sometime during the screening period (from 1 to 8 days before study day 1).  It is generally 
anticipated that patients may remain on the inpatient unit for at least 7 days after the first IM dose of long-
acting study drug is administered.  However, inpatient duration may vary for individual patients and 
potentially may range from 1 to 14 days.  If the investigator determines that a given patient should remain 
inpatient beyond study day 15, the medical monitor should be contacted to discuss the extension.   
Study drug will be administered as IM injections (see Section 5.1.2).  Treatment assignment for each 
individual patient will remain blinded for patients, investigators, and all study site staff, with the 
exception of identified individuals at each study site who will be unblinded in order to prepare and 
administer study drug for each patient at that study site.   
After initial dosing on study day 1, each study drug (Risperidone ISM or placebo) will be administered 
once every 4 weeks during the 12-week treatment period (i.e., at study days 29 and 57).   
Efficacy will be assessed by describing changes in scores on standard psychiatric assessment tools at each 
visit, and safety assessments will be conducted at each visit as well.   
Patients who complete planned participation in this study through to the end of the treatment period may 
be eligible to enter into an optional long-term extension segment of the study during which open-label 
Risperidone ISM (i.e., either 75 or 100 mg) will be administered to all participating patients once every 
4 weeks for approximately 12 months.  However, in order to preserve the blinding condition of the 
double-blind stage of the study, if a participating patient enters this OLE phase of the study prior to 
locking the database of the double-blind stage of the study, the allocation to either 75 or 100 mg of this 
patient will be still blinded at least up to locking the aforementioned database. Patients who enter into the 
extension segment of the study will begin participation in the extension segment immediately upon 
completion of the end-of-treatment visit assessments and procedures.  Patients who do not enter into the 
extension segment will have a final safety follow-up phone contact approximately 2 weeks after the end-
of-treatment visit.  
The planned total number of randomized patients in the double-blind segment of the study is 
approximately 436 patients total randomized planned (145 in each of the 3 treatment groups) (see Section 
7.4). Note: due to a potential accidental unblinding quality issue, it was considered that 43 patients were 
potentially compromised and therefore the sample size has been increased to compensate them. 
In addition to patients continuing from the double-blind segment of the study (rollover patients), patients 
not previously enrolled in the study (de novo patients) may be eligible to enter the long-term extension 
segment of the study.  These patients will be evaluated for eligibility at a screening visit and, if eligible, 
will be allocated to receive either 75 or 100 mg Risperidone ISM every 4 weeks for approximately 
12 months.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 19 of 114 
Approximately 100 de novo patients are planned to be enrolled in the extension segment of the study, in 
addition to rollover patients. 
The overall study design is depicted schematically in Figure 1.  A schedule of assessments and procedures 
is displayed by visit in Table 1, Table 2 and Table 3.   
Figure 1: Schematic of Study Design 
 
 
TREATMENT PERIOD 
  
 
 
 
Risperidone ISM 100 mg 
FOLLOW-UP 
VISIT a 
 
 
 
 
 
 
 
Risperidone ISM 75 mg 
Or 
SCREENING 
 
 
 
ENTER 
EXTENSION 
SEGMENT b,c 
 
 
Placebo 
 
 
Administer Study Drug: X 
 
 
 
X 
 
 
 
X 
 
 
 
 
 
 
 
Study Day: 1 
 
 
 
29 
 
 
 
57 
 
 
 
85 
 
 
Study Week: 
 
1 
 
 
4 
 
 
 
8 
 
 
 
12 
a If a patient does not enter the extension segment of the study, no additional doses of study drug will be administered to that 
patient.  
b Patients who complete planned participation through to the end of the treatment period may be eligible to enter into a 
long-term extension segment of the study, during which open-label Risperidone ISM (i.e., 75 or 100 mg) will be administered 
once every 4 weeks for approximately 12 months.  However, in order to preserve the blinding condition of the double-blind 
stage of the study, if a participating patient enters this OLE phase of the study prior to locking the database of the double-blind 
stage of the study, the allocation to either 75 or 100 mg of this patient will be still blinded at least up to locking the 
aforementioned database. Patients who enter into the extension segment will begin participation in the extension segment 
immediately upon completion of scheduled end-of-treatment assessments and procedures at the week 12 time point.  Patients 
who had been on active Risperidone ISM in the double-blind segment of the study will continue to receive active Risperidone 
ISM at the same dose (i.e., 75 or 100 mg) in the extension segment; patients who had been receiving placebo in the double-
blind segment of the study will be randomly assigned to receive either 75 or 100 mg during the extension segment.   
c De novo patients may also be eligible to enter the long-term extension segment of the study.  These patients will be evaluated 
for eligibility at a screening visit and, if eligible, will be allocated to receive either 75 or 100 mg Risperidone ISM every 4 
weeks for approximately 12 months.  De novo patients on 4 mg/day of oral risperidone will be assigned to 75 mg Risperidone 
ISM every 4 weeks, and patients on more than 4 mg/day to a maximum of 6 mg/day of oral risperidone will be assigned to 100 
mg Risperidone ISM every 4 weeks. 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 20 of 114 
Table 1 
Schedule of Assessments and Procedures 
Screening Baseline 
Treatment Period (Double-Blind) 
Follow 
-up 
Study Visit Number:
1 
2 
3 
4 
5 
6 
71 
8 
9 
10 
11 
12 
13 
142 
153 
Study Day4:
-8 to -15 
1 
3 
4 
8 
15 
22 
29 
31 
43 
57 
59 
71 
85 
99 
Treatment Week:
 
 
 
 
1 
2 
3 
4 
 
6 
8 
 
10 
12 
 
Overall Dosing Sequence:
 
1 
 
 
 
 
 
2 
 
 
3 
 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening assessments6 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligibility criteria review7 
X 
X 
 
 
 
 
 
 
Inpatient study unit8 
X 
X 
X 
X 
(X) 
(X) 
 
 
 
(Test oral risperidone)9 
(X) 
 
 
 
 
 
 
Randomization10 
X 
 
 
 
 
 
 
Inject IM study drug11 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
Efficacy scales:12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PANSS 
X 
X 
 
X 
X 
X 
 
X 
 
 
X 
 
 
X 
CGI-S 
X 
X 
 
X 
X 
X 
 
X 
 
 
X 
 
 
X 
CGI-I 
 
X 
X 
X 
 
X 
 
X 
X 
 
X 
X 
Socio-demographic 
information 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
X 
 
HRU data collection – 
center 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
HRU data collection – 
patient 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
X 
 
Health outcome scales13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSP (clinician 
administered) 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
X 
 
SWN-20 (patient 
reported) 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
X 
 
Safety assessments: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AEs14 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant meds15 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination 
X 
 
 
 
X 
X 
 
 
 
 
 
 
 
X 
 
Height 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight and body mass 
index 
X 
X 
 
 
X 
X 
 
X 
 
 
X 
 
 
X 
 
Vital signs16 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
ECG17 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Injection site evaluation18 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
Injection site pain VAS18 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
Safety scales:12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS 
X 
X 
 
X 
X 
X 
 
X 
 
X 
X 
 
X 
X 
BARS 
X 
X 
 
X 
X 
X 
 
X 
 
X 
X 
 
X 
X 
SAS 
X 
X 
 
X 
X 
X 
 
X 
 
X 
X 
 
X 
X 
C-SSRS 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
Ophthalmological 
examination19 
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Blood sample for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematology panel20 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 21 of 114 
Screening Baseline 
Treatment Period (Double-Blind) 
Follow 
-up 
Study Visit Number:
1 
2 
3 
4 
5 
6 
71 
8 
9 
10 
11 
12 
13 
142 
153 
Study Day4:
-8 to -15 
1 
3 
4 
8 
15 
22 
29 
31 
43 
57 
59 
71 
85 
99 
Treatment Week:
 
 
 
 
1 
2 
3 
4 
 
6 
8 
 
10 
12 
 
Overall Dosing Sequence:
 
1 
 
 
 
 
 
2 
 
 
3 
 
 
 
Chemistry panel21 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
Prolactin  
X 
X 
 
 
X 
 
 
 
X 
 
 
X 
 
 
X 
 
Pharmacokinetics22 
X 
X 
 
X23 
X23 X23 
X 
X 
X 
X 
X 
Genotype24 
X 
 
 
 
 
 
 
Serology panel25 
X 
 
 
 
 
 
 
Pregnancy test (serum) 
X 
 
 
 
 
 
 
Urine sample for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy test26 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
X 
 
Urinalysis27 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
Drug screen28 
X 
X 
 
 
(X) 
(X) 
 
(X) 
 
(X) (X) 
 
(X) 
(X) 
AE = adverse event; AIMS = Abnormal Involuntary Movement Scale; BARS = Barnes Akathisia Rating Scale; CGI-I = Clinical 
Global Impression – Improvement; CGI-S = Clinical Global Impression – Severity; C-SSRS = Columbia-Suicide Severity Rating 
Scale; ECG = electrocardiogram; HRU = healthcare resource utilization; IM = intramuscular; ISM = in situ microparticle; 
PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance Scale; SAS = Simpson-Angus Scale; 
SWN-20 = 20-item Subjective Well-Being Under Neuroleptics Treatment Scale; VAS = visual analog scale; (X) = assessment to 
be done as applicable.
                                                       
1  Study visit 7 (study day 22) is applicable to patients who participate in pharmacokinetic subgroup only. 
2  Visit 14, which is scheduled to occur at the week 12 time point, is the designated end-of-treatment visit.  However, if a patient 
withdraws or is withdrawn early from the study (i.e., before the week 12 time point), an early termination visit should occur at 
which time all assessments for the end-of-treatment visit (as listed for visit 14) will be performed.   
3  The follow-up visit will be conducted by telephone.  The follow-up visit is to occur 14 (± 3) days after the end-of-treatment 
visit (i.e., the week 12 time point or earlier in the case of an early termination).  This visit is not applicable for patients who 
enter into a long-term extension study. 
4 The study day 4 (visit 4) must occur 3 days after study day 1.  Allowable study visit time windows for treatment period study 
visits occurring after visit 4 (study day 4) are ± 1 day for study visit 5, ± 2 days for study visit 14, and ± 3 days for each of the 
other treatment period study visits (i.e., study visits 6 through 13, inclusive).   
5  If there is a valid reason for a given potential patient to extend the screening period duration beyond the designated 8 days, the 
investigator may contact the medical monitor to request an extension of up to 14 days; such an extension may be implemented 
only after medical monitor approval has been obtained.   
6  Screening assessments will include the following: informed consent, demographic data, medical and psychiatric history, and a 
diagnostic interview (which will include completion of the MINI International Neuropsychiatric Interview for Schizophrenia 
and Psychotic Disorders studies, version 7.0.2).  
7  Eligibility will be determined by the investigator, who will assess eligibility by confirming that that all inclusion criteria (see 
Section 4.1.1.1) have been met and that none of the exclusion criteria have been met (see Section 4.1.1.2).   
8  Patients who, after completion of all scheduled assessments on the screening visit day, are considered provisionally eligible 
will be admitted directly to the inpatient study that day.  Patients will subsequently remain in the inpatient study unit for the 
remainder of the screening period (i.e., through study day -1, inclusive).  Confirmed eligible patients will remain inpatient on 
study day 1.  No patient should be discharged from the inpatient before study day 2, and it is anticipated that most patients will 
remain on the inpatient unit through study day 8, and that thereafter patients will be discharged from the inpatient unit when 
the investigator has assessed the patient and determines that he or she is appropriately clinically stable and otherwise ready for 
safe discharge.  After study day 8, continuation of a patient on the inpatient unit from study day 9 through study day 15, 
inclusive, is an allowable option, as deemed clinically indicated.  If the investigator believes that a given patient should remain 
inpatient beyond study day 15, the investigator should contact the medical monitor to discuss the proposed inpatient duration 
extension.   
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 22 of 114 
                                                                                                                                                                                 
9  Patients who have never taken risperidone must take oral risperidone 2 mg/day for 3 days sometime during the screening 
period to ensure a lack of clinically significant hypersensitivity before the first IM dose of study drug is administered; this oral 
risperidone trial is not required for patients who have previously taken any formulation of risperidone.   
10  A unique randomization number will be assigned via interactive voice or web response system accessed immediately after 
eligibility confirmation of a patient.  The randomization process will determine (under double-blind conditions) for each 
individual patient the study drug regimen: an individual patient will receive either active Risperidone ISM or IM placebo.   
11 All study drug doses will be administered by deep IM injection (deltoid muscle or gluteal muscle).  The IM study drug doses 
will be prepared and administered by a designated unblinded individual at the study site (see Section 5.1.2).  The IM study 
drug will contain either active Risperidone ISM (75 or 100 mg) or placebo (double blind).   
12 See Appendix C – Rating Scale and Interview Descriptions. 
13 Health economics and outcomes research evaluations.  To be administered prior to medication dose.    
14  Monitoring for AEs will occur throughout a patient’s participation in this study, starting from the patient’s signature of 
informed consent form; required details of identified AEs are to be recorded.   
15  Information regarding concomitant medications, including new medications and changes to existing medications, will be 
elicited and recorded.   
16  Vital signs will include blood pressure, pulse rate, respiratory rate, and body temperature .  At each identified time point, vital 
signs will be measured after the patient has been resting in a supine position for at least 5 minutes.  On days when patients 
receive an IM injection of study drug, vital signs are to be measured within 1 hour before and then again within 3 hours after 
the study drug injection; at each of these time points, orthostatic blood pressure and pulse rate will be measured (immediately 
after completion of supine vital sign measurements) after the patient has risen from the supine to the standing position and has 
remained standing for approximately 3 minutes (see Section 6.4.3).   
17  A 12-lead ECG will be performed at identified visits; on days when patients receive an injection of IM study drug, an ECG 
will be performed both before and after dosing.  Pre-dose ECG is to be completed within 1 hour prior to dosing.  The post-dose 
ECG is to be completed within 3 hours post-dose.  All scheduled ECGs are to be performed after the patient has rested quietly 
for at least 5 minutes in the supine position (see Section 6.4.4).   
18 The patient will perform and record self-assessment of pain at the injection site using the injection site pain VAS (see 
Appendix D) approximately 1 hour after each study drug injection.  The investigator will inspect the recent injection site and 
all injection sites where IM study drug has been injected on previous visits, also approximately 1 hour after each study drug 
injection. 
19 Ophthalmological examination will include slit-lamp biomicroscopy examination (eyelids, conjunctiva, iris, crystalline lens, 
sclera, and cornea), best corrected visual acuity, visual field, and intraocular pressure (see Section 6.4.2).  
20 The hematology panel includes the following tests: hematocrit, hemoglobin, red blood cell count, white blood cell count and 
differential count (absolute values for basophils, eosinophils, lymphocytes, monocytes, and neutrophils), and platelets. 
21  The chemistry panel will include standard tests as well as hemoglobin A1c, thyroid-stimulating hormone, and a lipid panel.   
22  Pharmacokinetic samples will be obtained for all patients in the study on days 1, 3, 29, 31, 57, 59, and 85 (visits 2, 3, 8, 9, 11, 
12, and 14, respectively).  Pharmacokinetic samples will also be collected from patients who have a serious AE.   
23 A subgroup of 75 study participants will have additional pharmacokinetic samples collected on days 8, 15, and 22 (visits 5, 6, 
and 7, respectively). 
24 Genotype samples will be obtained only from those patients who sign a separate consent form for genotype sample collection. 
In these patients, a blood sample for genotype testing may be collected at any time point after randomization (see Section 
6.7.5.)  
25 A blood sample for a serology panel testing for hepatitis B surface antigen, antihepatitis C antibodies, and human 
immunodeficiency virus will be performed at screening only.   
26 On study day 1 and at identified visits thereafter, onsite dipstick tests will be used for urine pregnancy tests.  On each study 
drug dosing day, the urine pregnancy test must be performed and a negative result confirmed before the schedule dose of study 
drug for that day is administered.   
27 The urinalysis includes the following tests: color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, 
and occult blood.  Microscopic examination only if urinalysis dipstick results are abnormal. 
28  Urine drug screen is mandatory at screening and baseline and is optional thereafter.  On these timepoints, the sample will be 
sent to the laboratory for analysis (see Section 6.4.5.4.3).  The urine drug screen will include identification of the presence or 
absence of amphetamines, barbiturates, cocaine, methadone, opioids, and phencyclidine, as well as for tetrahydrocannabinol, 
alcohol, and benzodiazepines. In addition, onsite dipstick urine drug screen testing (with the exception of alcohol) may be 
optionally performed on the sample collected. 
 
 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 23 of 114 
Table 2 
Schedule of Assessments and Procedures: Optional Open-label Extension Segment for 
Rollover Patients 
Extension 
Baseline 
Extension Segment Treatment Period (Open-Label) 
Extension 
Follow-up 
Extension Visit Number:
   11 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 12 
13 142 
153 
Extension Study Day4:
   15 
29 
57 
85 113 141 169 197 225 253 281 309 337 365 
393 
Extension Treatment Week:
 
4 
8 
12 16 
20 
24 28 
32 
36 
40 44 
48 
52 
56 
Extension Dosing Sequence:
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 12 
13 
 
 
Informed consent6 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligibility criteria review7 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inject Risperidone ISM8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Efficacy scales: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PANSS 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
CGI-S 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
CGI-I10 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Socio-demographic 
information 
 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
HRU data collection – center 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
HRU data collection – patient 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Health outcome scales:11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSP (clinician administered) 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
X 
 
SWN-20 (patient reported) 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
X 
 
Safety assessments: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AEs12 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant meds13 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Weight and body mass index 
 X9 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Vital signs14 
X8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
ECG15 
X8 
X 
 
X 
 
X 
 
X 
 
 
X 
 
 
X 
 
Injection site evaluation16 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Injection site pain VAS16 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Safety scales: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
BARS 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
SAS 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
C-SSRS 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Blood sample for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematology panel17 
 X9 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Chemistry panel18 
 X9 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Prolactin 
 X9 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Pregnancy test19 (serum) 
(X) 
(X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) 
 
Urine sample for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy test20 
 X9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Urinalysis21 
 X9 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Drug screen22 
(X) 
(X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) 
  
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 24 of 114 
AE = adverse event; AIMS = Abnormal Involuntary Movement Scale; BARS = Barnes Akathisia Rating Scale; CGI-I = Clinical 
Global Impression – Improvement; CGI-S = Clinical Global Impression – Severity; C-SSRS = Columbia-Suicide Severity Rating 
Scale; ECG = electrocardiogram; HRU = healthcare resource utilization; IM = intramuscular; ISM = in situ microparticle; 
PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance Scale; SAS = Simpson-Angus Scale; 
SWN-20 = 20-item Subjective Well-Being Under Neuroleptics Treatment Scale; VAS = visual analog scale; (X) = assessment to 
be done as applicable  
                                                       
1  The extension baseline visit may occur on the same day as visit 14 (+ 3-day window) of the main part of the study (i.e., the day 
on which the designated end-of-treatment visit for the double-blind treatment period of the main part of the study occurs), 
which is scheduled to occur at the week 12 time point of the main part of the study.  However, in order to be eligible for 
transition into the extension segment, a patient must first complete all assessments and procedures scheduled for the end-of-
treatment visit for the double-blind treatment period of the main part of the study.  Patients who withdraw or are withdrawn 
early from the main part of the study (i.e., before the scheduled week 12 time point) are not eligible for enrollment into the 
extension segment.   
2  Visit 14 is the designated end-of-treatment visit.  However, if a patient withdraws or is withdrawn early from the study, an 
early termination visit should occur at which time all assessments for the end-of-treatment visit (as listed for visit 14) plus all 
the socio-demographic information and HRU (center and patient) data collection will be performed. 
3  The follow-up visit will be conducted by telephone.  
4 The allowable study visit time window for each of the extension baseline visit is within 3 days after visit 14 of the main part of 
the study occurs; however, it is generally preferable to conduct the extension baseline visit assessments and procedures later in 
the day (i.e., after completion of all assessments and procedures scheduled for the end-of-treatment visit for the double-blind 
treatment period of the main part of the study) on the same day on which the main study visit 14 occurs.  The allowable study 
visit time window for each of the subsequent extension visits is ± 3 days (i.e., extension visits 2 through 15, inclusive).   
5  Extension day 1 (the extension baseline visit time point) is planned to be the same day and date as day 85 of the main part of 
the study, though a + 3-day window for extension day 1, as compared with the day and date of the end-of- treatment visit for 
the main study day 85, is allowable.   
6  A separate informed consent form for participation in the optional extension segment of the study must be signed before any 
assessments or procedures for the extension segment are performed for a given patient and before any dose of open-label 
Risperidone ISM is administered to that patient.   
7  Eligibility will be determined by the investigator, who will assess eligibility by confirming that that all extension segment 
inclusion criteria (see Section 4.1.2.1) have been met and that none of the extension segment exclusion criteria have been met 
(see Section 4.1.2.2).   
8  In the extension segment of the study, all participating patients will receive active Risperidone ISM under open-label 
conditions.  Patients who had been on active Risperidone ISM in the double-blind segment of the study will continue to receive 
Risperidone ISM at the same dose (i.e., 75 or 100 mg) in the extension segment; patients who had been receiving placebo in 
the double-blind segment of the study will be randomly assigned to receive either 75 or 100 mg during the extension segment.  
All Risperidone ISM doses will be administered by deep IM injection (deltoid muscle or gluteal muscle).    
9  For identified assessments at the extension baseline visit time point (on extension day 1), results obtained as part of the main 
study visit 14 (i.e., the designated assessments performed for the end-of-treatment visit for the double-blind treatment period 
[week 12 time point] of the main part of the study) may be used as the extension baseline values and do not need to be repeated 
for the extension baseline visit time point if and only if the extension baseline visit occurs on the same day and date as the 
main study visit 14/week 12/end-of-treatment visit.  If the extension baseline visit instead occurs on a day 1 to 3 days after the 
main study visit 14/week 12/end-of-treatment visit (see extension segment footnotes 2 and 3), all of the designated 
assessments must be performed separately on the day of the extension baseline visit, and the main study visit 14/week 12/end-
of-treatment visit assessment results cannot be used as substitutes.   
10  Although a CGI-I score in reference to baseline of the main part of the study will be reported as part of the assessments for the 
end-of-treatment visit for the double-blind treatment period (visit 14 of the main part of the study), no CGI-I score in reference 
to the extension segment will be reported at the extension baseline time point (which may be later on the same day as the visit 
14 of the main part of the study).  For all subsequent visits in the treatment period of the extension segment (i.e., extension 
segment visits 2 through 14, inclusive), the reference time point for the CGI-I scores will be that patient’s overall status at the 
extension baseline time point.   
11  Health economics and outcomes research evaluations. To be administered prior to medication dose.     
12  Monitoring for AEs will occur throughout a patient’s participation in the extension segment of the study, starting from the 
patient’s signature of informed consent form; required details of identified AEs are to be recorded.   
13  Information regarding concomitant medications, including new medications and changes to existing medications, will be 
elicited and recorded.   
14  Vital signs will include blood pressure, pulse rate, respiratory rate, and body temperature.  At each identified time point, vital 
signs will be measured after the patient has been resting in a supine position for at least 5 minutes.  At each scheduled visit, 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 25 of 114 
                                                                                                                                                                                 
vital signs are to be measured within 1 hour before and then again within 3 hours after the Risperidone ISM injection; at each 
of these time points, orthostatic blood pressure and pulse rate will be measured (immediately after completion of supine vital 
sign measurements) after the patient has risen from the supine to the standing position and has remained standing for 
approximately 3 minutes (see Section 6.4.3).   
15  A 12-lead ECG will be performed at identified visits, both before and after dosing of risperidone ISM (with the exception of 
visit 14 when only 1 ECG is applicable).  Each pre-dose ECG is to be completed within 1 hour before dosing.  Each post-dose 
ECG is to be completed within 3 hours post-dose.  All scheduled ECGs are to be performed after the patient has rested quietly 
for at least 5 minutes in the supine position (see Section 6.4.4).   
16 The patient will perform and record self-assessment of pain at the injection using the injection site pain VAS (see Appendix D) 
approximately 1 hour after each study drug injection. The investigator will inspect the recent injection site and all injection 
sites where IM study drug has been injected on previous visits, also approximately 1 hour after each study drug injection. 
17 The hematology panel includes the following tests: hematocrit, hemoglobin, red blood cell count, white blood cell count and 
differential count (absolute values for basophils, eosinophils, lymphocytes, monocytes, and neutrophils), and platelets. 
18  The chemistry panel will include standard tests as well as hemoglobin A1c, thyroid-stimulating hormone, and a lipid panel.   
19 A blood sample for a serum pregnancy test is not required, but the investigator may order a serum pregnancy test at any time 
according to the investigator’s judgment.   
20 On extension segment day 1 and at each identified visit thereafter, onsite dipstick tests will be used for urine pregnancy tests.  
At each applicable visit, the urine pregnancy test must be performed and a negative result confirmed before the schedule dose 
of study drug for that day is administered.   
21 The urinalysis includes the following tests: color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, 
and occult blood. Microscopic examination only if urinalysis dipstick results are abnormal. 
22  Urine drug screen is optional at each study site visit. It will include identification of the presence or absence of amphetamines, 
barbiturates, cocaine, methadone, opioids, and phencyclidine, as well as for tetrahydrocannabinol, alcohol, and 
benzodiazepines.     
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 26 of 114 
Table 3 
Schedule of Assessments and Procedures: Open-label Extension Segment for De Novo 
Patients 
Screening Baseline 
Extension Segment Treatment Period (Open-Label) 
Extension 
Follow-up 
Extension Visit Number:
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 11 12 13 141 
15 
Extension Study Day2:
-8 to -13 
1 
29 57 85 113 141 169 197 225 253 281 309 337 365 
393 
Extension Treatment 
Week:
 
 
4 
8 
12 16 20 24 28 32 36 40 44 48 52 
56 
Extension Dosing
Sequence:
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 11 12 13 
 
 
Informed consent4 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening assessment* 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligibility criteria review2 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arm assignment5 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inject Risperidone ISM3 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Efficacy scales: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PANSS 
X 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
CGI-S 
X 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
CGI-I 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Socio-demographic 
information 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
HRU data collection – 
center 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
HRU data collection – 
patient 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Health outcome scales:6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSP (clinician 
administered) 
 
X 
 
 
X 
 
 
X 
 
 
 
 
 
 
X 
 
SWN-20 (patient 
reported) 
 
X 
 
 
X 
 
 
X 
 
 
 
 
 
 
X 
 
Safety assessments: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AEs7 
X 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant meds8 
X 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination 
X 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Weight and body mass 
index 
X 
 X 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Vital signs9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
ECG10 
X 
X 
X 
 
X 
 
X 
 
X 
 
 
X 
 
 
X 
 
Injection site 
evaluation9 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Injection site pain 
VAS11 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Safety scales: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS 
X 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
BARS 
X 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
SAS 
X 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
C-SSRS 
X 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Blood sample for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematology panel12 
X 
 X 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Chemistry panel13 
X 
 X 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Prolactin 
X 
 X 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Serology panel** 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy test14 
(serum) 
X 
(X) 
(X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 27 of 114 
Screening Baseline 
Extension Segment Treatment Period (Open-Label) 
Extension 
Follow-up 
Extension Visit Number:
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 11 12 13 141 
15 
Extension Study Day2:
-8 to -13 
1 
29 57 85 113 141 169 197 225 253 281 309 337 365 
393 
Extension Treatment 
Week:
 
 
4 
8 
12 16 20 24 28 32 36 40 44 48 52 
56 
Extension Dosing
Sequence:
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 11 12 13 
 
 
Urine sample for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy test15 
 
 X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Urinalysis16 
X 
 X 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
Drug screen17 
X 
X 
(X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) 
  
AE = adverse event; AIMS = Abnormal Involuntary Movement Scale; BARS = Barnes Akathisia Rating Scale; CGI I = Clinical 
Global Impression – Improvement; CGI-S = Clinical Global Impression – Severity; C-SSRS = Columbia-Suicide Severity Rating 
Scale; ECG = electrocardiogram; HRU = healthcare resource utilization; IM = intramuscular; ISM = in situ microparticle; 
PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance Scale; SAS = Simpson-Angus Scale; 
SWN-20 = 20-item Subjective Well-Being Under Neuroleptics Treatment Scale; VAS = visual analog scale; (X) = assessment to 
be done as applicable. 
                                                       
1  Visit 14 is the designated end-of-treatment visit.  However, if a patient withdraws or is withdrawn early from the study, an 
early termination visit should occur at which time all assessments for the end-of-treatment visit (as listed for visit 14) plus all 
the socio-demographic information and HRU (center and patient) data collection will be performed. 
2 The allowable study visit time window for baseline visit 1 is + 4-day window and for each of the subsequent extension visits is 
± 3 days (i.e., extension visits 2 through 15, inclusive).   
3  If there is a valid reason for a given potential patient to extend the screening period duration beyond the designated 8 days, the 
investigator may contact the medical monitor to request an extension of up to 14 days; such an extension may be implemented 
only after medical monitor approval has been obtained. 
4 An informed consent form for participation in the extension segment of the study must be signed before any assessments or 
procedures for the extension segment are performed for a given patient and before any dose of open-label Risperidone ISM is 
administered to that patient. Eligibility will be determined by the investigator, who will assess eligibility by confirming that 
that all inclusion criteria have been met and that none of the exclusion criteria have been met. 
5  In the extension segment of the study, all participating patients will receive active Risperidone ISM under open-label 
conditions.  Patients on 4 mg of oral risperidone will be assigned to 75 mg Risperidone ISM every 28 days. Patients on more 
than 4 mg to a maximum of 6 mg of oral risperidone will be assigned to 100 mg Risperidone ISM every 28 days. All 
Risperidone ISM doses will be administered by deep IM injection (deltoid muscle or gluteal muscle).   
6  Health economics and outcomes research evaluations. To be administered prior to medication dose. 
7  Monitoring for AEs will occur throughout a patient’s participation in the extension segment of the study, starting from the 
patient’s signature of informed consent form; required details of identified AEs are to be recorded. 
8 Information regarding concomitant medications, including new medications and changes to existing medications, will be 
elicited and recorded. 
9 Vital signs will include blood pressure, pulse rate, respiratory rate, and body temperature.  At each identified time point, vital 
signs will be measured after the patient has been resting in a supine position for at least 5 minutes.  At each scheduled visit, 
vital signs are to be measured within 1 hour before and then again within 3 hours after the Risperidone ISM injection; at each 
of these time points, orthostatic blood pressure and pulse rate will be measured (immediately after completion of supine vital 
sign measurements) after the patient has risen from the supine to the standing position and has remained standing for 
approximately 3 minutes (see Section 6.4.3).   
10  A 12-lead ECG will be performed at identified visits, both before and after dosing of risperidone ISM (with the exception of 
visit 14 when only 1 ECG is applicable).  Each pre-dose ECG is to be completed within 1 hour before dosing.  Each post-dose 
ECG is to be completed within 3 hours post-dose.  All scheduled ECGs are to be performed after the patient has rested quietly 
for at least 5 minutes in the supine position (see Section 6.4.4).   
11 The patient will perform and record self-assessment of pain at the injection using the injection site pain VAS (see Appendix D) 
approximately 1 hour after each study drug injection. The investigator will inspect the recent injection site and all injection 
sites where IM study drug has been injected on previous visits, also approximately 1 hour after each study drug injection. 
12 The hematology panel includes the following tests: hematocrit, hemoglobin, red blood cell count, white blood cell count and 
differential count (absolute values for basophils, eosinophils, lymphocytes, monocytes, and neutrophils), and platelets. 
13 The chemistry panel will include standard tests as well as hemoglobin A1c, thyroid-stimulating hormone, and a lipid panel.   
14 A blood sample for a serum pregnancy test is not required, but the investigator may order a serum pregnancy test at any time 
according to the investigator’s judgment.  
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 28 of 114 
                                                                                                                                                                                
15 On extension segment day 1 and at each identified visit thereafter, onsite dipstick tests will be used for urine pregnancy tests.  
At each applicable visit, the urine pregnancy test must be performed and a negative result confirmed before the schedule dose 
of study drug for that day is administered.  
16 The urinalysis includes the following tests: color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, 
and occult blood. Microscopic examination only if urinalysis dipstick results are abnormal. 
17 Urine drug screen is optional at each study site visit properly identified (X). It will include identification of the presence or 
absence of amphetamines, barbiturates, cocaine, methadone, opioids, and phencyclidine, as well as for tetrahydrocannabinol, 
alcohol, and benzodiazepines. 
* Screening assessments will include the following: informed consent, demographic data, medical and psychiatric history, and a 
diagnostic interview (which will include completion of the MINI International Neuropsychiatric Interview for Schizophrenia 
and Psychotic Disorders studies, version 7.0.2).  
**A blood sample for a serology panel testing for hepatitis B surface antigen, antihepatitis C antibodies, and human 
immunodeficiency virus will be performed at screening only. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 29 of 114 
3.2 Requirements and Restrictions 
3.2.1 
Contraception and Pregnancy 
All patients must agree to use an acceptable method of contraception for the duration of the study and 
for ≥ 6 months after the last dose of IM study drug has been administered.   
The following are considered acceptable methods:  
 
Condom (male or female) with or without a spermicidal agent 
 
Diaphragm or cervical cap with spermicide 
 
Intrauterine device 
 
Hormonal contraceptive (e.g., birth control pills or patches, vaginal ring, or contraceptive 
implant) 
Female patients who have had a hysterectomy, bilateral tubal ligation, or bilateral salpingo-
oophorectomy are considered surgically sterile and are thus are exempt from the requirement to use 
contraception.  Men with an exclusive female partner meeting 1 of these surgically sterile criteria, as 
well as men who have themselves had a vasectomy, are also exempt from the requirement to use 
contraception.   
Female patients who are postmenopausal are considered not of childbearing potential and thus exempt 
from the contraception requirement; for the purpose of this study, postmenopausal is defined as the 
permanent cessation of menstruation for at least 12 months prior to screening in women ≥ 45 years of 
age.   
Patients who are abstinent from sexual intercourse are eligible for participation in this study if they 
agree to use an acceptable contraceptive method should they engage in such sexual activity while 
participating in this study.   
If a female patient becomes pregnant while participating in the study, study drug must be discontinued 
immediately and early termination and safety follow-up visits should be scheduled.  Any pregnancy 
must be reported to the sponsor (see Section 6.4.9).   
3.2.2 
Concomitant Therapy 
All concomitant medications (including those used during ophthalmological examination, if any) and 
other therapies received during a patient’s participation in this study (i.e., from the date of the 
informed consent form is signed through to the date of the final study visit) should be recorded.   
The investigator may discontinue or adjust the dose of a concomitant medication to ensure patient 
safety; however, unnecessary changes in concomitant medications for reasons other than safety are 
generally discouraged to avoid confounding study evaluations.   
The medical monitor should be consulted for any questions concerning concomitant medications.   
3.2.2.1 Prohibited Therapy 
3.2.2.1.1 
Prohibited Medications 
3.2.2.1.1.1 Cytochrome P450 3A4 Inducers and Inhibitors and 2D6 Inhibitors 
Clinically significant inducers and inhibitors of cytochrome P450 3A4 and inhibitors of cytochrome 
P450 2D6 (whether prescription medications, over-the-counter medications, or dietary supplements) 
are prohibited during the course of the study and within 30 days before study day 1 (see Appendix B).   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 30 of 114 
3.2.2.1.1.2 Antipsychotics 
Antipsychotic medications, other than the study drugs administered according to this protocol, are not 
permitted during a patient’s participation in the treatment period of this study.  Existing antipsychotic 
medication must be discontinued during the screening period (for patients in the double-blind segment 
of the study, this will be while the patient is admitted to the inpatient study unit), if deemed clinically 
appropriate by investigator judgment.  The same applies to de novo patents where all antipsychotic 
medication other than oral risperidone must be discontinued during the screening period.  The last 
dose of oral risperidone should be administered on the day preceding baseline visit. 
This restriction applies also for antipsychotics given as sleep aids.   
The duration of the antipsychotic medication washout period (e.g., approximately 3 to 5 times the 
half-life of an oral antipsychotic, if appropriate and feasible) will be at the discretion of the 
investigator, in consultation with the medical monitor when deemed indicated.   
If administration of an additional or different antipsychotic medication (other than protocol-defined 
study drug), or any other treatment for schizophrenia, is considered clinically indicated during a 
patient’s participation in the study, the investigator should contact the medical monitor to discuss the 
circumstance and determine a course of action for the given patient.   
3.2.2.1.1.3 Other Psychotropic Medications 
Monoamine oxidase inhibitors (e.g., phenelzine, tranylcypromine, selegiline, moclobemide) are 
strictly prohibited during a patient’s participation in this study and for ≥ 14 days before the screening 
visit.  All other antidepressant medications are also not permitted during the treatment period.  
Patients taking antidepressants may be considered for washout of these medications during the 
screening period.    
Lithium and mood stabilizers are not permitted during a patient’s participation in the treatment period 
of this study.   
Nicotine replacement therapy, including nicotine replacement patch and oral nicotine gum, is 
permitted.  However, varenicline (Chantix®) is not permitted.   
Otherwise, in general, use of psychotropic medications other than study drug is discouraged during a 
patient’s participation in the study, with the exception of medications specifically identified in this 
protocol as permissible.   
The medical monitor should be consulted for any questions about use of any psychotropic 
medications during a patient’s participation in this study.   
3.2.2.1.1.4 Drugs of Abuse 
Prohibited substances include amphetamines, barbiturates, cocaine, methadone, opioids, and 
phencyclidine.  If it is determined that a patient has been using any of these substances during 
participation in this study, the investigator should contact the medical monitor to discuss the course of 
action.   
Tobacco and/or caffeine use is allowable if use is anticipated to remain relatively stable throughout a 
patient’s participation in the study.   
While it is preferable that patients do not use any alcohol or tetrahydrocannabinol (THC)-containing 
substances (e.g., marijuana), in certain cases patients with occasional and stable use of small amounts 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 31 of 114 
these substances may not be exclusionary if exclusion criterion 9 is not met, and only if the medical 
monitor provides approval (also see Section 6.4.5.4.3).   
3.2.2.1.2 
Prohibited Nonmedication Therapy 
Psychotherapy should not be started or changed during a patient’s participation in the study.  It is 
acceptable for a patient already receiving psychotherapy to participate in the study.   
While on the inpatient study unit during participation in the study, initiation of new augmenting 
psychotherapies (i.e., group therapy) is discouraged, though standard milieu-related activities are 
acceptable.   
Partial hospitalization after discharge from the inpatient study unit is discouraged, though the level of 
care after discharge from the inpatient study unit ultimately should be made based on investigator 
judgment.   
Psychiatric hospitalization during the treatment period after the patient has been discharged from the 
inpatient study unit could result in early withdrawal of that patient from the study (see Section 4.2).  
3.2.2.2 Permitted Therapy 
3.2.2.2.1 
Rescue Medication 
Permitted rescue medications for this study include the following:  
 
Benzodiazepines 
o Indications: agitation, anxiety, insomnia, and/or restlessness 
o Maximum dosage: 6 mg/day lorazepam or equivalent for other benzodiazepines 
o Notes:  
 
Short half-life benzodiazepines are preferable to longer half-life benzodiazepines due to 
the potential for lingering effects on daytime functioning and study assessments 
 
For treatment of agitation and/or anxiety, the dose benzodiazepines should be kept as 
stable as possible throughout the patient’s participation in study in order to avoid 
interference with daytime functioning and study assessments 
 
Anticholinergics 
o Indication: extrapyramidal symptoms 
o Maximum dosage: 4 mg/day benztropine or equivalent for other anticholinergics 
 
Propranolol 
o Indications: akathisia or tremor 
o Maximum dosage: 20 mg 3 times daily (60 mg/day total) 
4 Patients 
4.1 Eligibility 
To be eligible for participation in the study, at screening each patient must meet all of the inclusion 
criteria  and none of the exclusion criteria.   
4.1.1 
Eligibility Criteria for Enrollment into the Double-Blind Segment of the Study 
4.1.1.1 Inclusion Criteria 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 32 of 114 
To be eligible for enrollment into the double-blind segment of the study, each patient must meet all of 
the following criteria at screening:  
1. Capable of providing informed consent 
a. A signed informed consent form must be provided before any study assessments are 
performed 
b. Patients must be fluent in the language that is spoken by the investigator and the study site 
staff (including raters) and must be able to read and understand the words in which the 
informed consent is written 
2. Age ≥ 18 and ≤ 65 years 
3. Body mass index 18.5 to 40.0 kg/m2 (inclusive) 
4. Current diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5) criteria 
a. Currently experiencing an acute exacerbation or relapse with onset < 2 months before 
screening 
b. If inpatient at screening, has been hospitalized for < 2 weeks for the current exacerbation 
c. ≥ 2 years have elapsed since initial onset of active-phase schizophrenia symptoms 
5. Has been able to achieve outpatient status for > 4 months during the past year 
6. Has previously had a clinically significant beneficial response (improvement in schizophrenia 
symptoms), as determined by the investigator, to treatment with an antipsychotic medication other 
than clozapine 
7. Agrees to discontinue prohibited medications as applicable and as clinically indicated according 
to investigator instructions 
8. Dosages of all permitted medications are considered to have been stable (with the exception of 
medication to be used on an as-needed basis) for ≥ 2 weeks prior to the baseline visit and to 
remain stable during participation in this study 
9. Positive and Negative Syndrome Scale (PANSS) results at the screening and baseline visits meets 
the following criteria:  
a. Total score between 80 and 120, inclusive 
b. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale items:  
i. 
Item 1 (P1: delusions) 
ii. 
Item 2 (P2: conceptual disorganization) 
iii. 
Item 3 (P3: hallucinatory behavior) 
iv. 
Item 6 (P6: suspiciousness/persecution) 
10. Clinical Global Impression – Severity (CGI-S) score of ≥ 4 (moderately ill or worse) 
11. Resides in a stable living situation and is anticipated to return to that same stable living situation 
after discharge from the inpatient study unit, in the opinion of the investigator 
12. Has an identified reliable informant who is anticipated to remain the same after the patient is 
discharged from the inpatient study unit, in the opinion of the investigator 
13. Meets the following criteria:  
a. If a sexually active, is using a medically accepted contraceptive method, and will continue to 
use such throughout participation in this study (and for ≥ 6 months after the last dose of IM 
study drug has been administered); acceptable methods include the following:  
i. 
Condoms (male or female) with or without a spermicidal agent 
ii. 
Diaphragm or cervical cap with spermicide 
iii. 
Intrauterine device 
iv. 
Hormonal contraceptive 
b. If not currently sexually active, then meets the following criteria:  

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 33 of 114 
i. 
Agrees that if sexual activity resumes while participating in this study, a medically 
accepted contraception method will be used 
14. Willing and able to be confined to an inpatient study unit for up to 2 weeks (or longer if clinically 
indicated), as applicable and as clinically indicated according to investigator instructions 
15. Agrees not to post any personal medical data related to the study or information related to the 
study on any website or social media site (e.g., Facebook, Twitter, and others) during the study 
duration 
4.1.1.2 Exclusion Criteria 
An individual who meets any of the following criteria at screening will not be permitted to enroll in 
the study:   
1. History of proven inadequate clinical response to treatment with therapeutic doses (with good 
compliance) of risperidone or paliperidone 
2. History of treatment resistance, defined as failure to respond to 2 discrete adequate trials (≥ 4 
weeks with an adequate dose) of 2 different antipsychotic medications; history of clozapine use 
(exception: use was not because of treatment resistance or refractory psychotic symptoms) 
3. Improvement in PANSS total score 20% or greater between the initial screening visit and first 
injection 
4. Known or suspected intolerance of or allergy or hypersensitivity to risperidone, paliperidone, or 
any of the excipients in the IM formulations of these 
5. History of neuroleptic malignant syndrome, clinically significant tardive dyskinesia, or tardive 
dystonia 
6. History of any other medical condition that is considered to pose any unjustifiable risk or interfere 
with study assessments 
7. Clinically significant extrapyramidal symptoms at screening or baseline 
8. Answer of “yes” on item 4 or on item 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) 
(ideation) with the most recent episode occurring within the past 2 months, or answer “yes” to any 
of the 5 items (behavior) with an episode occurring within the last year 
9. Current diagnosis or a history of substance use disorder according to DSM-5 criteria within 
6 months prior to the screening visit (with the exception of tobacco, mild cannabis, or mild 
alcohol use disorder) or a positive drug screen test (with the exception of cannabis) verified by 
repeat testing 
10. Lifetime history of diagnosis of schizoaffective disorder or bipolar disorder 
11. Clinically significant comorbid neuropsychiatric disorders including any of the following:  
a. Current untreated or unstable major depressive disorder 
b. Clinically significant cognitive difficulties including dementia, delirium, or amnesic 
syndrome, within the past 2 years and would interfere with participation in the study 
c. Any other psychiatric condition that would, in the judgment of the investigator, interfere with 
participation in the study 
12. Clinically significant or unstable medical illness/condition/disorder that would be anticipated, in 
the investigator’s opinion, to potentially compromise patient safety or adversely affect the 
evaluation of efficacy, including (but not necessarily limited to) the following:  
a. Clinically significant hypotension or hypertension not stabilized by medical therapy (diastolic 
blood pressure > 105 mmHg) 
b. Unstable thyroid dysfunction in the past 6 months 
c. Malignant tumor within the last 5 years 
d. Neurologic conditions including the following: 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 34 of 114 
i. 
History of seizure disorder or condition associated with seizures 
ii. 
History of brain tumor, subdural hematoma, or other clinically significant neurological 
condition within the past 12 months 
iii. 
Head trauma with loss of consciousness within 12 months before screening 
iv. 
Active acute or chronic central nervous system infection 
v. 
Stroke within 6 months before screening 
e. Cardiac conditions including the following:  
i. 
Clinically significant cardiac arrhythmia, cardiomyopathy, or cardiac conduction defect 
ii. 
History of myocardial infarction or unstable angina within the last 3 months before 
screening, or clinically significant abnormality on screening or baseline 
electrocardiogram (ECG) including but not limited to the following: QT interval 
corrected for heart rate using Fridericia’s formula (QTcF) > 465 msec if male or > 485 
msec if female 
13. Laboratory abnormality that, in the opinion of the investigator, would compromise the well-being 
of the patient, or any of the following laboratory abnormalities at screening or baseline:  
a. Aspartate aminotransferase or alanine aminotransferase value ≥ 2 times the upper limit of the 
laboratory normal reference range 
b. Hemoglobin A1c > 9% 
c. Absolute neutrophil count ≤ 1.5 × 103 μL 
d. Platelet count ≤ 75 × 103 μL 
e. Creatinine clearance < 60 mL/min 
f. Positive test result for human immunodeficiency virus, hepatitis B surface antigen, or 
antihepatitis C virus antibody 
g. Positive pregnancy test result 
h. Urine drug screen at screening or baseline shows a positive result for any of the tested 
substances (potential exceptions: results positive for benzodiazepine may not be exclusionary 
if the investigator confirms that such medication was medically indicated and consults the 
medical monitor before enrolling a patient with such a finding; results positive for THC may 
not be exclusionary in certain cases only if exclusion criterion 9 is not met and only if the 
medical monitor provides approval) 
14. Pregnant, lactating, or breastfeeding 
15. Inadequate gluteal or deltoid musculature or excessive fat, as determined by the investigator, that 
would interfere with IM study drug injections 
16. Any contraindication for IM injections  
17. Receipt of any long-acting antipsychotic medication by IM injection within 60 days before 
screening 
18. Current involuntary hospitalization or incarceration 
19. Hospitalized for more than 30 days during the 90 days before screening 
20. Participation in another clinical study in which the patient received an experimental or 
investigational drug or agent within 6 months before screening 
21. Participation in a clinical study with Risperidone ISM within 12 months before screening 
22. Study site personnel and/or persons employed by the investigator or study site or is an immediate 
family member of such persons 
23. Patients taking any prohibited concomitant medication (see Section 3.2.2.1.1) at the time of 
randomization visit 
24. Clinically significant ocular disease or visual impairment interfering with the planned 
ophthalmological examinations or that in the investigator’s opinion could potentially compromise 
patients’ ocular safety 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 35 of 114 
25. Patients with planned or anticipated need for ocular surgery during the treatment period of the 
trial 
4.1.2 
Eligibility Criteria for Entry into Optional Extension Segment of the Study (Rollover 
Patients) 
Participation in the open-label extension segment of the study is optional, and patients who complete 
participation in the main segment of the study may opt to not participate.  Patients who are interested 
in participating must meet all eligibility criteria in order to enter into the extension segment.  
4.1.2.1 Inclusion Criteria for Extension Segment 
To be eligible for entry into the extension segment of the study, a patient must meet all of the 
following criteria at the extension baseline time point (immediately upon completion of the end-of-
treatment visit assessments and procedures for the main part of the study): 
1. Has completed scheduled participation in the main part of the study, through to the end of the 
treatment period and including the end-of-treatment visit 
2. Continues to require long-term treatment with an antipsychotic medication, in the opinion of the 
investigator 
3. Continues to meet contraceptive requirements of the study (see Section 3.2.1) 
4. Is willing to participate in the extension segment of the study and remains capable of providing 
informed consent 
a. A signed informed consent form must be provided before any study assessments are 
performed for the extension segment 
5. Continues to reside in a stable living situation, in the opinion of the investigator 
6. Continues to have an identified reliable informant, in the opinion of the investigator 
4.1.2.2 Exclusion Criteria for Extension Segment 
An individual who meets any of the following criteria at the extension baseline time point 
(immediately upon completion of the end-of-treatment visit assessments and procedures for the main 
part of the study) will not be permitted to enter into the extension segment of the study:   
1. Missed more than 1 scheduled study visit during participation in the main part of the study 
2. Had an abnormal clinical laboratory value, vital sign, or ECG finding during participation in the 
main part of the study that, in the opinion of the investigator, was clinically relevant, related to 
study drug, and would compromise the well-being of the patient in the extension segment 
3. Had a clinically significant or unstable medical illness/condition/disorder during the main part of 
the study that would be anticipated, in the investigator’s opinion, to potentially compromise 
patient safety in the extension segment 
4. Is taking or is anticipated to require any prohibited concomitant medication (see Section 3.2.2.1.1)  
5. Pregnant, lactating, or breastfeeding 
6. Any contraindication for continued IM injections (e.g., treatment with anticoagulant) 
7. Inadequate gluteal or deltoid musculature or excessive fat, as determined by the investigator, that 
would interfere with IM study drug injections 
8. Study site personnel and/or persons employed by the investigator or study site or is an immediate 
family member of such persons 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 36 of 114 
4.1.3 
Eligibility Criteria for Entry into Optional Extension Segment of the Study (De Novo 
Patients) 
4.1.3.1 Inclusion Criteria: de novo patients  
To be eligible for entry into the extension segment of the study, a de novo patient must meet all of the 
following criteria at the extension segment screening visit: 
1. Capable of providing informed consent 
a. A signed informed consent form must be provided before any study assessments are 
performed 
b. Patients must be fluent in the language that is spoken by the investigator and the study site 
staff (including raters) and must be able to read and understand the words in which the 
informed consent is written 
2. Age ≥ 18 and ≤ 65 years old, inclusive, at screening 
3. On a stable dose of oral risperidone from 4 to 6 mg daily as maintenance therapy for at least the 
last 4 weeks prior/before screening/baseline and would potentially benefit from conversion to an 
extended release injectable, in the opinion of the investigator 
4. Current diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5) criteria that is clinically stable as evidenced by: 
 
No hospitalizations for acute exacerbations of schizophrenia and psychiatrically stable 
without significant symptom exacerbation over the last 3 months before screening based on 
the investigator’s judgment  
 
PANSS total score < 70 at screening 
 
CGI-S score of ≤ 3 (mild) at screening 
5. Has previously had a clinically significant beneficial response (improvement in schizophrenia 
symptoms), as determined by the investigator, to treatment with an antipsychotic medication other 
than clozapine 
6. At least 2 years elapsed since initial onset of active-phase schizophrenia symptoms 
7. Subject is outpatient; not hospitalized for worsening of schizophrenia within the last 3 months 
(hospitalization for social management within this time period is acceptable) 
8. Medically stable over the last month prior to screening based on the investigator’s judgment 
9. BMI of 18.5 to 40.0 kg/m2 (inclusive) at screening 
10. Agrees to discontinue prohibited medications as applicable and as clinically indicated according 
to investigator instructions 
11. Dosages of all permitted medications are considered to have been stable (with the exception of 
medication to be used on an as-needed basis) for ≥ 2 weeks prior to the baseline visit and to 
remain stable during participation in this study 
12. Resides in a stable living situation, in the opinion of the investigator 
13. Has an identified reliable informant, in the opinion of the investigator 
14. Meets the following contraceptive criteria: 
a.  If sexually active, is using a medically accepted contraceptive method, and will continue to 
use such throughout participation in this study (and for ≥ 6 months after the last dose of IM 
study drug has been administered); acceptable methods include the following: 
i.  Condoms (male or female) with or without a spermicidal agent 
ii.  Diaphragm or cervical cap with spermicide 
iii.  Intrauterine device 
iv.  Hormonal contraceptive 
b. If not currently sexually active, then meets the following criteria: 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 37 of 114 
i.  Agrees that if sexual activity resumes while participating in this study, a medically 
accepted contraception method will be used 
15. Agrees not to post any personal medical data related to the study or information related to the 
study on any website or social media site (e.g., Facebook, Twitter, and others) during the study 
duration 
 
4.1.3.2 Exclusion criteria: de novo patients 
An individual who meets any of the following criteria at screening will not be permitted to enroll in 
the study:   
1. History of proven inadequate clinical response to treatment with therapeutic doses (with good 
compliance) of risperidone or paliperidone 
2. History of treatment resistance, defined as failure to respond to 2 discrete adequate trials (≥ 4 
weeks with an adequate dose) of 2 different antipsychotic medications; history of clozapine use 
(exception: use was not because of treatment resistance or refractory psychotic symptoms) 
3. Known or suspected intolerance of or allergy or hypersensitivity to risperidone, paliperidone, or 
any of the excipients in the IM formulations of these 
4. History of neuroleptic malignant syndrome, clinically significant tardive dyskinesia or tardive 
dystonia 
5. History of any other medical condition that is considered to pose any unjustifiable risk or interfere 
with study assessments  
6. Clinically significant extrapyramidal symptoms at screening or baseline 
7. At significant risk of suicidal, homicidal or violent ideation or behavior, by history or as clinically 
assessed by the investigator at screening visit 
8. Answer of “yes” on item 4 or on item 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) 
(ideation) with the most recent episode occurring within the past 2 months, or answer “yes” to any 
of the 5 items (behavior) with an episode occurring within the last year 
9. Current diagnosis or a history of substance use disorder according to DSM-5 criteria within 6 
months prior to the screening visit (with the exception of tobacco, mild cannabis, or mild alcohol 
use disorder) or a positive drug screen test (with the exception of cannabis) verified by repeat 
testing 
10. Lifetime history of diagnosis of schizoaffective disorder or bipolar disorder 
11. Clinically significant comorbid neuropsychiatric disorders including any of the following: 
a.  Current untreated or unstable major depressive disorder 
b.  Clinically significant cognitive difficulties including dementia, delirium, or amnesic 
syndrome, within the past 2 years and would interfere with participation in the study 
c.  Any other psychiatric condition that would, in the judgment of the investigator, interfere with 
participation in the study 
12. Clinically significant or unstable medical illness/condition/disorder that would be anticipated, in 
the investigator’s opinion, to potentially compromise patient safety or adversely affect the 
evaluation of efficacy, including (but not necessarily limited to) the following:  
a.  Clinically significant hypotension or hypertension not stabilized by medical therapy (diastolic 
blood pressure > 105 mmHg) 
b. Unstable thyroid dysfunction in the past 6 months 
c. Malignant tumor within the last 5 years 
d. Neurologic conditions including the following: 
i.  History of seizure disorder or condition associated with seizures 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 38 of 114 
ii.  History of brain tumor, subdural hematoma, or other clinically significant neurological 
condition within the past 12 months 
iii.  Head trauma with loss of consciousness within 12 months before screening 
iv.  Active acute or chronic central nervous system infection 
v.  Stroke within 6 months before screening 
e. Cardiac conditions including the following:  
i. 
Clinically significant cardiac arrhythmia, cardiomyopathy, or cardiac conduction defect 
ii. History of myocardial infarction or unstable angina within the last 3 months before 
screening, or clinically significant abnormality on screening or baseline 
electrocardiogram (ECG) including but not limited to the following: QT interval 
corrected for heart rate using Fridericia’s formula (QTcF) > 465 msec if male or > 485 
msec if female 
13.  Laboratory abnormality that, in the opinion of the investigator, would compromise the well-being 
of the patient, or any of the following laboratory abnormalities at screening or baseline:  
a. Aspartate aminotransferase or alanine aminotransferase value ≥ 2 times the upper limit of the 
laboratory normal reference range 
b. Hemoglobin A1c > 9% 
c. Absolute neutrophil count ≤ 1.5 × 103 μL 
d. Platelet count ≤ 75 × 103 μL 
e. Creatinine clearance < 60 mL/min 
f. Positive test result for human immunodeficiency virus, hepatitis B surface antigen, or 
antihepatitis C virus antibody 
g. Positive pregnancy test result 
h. Urine drug screen at screening or baseline shows a positive result for any of the tested 
substances (potential exceptions: results positive for benzodiazepine may not be exclusionary 
if the investigator confirms that such medication was medically indicated and consults the 
medical monitor before enrolling a patient with such a finding; results positive for THC may 
not be exclusionary in certain cases only if exclusion criterion 9 is not met and only if the 
medical monitor provides approval) 
14. Pregnant, lactating, or breastfeeding 
15. Inadequate gluteal or deltoid musculature or excessive fat, as determined by the investigator, that 
would interfere with IM study drug injections 
16. Any contraindication for IM injections  
17. Receipt of any long-acting antipsychotic medication by IM injection within 60 days before 
screening 
18. Current involuntary hospitalization or incarceration 
19. Hospitalized for more than 30 days during the 90 days before screening 
20. Participation in another clinical study in which the patient received an experimental or 
investigational drug or agent within 6 months before screening 
21. Participation in a clinical study with Risperidone ISM within 12 months before screening 
22. Study site personnel and/or persons employed by the investigator or study site or is an immediate 
family member of such persons 
23. Patients taking or anticipated to require any prohibited concomitant medication (see 
Section 3.2.2.1.1)  

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 39 of 114 
4.2 Patient Withdrawal 
A patient may be withdrawn from the study at any time if the patient, investigator, or sponsor 
determines that it is not in the best interest of the patient to continue.   
Reasons for patient withdrawal may include, but are not limited to, noncompliance, safety, 
development of a medical condition that requires treatment with a prohibited medication, a positive 
result on a pregnancy or urine drug screen test, or patient withdrawal of consent.  In addition, if a 
patient’s condition changes during the course of the study so that he or she no longer satisfies the 
inclusion and exclusion criteria, he or she may be withdrawn.   
If psychiatric hospitalization for worsening, relapse, or exacerbation of schizophrenia symptoms 
occurs during the treatment period at a time point after the patient has been discharged from the 
inpatient study unit, the medical monitor should be contacted to discuss whether early withdrawal of 
that patient from the study may be indicated.   
All efforts should be made to perform an early termination visit for any patient who withdraws or is 
withdrawn from the study, except for patients who withdraw consent.   
If a patient is withdrawn because of an AE or other medical reason, the patient should be followed 
until the AE resolves or is deemed stable by the investigator or until the patient is deemed by the 
investigator to be lost to follow-up.   
If, in the opinion of the investigator, it is clinically indicated to monitor a patient beyond the early 
termination visit, subsequent clinical contacts (in addition to protocol-designated study visits) may be 
extended on an as-needed basis.  In such instances, the medical monitor should be contacted so that 
the sponsor or designee and the investigator can agree to an acceptable clinical follow-up schedule.   
In the event that a patient chooses to withdraw from the study, the investigator should make a 
reasonable effort to ascertain the reason for withdrawal while fully respecting the patient’s rights to 
withdraw.   
The investigator will determine the most appropriate post-study treatment for each withdrawn patient, 
which may include conferring with the patient’s treating psychiatrist. 
The investigator must maintain a record of all patients who withdraw from the study and the reasons 
for discontinuation.  The reason for discontinuation will be documented.  If a patient is lost to follow-
up, a reasonable attempt to contact the patient must be made and documented.   
5 Study Treatment 
The following 3 study drug treatments will be used in the study:  
 
Risperidone ISM 75 mg (Double-Blind and Open-label Segment) 
 
Risperidone ISM 100 mg (Double-Blind and Open-label Segment) 
 
Placebo (Double-Blind Segment only) 
In the double-blind segment of the study, the treatment assignment for each patient will remain 
blinded for patients, investigators, and all study site staff, with the exception of identified individuals 
at each study site who will be unblinded in order to prepare and administer IM study drug for each 
patient at that study site.  In the extension segment of the study, all participating patients will receive 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 40 of 114 
active Risperidone ISM under open-label conditions. However, in order to preserve the blinding 
condition of the double-blind stage of the study, if a participating rollover patient enters this OLE 
phase of the study prior to locking the database of the double-blind stage of the study, the allocation to 
either 75 or 100 mg of this patient will be still blinded at least up to locking the aforementioned 
database. 
5.1 Study Drugs 
5.1.1 
Study Drugs 
Risperidone ISM is the active study drug being evaluated in this study.   
Risperidone ISM is a long-acting formulation of risperidone that uses ISM technology.  Laboratorios 
Farmacéuticos ROVI, S.A. is the manufacturer of Risperidone ISM.  The World Health Organization 
Anatomical Therapeutic Chemical class of risperidone is N05AX08 (other antipsychotics).   
The active moiety of Risperidone ISM is risperidone.   
The following excipients are contained in both, Risperidone ISM and placebo: poly lactic-co-glycolic 
acid (PLGA; copolymer of lactic and glycolic acids) and dimethyl sulfoxide (DMSO).  Risperidone 
ISM and placebo are formulated as a suspension and dissolution for injection, respectively.  
The manner in which Risperidone ISM and placebo study drugs are provided to study sites requires a 
reconstitution procedure to be performed at the study site for each dose to be administered.   
Risperidone ISM/placebo kits will be provided to study sites, and they will be stored refrigerated at a 
temperature between 2ºC and 8ºC.  Each kit includes 2 syringes, 1 of which contains the Risperidone 
ISM study drug (except for placebo) plus PLGA in the form of a solid powder, and the other of which 
contains DMSO solvent.   
Each kit will also contain 2 needles: a 2-inch 20 gauge safety needle and a 1-inch 21 gauge safety 
needle.   
Risperidone ISM study drug kits will be provided for the dose levels of 75 and 100 mg.  
Corresponding placebo study drug will also be provided.  Risperidone ISM and corresponding 
placebo kits will be labelled appropriately.   
5.1.1.1 Justification of Selected Doses 
Results from previously conducted phase I and phase II studies as well as pharmacokinetic modeling 
are considered to support the doses selected for this study (see Section 1).   
5.1.1.2 Oral Test Doses for Risperidone-Naïve Patients 
Patients who have never taken risperidone must have a brief trial of oral risperidone 2 mg/day for 3 
days during the screening period in order to ensure a lack of any hypersensitivity reactions before the 
first dose of IM study drug is administered.   
A trial of oral risperidone is not required or indicated for patients who have previously taken any 
formulation of risperidone. 
Risperidone tablets will be provided by study sponsor to all participating sites for risperidone-naïve 
patients testing. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 41 of 114 
5.1.2 
Preparation and Administration of Study Drug 
At each study site, during the double-blind treatment period (and until the Data Base lock of the 
Double-blind segment), each dose of study drug for each patient will be prepared individually by 1 or 
more identified members of the study site personnel; such designated individuals will be unblinded to 
the study drug identities and assignments to patients.  An unblinded individual will also administer the 
IM injections of study drug to each patient in a manner that maintains the blind.  The designated 
unblinded individuals must be considered appropriately experienced, trained, and qualified to perform 
these critical functions.   
The study days on which administration of double-blind study drug injections are scheduled are study 
day 1, study day 29 (treatment week 4), and study day 57 (treatment week 8). 
An unblinded study staff member will reconstitute the appropriate dosage of the study drug according 
to the instructions provided by the sponsor and will administer the study drug immediately after 
reconstitution.  
For a given patient, each of the IM injections of study drug should be administered at approximately 
the same time of day, if possible.  Generally, at a given study visit, the IM injection of study drug 
should be administered after efficacy evaluations have been performed and after any required blood 
samples (e.g., pharmacokinetic sample), if applicable at the given study visit, have been collected.   
For each injection, the study drug should be injected slowly, deep into the muscle.  Care should be 
taken to avoid inadvertent injection into a blood vessel.  Each individual dose is to be administered in 
a single injection; divided injections are not permitted.   
Generally, serial gluteal injections should be alternated between the 2 gluteal muscles, and serial 
deltoid injections should be alternated between the 2 deltoid muscles.  However, the investigator may 
determine which injection site is most appropriate for a given patient.  
The recommended needle size for administration of study drug into the gluteal muscle for most 
patients is the 2-inch 20 gauge needle.  The injection should be administered into the upper-outer 
quadrant of the gluteal muscle.   
The recommended needle size for administration of study drug into the deltoid muscle is 1-inch 21 
gauge needle.   
Risperidone ISM doses are summarized for each double-blind treatment group by study day in Table 
4. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 42 of 114 
Table 4 
Risperidone ISM Doses by Study Day 
Study Drug Treatment Group 
Study Day 1 
 
Study Day 29 
 
Study Day 57 
Risperidone 75 mg 
75 mg 
 
75 mg 
 
75 mg 
Risperidone 100 mg 
100 mg  
 
100 mg 
 
100 mg  
Placebo 
0 mg 
 
0 mg 
 
0 mg  
ISM = in situ microparticle. 
Note: During the conduct of the study, assignments of double-blind study drug treatments to patients will be under double-
blind conditions and will not be revealed to investigators, study staff (except for specifically identified unblinded individuals 
only), or patients. 
5.2 Study Site Inpatient Unit 
A patient who, after completion of all scheduled assessments on the screening visit day, is considered 
provisionally eligible for participation in the double-blind segment of this study will be admitted 
directly to the inpatient study unit that day.  Patients subsequently will remain on the inpatient study 
unit for the remainder of the screening period (i.e., through study day -1, inclusive).   
All confirmed eligible patients will remain inpatient on study day 1.  No patient should be discharged 
from the inpatient unit before study day 2, and it is anticipated that most patients will remain on the 
inpatient unit through study day 8, and that thereafter patients will be discharged from the inpatient 
unit when the investigator has assessed the patient and determines that he or she is appropriately 
clinically stable and otherwise ready for safe discharge.  After study day 8, continuation of a patient 
on the inpatient unit from study day 9 through study day 15, inclusive, is an allowable option, as 
deemed clinically indicated.  If the investigator believes that a given patient should remain inpatient 
beyond study day 15, the investigator should contact the medical monitor to discuss the proposed 
inpatient duration extension to discuss the extension.   
De novo patients entering the extension segment of the study are not planned to be admitted to the 
inpatient study unit. 
5.3 Treatment Assignment and Blinding 
5.3.1 
Treatment Assignment 
Upon confirmation of eligibility for a given patient to participate in the double-blind segment of the 
study, a unique randomization number for that patient will be assigned via an interactive voice or web 
response system that is to be accessed by study site personnel immediately after confirmation of 
patient eligibility has been recorded.   
The randomization number for a given patient will be used to identify the study drug (i.e., blinded 
Risperidone ISM 75 mg, Risperidone ISM 100 mg, or placebo) that will be administered to that 
patient.   
The randomization scheme will automatically ensure that the study drug assignment for a given 
patient is random and that an overall 1:1:1 ratio of assignments to each of the 3 study drug treatments 
is approximated.   
In addition, the randomization scheme will include the following stratification parameters to ensure 
balanced distribution of assignment to the 3 treatments: country where enrolled and PANSS total 
score (i.e., ≥ 95 versus < 95) at baseline/randomization.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 43 of 114 
An independent biostatistician will maintain the randomization scheme key, which will remain 
unavailable to all other individuals until after study completion and subsequent locking of the study 
database.   
Once a randomization number has been assigned, that number must not be used again for any other 
patient (e.g., when patient is withdrawn from the study, that patient’s randomization number must not 
be reused for any other patient).   
5.3.1.1 Extension Segment of the Study 
In the extension segment of the study, all participating patients will receive active Risperidone ISM 
under open-label conditions.  Patients who had been on active Risperidone ISM in the double-blind 
segment of the study will continue to receive active Risperidone ISM at the same dose (i.e., 75 or 
100 mg) in the extension segment; patients who had been receiving placebo in the double-blind 
segment of the study will be randomly assigned to receive either 75 or 100 mg during the extension 
segment. However, in order to preserve the blinding condition of the double-blind stage of the study, 
if a participating patient enters this OLE phase of the study prior to locking the database of the 
double-blind stage of the study, the allocation to either 75 or 100 mg of this patient will be still 
blinded at least up to locking the aforementioned database.   
De novo patients participating in the extension segment of the study will receive either 75 or 100 mg 
Risperidone ISM depending on their previous oral risperidone dose.  Patients on 4 mg of oral 
risperidone will be assigned to 75 mg Risperidone ISM, and patients on more than 4 mg to a 
maximum of 6 mg of oral risperidone will be assigned to 100 mg Risperidone ISM.  Upon 
confirmation of eligibility for a given de novo patient, the corresponding IMP kit will be assigned via 
an interactive voice or web response system that is to be accessed by study site personnel immediately 
after confirmation of patient eligibility has been recorded. 
5.3.2 
Blinding 
During the double-blind segment of the study, the IM study drug will be administered under double-
blind conditions so that investigators, site staff, and patients will not be aware about the identity of the 
study drug (i.e., blinded Risperidone ISM 75 mg, Risperidone ISM 100 mg, or placebo) administered 
to any given patient.   
The packaging and labelling for placebo or Risperidone ISM 75 or 100 mg will be identical during the 
whole study in order to keep the blinding.  The placebo and Risperidone ISM doses are practically 
indistinguishable before or after reconstitution.  Reconstitution follows same process for placebo or 
Risperidone ISM.  Any small differences in final volumes are not perceptible.  For de novo patients, 
the corresponding IMP kit will be assigned via an interactive voice or web response system based on 
the above described criteria (see Section 5.3.1.1) so that both investigator and patient can know the 
treatment administered, consistent with the open-label definition of this segment of the study. 
Nevertheless, the management of the study drug will be performed by different study personnel (see 
Section 5.4).  Only designated unblinded individuals at sites will be dealing with the study drug 
reconstitution and administration of the study drug to the patient, and will not be involved in any 
clinical evaluation.  These individuals will be appropriately qualified and trained to perform the 
required study drug reconstitution and study drug administration to patients.   
Oral risperidone test doses, if applicable for a given patient, will be administered under open-label 
conditions.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 44 of 114 
5.3.2.1 Breaking the Blind 
If an investigator deems it necessary to break the treatment assignment blind, he or she should 
promptly document and explain to the medical monitor or designee reason of the unblinding (e.g., 
accidental unblinding, unblinding due to an SAE) of study drug.   
Once it has been determined that breaking the blind is necessary, the investigator or other designated 
study site staff member will contact the interactive voice or web response system to obtain disclosure 
of the identified patient’s treatment assignment.   
Breaking the blind for a single patient will not affect the blind for the remaining patients.   
5.3.2.2 Extension Segment of the Study 
All patients who participate in the optional extension segment of the study will receive active 
Risperidone ISM (i.e., 75 or 100 mg; see Section 5.3.1.1) under open-label conditions.  However, in 
order to preserve the blinding condition of the double-blind stage of the study, if a participating 
rollover patient enters this OLE phase of the study prior to locking the database of the double-blind 
stage of the study, the allocation to either 75 or 100 mg of this patient will be still blinded at least up 
to locking the aforementioned database.  For de novo patients, the corresponding IMP kit will be 
assigned via interactive voice or web response system based on the above described criteria (=4 mg or 
>4 to 6 mg oral risperidonesee Section 5.3.1.1) so that both investigator and patient can know the 
treatment administered, consistent with the open-label definition of this segment of the study. 
 
5.4 Study Drug Accountability, Adherence, Handling, and Disposal 
The clinical site is required to maintain current drug dispensation and accountability logs throughout 
the study for study drug. 
The study drug injections will be reconstituted and administered directly by appropriately qualified 
and trained unblinded study site personnel until the Data Base lock of the Double-blind segment.  The 
date and time of each study drug administration will be recorded for each patient and as such will 
serve to document adherence.   
Unused supplies will be checked against study drug records periodically throughout the study.   
After completion and verification of accountability logs by the study monitor, all remaining study 
drug must be destroyed.  Packages may be destroyed on site according to Good Clinical Practice 
(GCP) and site practice; alternatively, the sponsor may arrange for destruction with a third-party 
vendor operating in accordance with GCP.   
The same procedure applies to risperidone tablets provided for risperidone-naïve patients testing, as 
applicable. 
6 Procedures 
The overall schedules of assessments and procedures by visit are displayed in Table 1, Table 2, and 
Table 3. 
A by-visit list of assessments and procedures is provided in Appendix A.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 45 of 114 
6.1 General 
6.1.1 
Informed Consent 
During the screening visit, the nature of the study and anticipated risks and benefits of participation 
will be explained to the patient by the investigator or designated study personnel.  Each patient will 
receive an informed consent form that summarizes pertinent study information and will be given 
ample time to read it and to ask questions about the study.  If a patient chooses to participate, the 
patient must sign the informed consent form before any study-specific procedures are conducted (see 
Section 10.3).   
Screen Failure patients (applicable for patients entering the double-blind segment and de novo 
patients entering the extension segment) can be considered to be allowed for Re-Screening purposes 
as long as they have previously been discussed between the Principal Investigator and the Medical 
Monitor. More than 14 days, from the initial ICF signature, should be elapsed and all the procedures 
required (except the Ophthalmological examination, if this is not the reason of the re-screening), 
including the signature of a new ICF, should be repeated within the established screening period. In 
these specific cases a new ID number will be assigned.   
6.1.2 
Demographics, Medical History, and Psychiatric History 
To determine eligibility during screening, the patient’s demographic data, medical history, and 
psychiatric history will be reviewed and documented.  At later visits, each patient’s medical and 
psychiatric history since the prior visit will be reviewed and any significant change will be recorded in 
the source documents and electronic case report form (eCRF) as an AE as appropriate.   
6.1.3 
Concomitant Medication Review 
At screening, patients will be asked about all medications they have taken in the last 30 days, 
including prescription and nonprescription medications, vitamins, and supplements.   
Patients will also be asked about any long-acting injectable antipsychotic medications taken in the last 
60 days (see inclusion criterion 6 in Section 4.1.1.1, exclusion criterion 17 in Section 4.1.1.2, 
inclusion criterion 5 in Section 4.1.3.1, and exclusion criterion 17 in Section 4.1.3.2) as well as any 
past use of risperidone (see exclusion criteria 1 and 4 in Section 4.1.1.2, and exclusion criteria 1 and 3 
in Section 4.1.3.2).  Patients will also be asked about any history of failure to respond to adequate 
trials of antipsychotic medications, as well as about any history of clozapine use (see exclusion 
criterion 2 in Section 4.1.1.2 and Section 4.1.3.2).  The investigator will record in the eCRF the use of 
all medications taken in a period of 30 days prior to the trial, and the use of any long-acting injectable 
antipsychotic medications taken in the period of 60 days prior to the trial. 
At each subsequent visit, enrolled patients will be asked about use of concomitant medications since 
the previous visit.  Any new medications or changes in previously recorded medications will be 
documented.  The investigator will record the following data on all medications used by the patient: 
medication name, dose, regimen, route of administration, start and stop dates, and the indication for 
use.   
6.1.4 
MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic 
Disorders Studies 
The MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders 
studies, version 7.0.2 (see Appendix C) will be completed at the screening visit to verify 
schizophrenia and any other psychiatric diagnoses according to the DSM-5 (see inclusion criterion 4 
and exclusion criterion 9 in Section 4.1.1 and Section 4.1.3).   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 46 of 114 
6.2 Efficacy Assessments 
6.2.1 
Positive and Negative Syndrome Scale and Clinician Global Impression 
Efficacy assessments will include the PANSS, CGI-S, and Clinical Global Impression – Improvement 
(CGI-I).  The PANSS, CGI-S, and CGI-I are performed at scheduled time points throughout the 
treatment period as indicated in Table 1, Table 2 and Table 3.   
The investigator or qualified designee will complete these scale ratings.   
The PANSS total score is defined as the sum of scores on the PANSS positive, negative, and general 
psychopathology subscales.  The PANSS results will be used for the primary efficacy variable 
(Section 6.7.1.1) as well as secondary variables (Section 6.7.1.2).   
6.3 Health Economics and Outcomes Research Assessments 
6.3.1 
Healthcare Resource Utilization 
Healthcare resource utilization data will be collected in 2 ways: site-based reporting and patient-based 
(or informant-based) reporting. Study site staff will retrospectively record any HRU that occurred 
within the clinical trial center into the applicable forms of the eCRF.  Detailed resource use in 
following categories is collected: medication, emergency visits, inpatient services, outpatient services 
(specialist consultations and other outpatient hospital care contacts), and therapy.  During the double-
blind phase, clinician-reported data will be recorded once at 3 months (see Table 1).  During the open-
label extension, data will be recorded every 6 months for a total of 2 measurement points (see Table 2 
and Table 3). 
Study site staff will administer a survey to patients (or their informant) to report any HRU that 
occurred outside the clinical trial center.  The patient survey will be administered at the clinical trial 
center by designated study site staff (paper and pencil).  The information will subsequently be 
recorded into the applicable forms of the eCRF.  Detailed resource use in the following categories is 
collected: medication, emergency visits, inpatient services, outpatient services, therapy, community-
based day services, primary and community care contacts, criminal justice services, and days absent 
from work due to illness.  During the double-blind phase, patient- (or informant)-reported data will be 
administered every month for a total of 3 measurement points (see Table 1).  During the open-label 
extension, the survey will be administered every month for a total of 12 measurement points (see 
Table 2 and Table 3). 
Clinician-reported and patient- (or informant)-reported HRU will be combined for analysis.  For each 
item, total quantity of resources used will be calculated as the sum of resources both within and 
outside the participating center during the double-blind and open-label extension phases, respectively.  
This will define the secondary HRU variables (Section 6.7.2).  
6.3.2 
Health-Related Quality of Life 
Health-related Quality of Life will be assessed by the patient-completed 20-item Subjective Well-
Being Under Neuroleptics Treatment Scale (SWN-20).  The SWN is a 38-item instrument developed 
to measure subjective effects of neuroleptic medications in patients with schizophrenia and consists of 
20 positive statements and 18 negative statements.11  The short form of the SWN, the 20-item SWN-
20, was developed in order to allow for quick assessment of subjective side effects in a clinical 
setting.12  Like in the original SWN, with the SWN-20 the patient is asked to rate well-being items 
that have been identified as related to antipsychotic treatment on a 6-point scale ranging from “Not at 
all” to “Very much.”  The SWN-20 is scored on a scale ranging from 20 to 120, with higher scores 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 47 of 114 
indicating better HRQL.  The SWN-20 contains five 4-item subscales: mental functioning, self-
control, emotional regulation, physical functioning, and social integration.  Each subscale score 
ranges from 4 to 24, with higher scores indicating better HRQL.  The SWN-20 will be performed at 
scheduled time points throughout the treatment period as indicated in Table 1, Table 2 and Table 3.  
The baseline administration of the SWN-20 should occur prior to the administration of the medication 
dose on study day 1 (double blind segment) or extension study day 1 (de novo patients in the 
extension segment). 
6.3.3 
Social Functioning 
Social functioning will be assessed by the clinician-administered Personal and Social Performance 
Scale (PSP).  The PSP is a 100-point single-item rating scale that is based on 4 areas: family and 
social functioning, self-care, work and socially useful activities, and disturbing and aggressive 
behaviors.13  Higher scores indicate better social functioning.  The PSP will be administered by a 
trained clinician, either the study investigator or a qualified designee.  The PSP will be performed at 
scheduled time points throughout the treatment period as indicated in Table 1, Table 2 and Table 3.  
The baseline administration of the PSP should occur prior to the administration of the medication dose 
on study day 1 (double blind segment) or extension study day 1 (de novo patients in the extension 
segment). 
6.4 Safety Assessments 
Safety assessments will include AEs, vital signs (blood pressure, pulse rate, respiratory rate, and body 
temperature), weight, body mass index, laboratory tests (i.e., hematology, chemistry [including 
prolactin], urinalysis, urine drug screen), ECGs, physical examinations, injection site reactions, and 
selected safety scales.  Safety scales will include the C-SSRS and the following 3 scales to assess 
extrapyramidal symptoms: the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia 
Rating Scale (BARS), and the Simpson-Angus Scale (SAS).   
6.4.1 
Physical Examination, Body Height, Weight 
A physical examination will be performed at time points identified in Table 1, Table 2 and Table 3.  
The physical examination will include assessment of the following: general appearance, skin, 
lymphatic, eyes, ears, nose, throat, neck, respiratory, cardiovascular, gastrointestinal, musculoskeletal, 
and neurological.   
Body height (cm) will be measured at screening only.  Body weight (kg) will be measured at time 
points identified in Table 1, Table 2 and Table 3. 
The body mass index value at each of these time points will be calculated; the body mass index value 
must be within the range of 18.5 to 40.0 kg/m2, inclusive, at screening.   
6.4.2 
Ophthalmological Examination 
The Risperidone ISM formulation is composed of risperidone and 2 excipients: PLGA and DMSO.  
Although DMSO is widely used in the pharmaceutical product formulations for topical, subcutaneous, 
and intravenous dosage forms and during pharmaceutical manufacturing processes, there have been 
published reports of toxicity to the eyes in animals treated with DMSO, including crystalline lens 
opacity.  Therefore, an ophthalmological examination of study patients is required.  All efforts should 
be made to have both examinations performed by the same ophthalmologist in order to get consistent 
data. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 48 of 114 
An ophthalmological examination will be performed at any time during the screening period of the 
double-blind segment of the study, and the result must be available by study day -1.  This examination 
needs to be done again at visit 14 or at an early termination visit during the Double-blind period.     
Ophthalmological examination includes best corrected visual acuity, visual field, intraocular pressure 
(IOP) measurements, and slit-lamp biomicroscopy examination of the eyelids, conjunctiva, iris, 
crystalline lens, sclera, and cornea.  
Slit-lamp examination must be performed prior to IOP measurements or instillation of the fluorescein 
agent. 
6.4.2.1 Best Corrected Visual Acuity Testing 
A standard procedure is to be used to obtain best corrected visual acuity measurements.  This activity 
may be performed by an optometrist, ophthalmologist, or certified ophthalmic technician. 
6.4.2.2. Slit-Lamp Examination (Biomicroscopy) 
A slit-lamp examination of the eyelids, conjunctiva, iris, crystalline lens, sclera, and cornea will be 
performed without pupil dilation (unless needed).  Any abnormalities will be graded as mild, 
moderate, or severe.  Any abnormality found during the slit-lamp examination should be noted. 
Presence of cataract (absent, mild, moderate, severe), aphakia, or intraocular lens (anterior chamber 
intraocular lens, posterior chamber intraocular lens, or iris clip) and status of the posterior lens capsule 
(intact, open, or absent) should be specified. Slit-lamp examination should precede IOP measurement.  
6.4.2.3. Intraocular Pressure  
The IOP will be measured by a routinely used applanation tonometer.  Study sites should calibrate the 
applanation tonometer according to the manufacturer’s instructions.  The IOP in both eyes will be 
measured, with the right eye preceding the left eye. If it is a routine practice at the site, a non-contact 
air-puff tonometry can also be used. 
6.4.2.4. Visual Fields 
The visual field will be examined using a standard procedure at the site.  The recommended visual 
fields examination is automated perimetry including Humphrey (24-2 full threshold, 24-2 SITA 
standard, 30-2 central threshold, [Note: 24-2 SITA fast not allowed]) and Octopus (GI dynamic 
strategy, GI normal strategy, 24-2 dynamic strategy, 24-2 normal strategy) perimetry.  
If this procedure was performed within the past 90 days and documented in the patient’s medical 
record, this procedure need not be repeated (unless the investigator suspects a change).  This may be 
performed by a trained certified ophthalmic assistant, certified ophthalmic technician, nurse, or 
research coordinator. 
6.4.3 
Vital Signs 
Vital signs will include blood pressure, pulse rate, respiratory rate, and body temperature.   
Vital signs will be measured at time points identified in Table 1, Table 2 and Table 3. 
At each of these time points, vital signs will be measured after the patient has been resting in a supine 
position for at least 5 minutes.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 49 of 114 
On days when patients receive IM injections of study drug, vital signs are to be measured within 1 
hour before and then again within 3 hours after the study drug injection; at each of these time points, 
orthostatic blood pressure and pulse rate will be measured (immediately after completion of supine 
vital sign measurements) after the patient has risen from the supine to the standing position and has 
remained standing for approximately 3 minutes.   
Efforts should be made to take all blood pressure and pulse rate measurements from the same arm 
(preferably the patient’s dominant arm) throughout the study.  The same blood pressure cuff should be 
used to measure blood pressure each time.  Automated measurement is preferred, but if measurements 
are performed manually, pulse rate will be measured in the brachial artery for at least 30 seconds.   
6.4.4 
Electrocardiogram 
A 12-lead ECG will be performed at the study visits identified in Table 1, Table 2 and Table 3. 
On days when patients receive injections of IM study drug, an ECG will be performed both within 1 
hour before dosing and within 3 hours post-dose.   
All scheduled ECGs must be performed after the patient has rested quietly for at least 5 minutes in the 
supine position.   
Absolute values for QT intervals should be automatically corrected for heart rate by the ECG machine 
using both Bazett’s fomula (QTcB) and Fridericia’s formula (QTcF).   
The ECGs will be evaluated by a central reader.  Additional details regarding recording and 
evaluation of ECGs will be described in a manual provided to the study site.   
6.4.5 
Laboratory Assessments 
Blood and urine samples for laboratory assessments will be collected at screening and at time points 
identified in in Table 1, Table 2 and Table 3. 
Samples will be collected in accordance with the study site’s usual procedures and analyzed by a 
central laboratory.   
In the event of abnormal laboratory test values, follow-up samples may be obtained for repeat testing 
if deemed clinically indicated by the investigator.   
Each out-of-range laboratory value will be assessed by the investigator as either clinically significant 
or not clinically significant.  Clinically significant values should be considered AEs and recorded as 
such.   
Additional details regarding laboratory sample collection and processing will be described in a 
manual provided to the study site.   
6.4.5.1 Hematology  
The hematology panel includes the following tests:  
 
Hematocrit, hemoglobin, red blood cell count, white blood cell count and differential count 
(absolute values for basophils, eosinophils, lymphocytes, monocytes, and neutrophils), and 
platelets 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 50 of 114 
6.4.5.2 Chemistry  
The chemistry panel includes the following tests:  
 
Sodium, potassium, glucose, creatinine, creatinine clearance [Estimated Glomerular Filtration 
Rate (eGFR) using Modification of Diet in Renal Disease (MDRD) formula], total protein, blood 
urea nitrogen, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase, lactic 
dehydrogenase, gamma-glutamyl transferase, alkaline phosphatase, and creatine phosphokinase 
 
Prolactin (see Section 6.4.9.3) 
 
Hemoglobin A1c  
 
Thyroid-stimulating hormone 
 
Lipid panel: low-density lipoprotein, high-density lipoprotein, total cholesterol, and triglycerides 
6.4.5.3 Urinalysis  
The urinalysis includes the following tests:  
 
Color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, and occult 
blood 
 
Microscopic examination only if urinalysis dipstick results are abnormal 
6.4.5.4 Other Laboratory Tests 
6.4.5.4.1 
Serology 
A blood sample for a serology panel testing for hepatitis B surface antigen, antihepatitis C antibodies, 
and human immunodeficiency virus will be performed at screening only.   
6.4.5.4.2 
Pregnancy Testing 
A serum pregnancy test will be performed for all women at screening.  Results must be negative for 
initial study eligibility.  Urine pregnancy test (dipstick) will be performed on site for all women at 
baseline and subsequently at time points identified in Table 1, Table 2 and Table 3. Results at baseline 
must be negative for initial study eligibility.   
Results must be negative for continued participation.  On each IM study drug dosing day, the urine 
pregnancy test must be performed and a negative result confirmed before the scheduled dose of study 
drug for that day is administered.   
A serum pregnancy test is not required during the open-label extension stage but may be performed.  
The investigator may order a serum pregnancy test at any time according to her or his judgment. 
6.4.5.4.3 
Drug Screening 
A urine drug screen for prohibited substances will be performed at time points identified in Table 1 
and Table 3 (mandatory at screening and baseline) and on as-needed basis as indicated in Table 1, 
Table 2 and Table 3.  The urine drug screen will include identification of the presence or absence of 
amphetamines, barbiturates, cocaine, methadone, opioids, and phencyclidine, as well as for THC, 
alcohol, and benzodiazepines.   
 Urine drug screen will be performed at each scheduled timepoint and the collected sample will be 
sent to the central laboratory for analysis. In addition, onsite dipstick urine drug screen testing may be 
optionally performed on the sample collected. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 51 of 114 
Results at screening or baseline indicating the presence of a prohibited substance will exclude a 
patient from further participation in the study (see Section 3.2.2.1.1.4 and exclusion criterion 13.h in 
Section 4.1.1.2 and Section 4.1.3.2).   
If a patient has a positive result for benzodiazepines, the investigator should determine if 
benzodiazepine use was medically indicated; a positive benzodiazepine result may not be 
exclusionary if the investigator determines that the benzodiazepine use is clinically appropriate and is 
not indicative of abuse (see Section 4.1.1.2 and Section 4.1.3.2).   
A positive result for THC and/or alcohol generally is to be considered exclusionary; however, such a 
finding may not necessarily be exclusionary in certain cases only if exclusion criterion 9 is not met 
and only if the medical monitor provides approval.   
6.4.6 
Injection Site Reactions 
Approximately 1 hour after an injection, the investigator will inspect the injection site where the study 
drug has been administered for redness, swelling, and induration.  The investigator will also observe 
all injection sites where IM study drug has been injected on previous visits.  At the same time 
(approximately 1 hour after injection), the study patient will perform and record self-assessment of 
pain at the injection site using a visual analog ccale (VAS; see Appendix D).  If clinically significant, 
the injection site reaction will be recorded as an AE and the nature, duration, intensity, and 
relationship to the study drug will be recorded. 
Any injection site reaction that occurs outside the schedule established in Table 1, Table 2 and 
Table 3 will be recorded as AE. 
6.4.7 
Extrapyramidal Symptoms Rating Scales 
Extrapyramidal symptoms rating scales will include the AIMS, BARS, and SAS.  The investigator or 
designee will complete the set of abnormal movement rating scales at time points identified in Table 
1, Table 2 and Table 3.  Clinically significant changes from baseline in extrapyramidal symptoms are 
to be recorded as AEs.   
6.4.8 
Columbia-Suicide Severity Rating Scale 
The investigator or designee will complete the C-SSRS at time points identified in Table 1, Table 2 
and Table 3.   
At screening, the baseline version will be administered.  At subsequent visits, the since-last-visit 
version will be administered.   
The C-SSRS results for each patient should be reviewed by the investigator at each applicable visit.  If 
at any time the C-SSRS results for a given patient reveal potential suicidality, the investigator should 
assess the clinical significance of such results.  If a clinically significant risk of suicidality is identified 
for a patient, the investigator should consider further clinical evaluation of that patient and 
implementation of appropriate clinical measures as deemed indicated to help ensure patient safety.   
Clinically significant changes from baseline in the level of suicidality are to be recorded as AEs.   
6.4.9 
Adverse Events 
An AE is any symptom, physical sign, syndrome, or disease that either emerges during the study 
(from the informed consent form signature) or, if present at screening, worsens during the study, 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 52 of 114 
regardless of the suspected cause of the event.  All medical and psychiatric conditions (except those 
related to the indication under study) that are present at screening will be documented on the 
appropriate page of the eCRF.  Changes in these conditions and new symptoms, physical signs, 
syndromes, or diseases are to be noted on the source documents and the AE page of the eCRF during 
the rest of the study.  Clinically significant laboratory abnormalities are also to be recorded as AEs.   
Collection of AE data will begin after a patient signs the informed consent form and will continue 
until completion of the final follow-up visit.  Any AE having an onset after the final safety follow-up 
visit will not be collected or reported unless the investigator feels that the event may be related to the 
IM study drug.   
Adverse events may be volunteered spontaneously by the patient, discovered as a result of general 
questioning by the study staff, or determined by physical examination.  At each study visit, the patient 
will be asked the open-ended question, “Have you experienced any health problems since your last 
visit?”  All AEs will be recorded on the source documents and the eCRF.  For all AEs, the 
investigator must pursue and obtain information that is adequate both to determine the outcome of the 
AE and to assess whether it meets the criteria for classification as an SAE requiring immediate 
notification.  If the AE persists, follow-up even after the date of therapy discontinuation is required 
until the event resolves or stabilizes at a level acceptable to the investigator.  Patients will be 
instructed to contact the investigator at any time after randomization if any symptoms develop.  
In order to avoid vague, ambiguous, or colloquial expressions, all AEs should be recorded in standard 
medical terminology rather than in the patient’s own words.  Each AE will also be described in terms 
of duration, frequency, intensity, association with the study drug, assessment of possible causes, 
actions taken, and outcome, using choices given on the eCRF.  Specific guidelines for classifying AEs 
by intensity and by relationship to study drug are given below:  
Classification of Adverse Events by Intensity 
The severity (or intensity) of an AE refers to the extent to which it affects the patient’s daily activities 
and will be classified as mild, moderate, or severe using the following criteria: 
 
Mild: An event that is easily tolerated by the patient, causing minimal discomfort and not 
interfering with everyday activities 
 
Moderate: An event that is sufficiently discomforting to interfere with normal everyday activities 
 
Severe: An event that prevents normal everyday activities 
When changes in the intensity of an AE occur within a day, the maximum intensity for that day 
should be noted.  If the intensity category changes over a number of days, those changes should be 
recorded separately (with distinct onset dates).   
Classification of Adverse Events by Relationship to Study Drug  
The investigator’s assessment of an AE’s relationship to study drug is part of the documentation 
process but is not a factor in determining what is or is not reported in the study. 
The investigator will assess causality (i.e., whether there is a reasonable possibility that the study drug 
caused the event) for all AEs and SAEs.  The relationship will be characterized using the following 
classification: 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 53 of 114 
 
Suspected: The temporal relationship of the AE with the investigational medicinal product makes 
causality possible, and the AE cannot be due to another cause such as other drugs, a surgical 
intervention, or an underlying disease 
 
Not suspected: The temporal relationship of the AE with the investigational medicinal product 
makes causality improbable, and the AE may be due to another cause such as other drugs, surgical 
intervention, or underlying disease 
6.4.9.1 Serious Adverse Events 
An SAE is defined as any AE that meets 1 or more of the following criteria:  
 
The event is fatal or life threatening 
 
The event is permanently disabling (incapacitating or interfering with the ability to resume usual 
life patterns) 
 
The event results in unplanned inpatient hospitalization or prolongation of existing hospitalization 
 
The event is a congenital anomaly 
 
The event requires medical intervention of any kind in order to prevent any of the aforementioned 
outcomes 
Important medical events that may not result in death, be life threatening, or require hospitalization 
may be considered serious when, based upon appropriate medical judgment, they may jeopardize the 
patient and may require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse. 
An AE is considered “life threatening” if, in the view of either the investigator or sponsor, its 
occurrence places the patient at immediate risk of death. It does not include an AE that, had it 
occurred in a more severe form, might have caused death. 
An SAE is not necessarily severe; for example, an overnight hospitalization for a diagnostic procedure 
must be reported as an SAE even though the occurrence is not medically serious.  By the same token, 
a severe AE is not necessarily serious: nausea of several hours’ duration may be rated as severe but 
may not be considered serious.   
Protocol-allowed psychiatric inpatient stays (e.g., during the screening period and for up to 2 weeks 
during the first part [administration] of the treatment period or longer if needed) will not be reported 
as AEs.  Subsequent hospitalizations will be recorded and tracked as SAEs.   
6.4.9.2 Reporting Adverse Events  
The investigator is responsible for recording all AEs that are observed or reported during the study, 
regardless of their relationship to study drug or their clinical significance.  If there is any doubt as to 
whether a clinical observation is an AE, the event should be recorded. 
All AEs, regardless of causality and severity, occurring during the conduct of the clinical trial whether 
observed by the investigator or spontaneously reported by the patient or in response to an open-ended 
question about any medical problems since the last visit, must be recorded in the source document and 
in the relevant section of the eCRF.  Adverse events will be recorded from informed consent signature 
until completion of the final follow-up visit. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 54 of 114 
Any SAE due to any cause, whether or not related to the study drug, must be reported within 24 
hours of occurrence or when the investigator becomes aware of the event.  The investigator must 
send a preliminary report of the SAE to the ROVI Pharmacovigilance Department by fax/email within 
24 hours (see Appendix F), using an SAE Report Form.   
ROVI Pharmacovigilance Department 
Phone: +34 917617561/+34 911863678 
Fax: +34 912444421 
Email: farmacovigilancia@rovi.es 
The event must also be recorded on the standard AE eCRF page.  Preliminary reports of SAEs must 
be followed by detailed descriptions, including legible photocopies of hospital case reports, consultant 
reports, autopsy reports, and other documents when requested and applicable.  The SAE reports must 
be made whether or not the investigator considers the event to be related to the study drug. 
Appropriate remedial measures should be taken to treat the SAE, and the response should be recorded. 
Patients must be closely followed until sufficient information is obtained to indicate a return to normal 
status or until the event stabilizes at a level acceptable to the investigator.  
Clinical, laboratory, and diagnostic measures should be employed as needed in order to determine the 
etiology of the event.  For this purpose, additional blood samples (as needed) will be collected and 
analyzed whenever an SAE is identified until the event stabilizes at a level acceptable to the 
investigator.  The results must be reported promptly to the sponsor. 
During the double-blind part of the study and until Data Base lock (of the double-blind part), this 
process must be conducted in a manner that maintains blinding of study drug assignment.   
As information is available, a pregnancy diagnosed during a patient’s active participation in the study 
(and any voluntarily provided notice of a pregnancy that is received within 6 months after a patient’s 
last dose of study drug) as patients staff that is will be reported immediately to the sponsor or 
designee, including pregnancy in female partners of male patients.  The pregnancy may be followed to 
term and/or outcome, and this outcome may be reported to the sponsor.  Pregnancy, in and of itself, is 
not regarded as an AE or SAE unless the birth results in a congenital anomaly/birth defect or there is 
suspicion that the study drug may have interfered with the effectiveness of a contraceptive medication 
or method.   
6.4.9.3 Other Significant Adverse Events 
To ensure patient safety, the investigator should also notify the safety coordinator or medical monitor 
should any AE occur that is considered significant but does not meet the criteria for an SAE or that is 
considered unexpected.  An unexpected AE is an AE that is not identified in nature, intensity, or 
frequency in the reference safety information of the investigator brochure.  In addition, any field 
monitor who notes a significant AE or medical condition while reviewing eCRFs or source documents 
at the study site must immediately convey this information to the medical monitor.   
An increase in prolactin plasma levels should be considered an AE when any of the following criteria 
are present:  
 
Values above 1000 mIU/L for 3 consecutive determinations after randomization, although no 
clinical symptoms are present 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 55 of 114 
 
Values above 530 mIU/L if clinical symptoms of hyperprolactinemia are present (e.g., headache, 
decreased libido, oligo-amenorrhea) 
However, where patients have prolactin concentrations above the upper limit of normal at screening, 
the following criteria could be used by the investigator as a guideline:  
 
For patients at screening with prolactin blood levels above the normal limit, an increase of 
prolactin from baseline (day 1, pre-dose) values is recommended to be considered as an AE when 
the patient presents 3 consecutive determinations with a prolactin value above 1000 mIU/L, if the 
increase is > 20% even though no other clinical symptoms are associated 
 
For patients at screening with prolactin blood levels above 1000 mIU/L, it is recommended to 
consider it as an AE when there is an increase > 20% of the baseline (day 1, pre-dose) level in 3 
consecutive determinations even though no other clinical symptoms are associated 
As a general rule, it should be considered that the “hyperprolactinemia” event has finished the day 
when a prolactin value lower to 1000 mIU/L is obtained, or when levels return to the basal value for 
patients with prolactin concentrations above the upper normal limit at screening.   
 
The day and time of the determination should be recorded in the eCRF.  It has to be noted that 
same date could be registered as the end of hyperprolactinemia for 1 event (AE #1) and the start 
of another hyperprolactinemia for another event (AE #2).  As an example: if the day when 4 
prolactin determinations are made matches that in the first determination the hyperprolactinemia 
has finished (AE #1) but after the injection of Risperidone ISM, a new event of 
hyperprolactinemia (AE #2) is considered as started (as per protocol), and that date should be 
registered as the date of the end of AE #1 and start date of AE #2.  The times of finalization and 
starting of both events should be recorded.   
To this end, the date of the third abnormal determination will be considered as the start date of the 
AE.   
Those patients with values out of range that are considered an AE will be monitored either until the 
values do not fulfill the aforementioned AE criteria or stabilize at a level acceptable to the 
investigator.   
6.5 Pharmacokinetic Sample Collection 
During the double-blind segment of the study, pharmacokinetic samples will be collected from all 
patients participating in the study in a manner that maintains the double-blind with respect to patient 
treatment assignment.  All patients will have pharmacokinetic samples collected on days 1, 3, 29, 31, 
57, 59, and 85 (visits 2, 3, 8, 9, 11, 12, and 14, respectively).  Additionally, 75 patients irrespective of 
randomized treatment will be selected to have additional sampling on days 8, 15, and 22 (visits 5, 6, 
and 7, respectively).  In addition, pharmacokinetic samples will be collected at the time of an SAE.   
In order to maintain study drug blinding, at the selected study sites, pharmacokinetic samples will be 
collected from all enrolled patients (regardless of treatment assignment); however, only samples from 
patients receiving active Risperidone ISM will be analyzed.   
A blood sample (approximately 4 mL each) for measurement of concentration in plasma of 
risperidone and its active metabolite (9-OH-risperidone) will be obtained at time points shown in 
Table 1.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 56 of 114 
These pharmacokinetic samples will be obtained before administration of study drug as applicable 
(i.e., on study days when pharmacokinetic samples and study drug administration both occur).  
Pharmacokinetic blood samples will be processed at the study site (e.g., centrifugation, separation of 
plasma, and freezing) according to instructions that will be provided to the study site in a manual.  
Contact information and sample handling and shipment instructions will be described in the manual.   
Pharmacokinetic samples from patients receiving active Risperidone ISM will be analyzed by a 
central laboratory; however, the samples from patients receiving placebo will not be analyzed (they 
are collected nevertheless in order to maintain the double-blind).  The process for this selective 
pharmacokinetic analysis will be performed in a manner than maintains the double-blind with respect 
to patient treatment assignment.   
6.6 Genotype Sample Collection 
Genotype samples will be collected from all patients who will sign the appropriate consent in the 
double-blind segment of the study.   
A separate informed consent form for participation genotype sample collection must be signed before 
any blood samples for genotype assessment sample are collected for a given patient.   
A single blood sample will be collected from each patient for evaluation of genotypes for cytochrome 
P450 enzymes and/or genes considered potentially related to response.  The blood sample for 
genotype testing may be collected at any time point after randomization during the Double-blind 
period.   
6.7 Outcome Variables 
6.7.1 
Efficacy Variables 
Efficacy variables are listed within this section.  In this context, endpoint is defined as study day 85 or 
the last post-baseline double-blind assessment.   
6.7.1.1 Primary Efficacy Variable 
The primary efficacy variable is the following:  
 
PANSS total score mean change from baseline to endpoint  
6.7.1.2 Secondary Efficacy Variables 
6.7.1.2.1 
Key Secondary Efficacy Variable 
The key secondary efficacy variable is the following:  
 
CGI-S score mean change from baseline to endpoint 
6.7.1.2.2 
Other Secondary Efficacy Variables 
Other secondary efficacy variables include the following:  
 
CGI-I score mean at endpoint 
 
Overall response rate at endpoint 
o Overall response is defined as either of the following:  
 
PANSS total score ≥ 30% decrease (improvement of symptoms) from baseline to 
endpoint 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 57 of 114 
 
CGI-I score of 2 (much improved) or 1 (very much improved) at endpoint 
 
PANSS response rate at endpoint 
o PANSS response is defined as the following:  
 
PANSS total score ≥ 30% decrease (improvement of symptoms) from baseline at 
endpoint 
 
Time to reach PANSS response 
 
PANSS total score mean change from baseline at each post-baseline assessment time point 
 
PANSS subscale score mean change from baseline at endpoint and at each post-baseline 
assessment time point for each of the positive, negative, and general psychopathology subscales 
 
Overall response rate at each post-baseline assessment time point 
 
Time to reach overall response 
 
PANSS response rate at each post-baseline assessment time point 
 
CGI-S score mean change from baseline at each post-baseline assessment time point 
 
CGI-I score mean at each post-baseline assessment time point 
6.7.2 
Health Economics and Outcomes Research Variables 
Health economics and outcomes research variables are listed within this section.  In this context, 
endpoint is defined as study day 85 or the last post-baseline double-blind assessment.   
 
HRU and cost variables include the following: 
o For each item, total quantity of resources used within and outside the participating center at 
endpoint.  For each item, mean number at endpoint and rate of use per 3 months will be 
calculated 
o By-resource use category (e.g., inpatient services, outpatient services) and total direct medical 
costs (reflecting resources used within and outside the participating center) at endpoint and 
average cost per 3 months will be calculated. 
o For all resource use categories combined, total direct medical costs at endpoint and average 
cost per 3 months will be calculated. 
o Indirect costs (days absent from work due to illness) at endpoint 
 
PSP total score mean change from baseline at each post-baseline assessment time point 
 
PSP domain  score mean change from baseline at each post-baseline assessment time point 
 
SWN-20 total score mean change from baseline at each post-baseline assessment time point 
 
SWN-20 subscale score mean change from baseline at each post-baseline assessment time point 
6.7.3 
Safety Variables 
Safety variables include the following:  
 
Occurrence, nature, duration, intensity, and relationship to study drug of injection site reactions.  
o Injection site pain, assessed by patients using a VAS after each dose.  
o Injection site evaluation of redness, swelling, and induration, evaluated by designated study 
site personnel after each injection 
o Occurrence (incidence), nature, onset time, duration, intensity, action taken, and relationship 
to study drug of treatment-emergent AEs 
 
Occurrence, nature, time to onset, duration, seriousness criteria, relationship to study drug, and 
outcome of treatment-emergent SAEs 
 
Occurrence of extrapyramidal symptoms, as assessed using the SAS, BARS, and AIMS 
 
C-SSRS 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 58 of 114 
 
Physical examination, vital signs, weight, body mass index, clinical laboratory test results, and 
ECG findings 
 
Time to early termination 
6.7.4 
Pharmacokinetic Variables 
The pharmacokinetic variables are the following:  
 
Summary plasma concentrations of risperidone, its active metabolite (9-OH-Risperidone), and the 
active moiety (i.e., risperidone plus 9-OH-risperidone) by injection site (gluteal and deltoid) and 
by study drug dose level 
 
Trough concentrations and accumulation index for steady state by injection site (gluteal and 
deltoid) and by study drug dose level 
 
Exploratory associations of pharmacokinetic results with efficacy results 
6.7.5 
Genotype Sampling  
For all study patients who consent to collecting genotype sample and sign a separate consent form, a 
blood sample will be collected for evaluation of genotypes for cytochrome P450 enzymes and/or 
genes that are potentially related to efficacy response and/or adverse effects.  The sample may be 
obtained at any point after randomization occurs during the Double-blind period.  The samples will be 
tested for all patients for correlation with pharmacokinetic and/or efficacy results.  
7 Statistics 
7.1 General Considerations 
The statistical analysis methods are described below and refer to the main (double-blind) part of the 
study.  Additional details will be provided in a separate Statistical Analysis Plan document, which will 
be finalized before database lock and unblinding of the study.  Analysis for the extension segment of 
the study will be descriptive only.   
In general, summary statistics (n, mean, standard deviation, median, minimum, and maximum values 
for continuous variables, and number and percentage of patients in each defined category for 
categorical variables) will be provided by treatment group for all variables.  Source data for the 
summary tables and statistical analyses will be presented as patient data listings.   
Baseline in the main (double-blind) part of the study will be defined as last non-missing observation 
before first dose of study drug.  Baseline in the extension segment of the study will be defined as last 
non-missing observation before first dose of Risperidone of the extension segment of the study. 
7.2 Analysis Populations 
The randomization population will consist of all patients that are randomized in the study. Analyses 
performed on the randomization population will be as randomized.  This population will be used for 
sensitivity analysis of the primary variable. 
The safety population will include all patients who receive at least 1 dose of study drug.  Analyses 
performed on the safety population will be as treated. 
The modified safety population will consist of all patients in the safety population for whom blinding 
was not potentially compromised. Analyses performed on the modified safety population will be as 
treated.  This population will be used for selected safety analyses.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 59 of 114 
The intent-to-treat (ITT) population will consist of all randomized patients who received at least 1 
dose of study drug with a baseline measurement and ≥ 1 post-baseline evaluation of the PANSS.  
Analyses performed on the ITT population will be as randomized.  The ITT population will be used 
for analyses of efficacy endpoints, including health economics and outcomes research endpoints. 
The modified intent-to-treat (mITT) population will consist of all patients in the ITT population for 
whom blinding was not potentially compromised. Analyses performed on the mITT population will 
be as randomized.  The mITT population will be used for analyses of efficacy endpoints. 
The per-protocol (PP) population will consist of patients from the ITT population who receive ≥ 2 
injections of study drug (active or placebo) during the treatment period and have no major protocol 
deviations that may impact the primary efficacy variable.  Patients will be analyzed according to 
assigned treatment.  The PP population will be used for supporting analyses of efficacy endpoints. 
The modified per-protocol (mPP) population will consist of all patients in the PP population for whom 
blinding was not potentially compromised. Analyses performed on the mPP population will be as 
treated.  This population will be used for selected efficacy analyses. 
The pharmacokinetic population will include patients in the safety population who have at least 
1 measured plasma concentration value.  In cases where a protocol deviation is identified to 
potentially affect plasma concentration data, the identified concentration values will be flagged and 
excluded from summarization as indicated, and in some cases may be excluded from the 
pharmacokinetic analysis overall; excluded concentration values will be identified before database 
lock based on a protocol deviations log and confirmed with sponsor. An intense pharmacokinetic 
subset of patients with additional samples measured after dose 1 will be used to evaluate non-
compartmental pharmacokinetic parameters during dosing interval after dose 1. 
Explanations for pharmacokinetic parameters that could not be estimated will be provided in the 
clinical study report as applicable.   
Genotyping data will be listed and summarized for all patients in safety population if available. 
A blinded data review meeting will be held before database lock and unblinding of the double-blind 
phase to clarify any open questions or doubts and agree upon the PP and pharmacokinetic 
populations.  Attendees will include appropriate individuals from the sponsor and Contract Research 
Organization (CRO).  All decisions will be documented.  Details regarding the data to be reviewed at 
the meeting will be documented in the Statistical Analysis Plan, and a separate blinded data review 
meeting plan. Prior consideration will be given to ensure that no data will be reviewed which has 
potential to present blinding issues (e.g., pharmacokinetic concentration data).  Reasons for excluding 
patients from the PP or pharmacokinetic population will be determined and documented before 
database lock.  All patients satisfying the ITT and mITT population definition will be included in the 
respective efficacy analyses. 
The open-label population will consist of all patients who received at least 1 dose of study drug in the 
extension segment of the study.  Analyses performed on the open-label population will be as treated, 
and by double-blind segment treatment arm and de novo entry at the time of OLE phase. 
7.3 
Planned Analyses 
7.3.1 
Patient Disposition 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 60 of 114 
The number of patients who enter and complete the main (double-blind) part of the study will be 
tabulated.  Patients who fail to complete the main (double-blind) part of the study will be summarized 
and categorized by reason for termination.  Similarly, the description of the patients’ dispositions in 
the extension segment of the study (including whether the patient was a rollover or de novo patient) 
will be performed. 
In addition, the numbers of patients randomly assigned to each study drug treatment and the number 
of patients included in each analysis population (e.g., safety, modified safety, ITT, mITT, PP, mPP, 
open label, and pharmacokinetic) will be summarized by treatment group, along with reasons for 
exclusion as applicable.   
7.3.2 
Demographics and Baseline Data 
Demographics and baseline characteristics will be summarized by treatment group for safety, ITT, 
mITT, PP, mPP, open-label, and pharmacokinetic populations using descriptive statistics as described 
in Section 7.1.   
Cytochrome P450 2D6 inferred metabolic status will be summarized and details of the genotype will 
be listed and summarized by treatment group for safety modified safety, ITT, mITT, PP, mPP, open-
label, and pharmacokinetic populations using descriptive statistics.  Predicted phenotypes will be 
determined following the activity score system published by Gaedigk et al (2008).14  Patients with an 
activity score > 2 will be considered as ultra-rapid metabolizers, a value of 1.5 to 2 as extensive 
metabolizers, 0.5 to 1 as intermediate metabolizers, and a value of 0 as poor metabolizers. 
Medical and psychiatric history will be summarized by treatment group for the safety and open-label 
populations.   
7.3.3 
Study Drug Administration 
Study drug administration data will be summarized for all randomized patients by treatment group.  
Study drug administration data from the extension segment of the study will be similarly summarized 
for the open-label population. 
7.3.4 
Efficacy 
Results for efficacy variables will be summarized by treatment group for the mITT, ITT and PP 
populations using descriptive statistics (see Section 7.1) for data obtained during the main (double-
blind) part of the study. The analyses of primary and key secondary endpoints will also be provided 
for the mPP population. Although any confirmatory findings related to efficacy must be substantiated 
in both the mITT and ITT populations, the mITT will be used as the primary population to describe 
efficacy results in the CSR. For the primary and key secondary variables, results will also be 
summarized separately for stage 1 and stage 2 of the study (see Section 7.5).  
Efficacy variables (PANSS, CGI-S, CGI-I) from the extension segment of the study will be 
summarized similarly for the open-label population, as applicable, for descriptive purposes. 
To account for patients for whom the post-baseline endpoint (i.e., at the time when the last post-
baseline double-blind assessment was performed) occurs at a time point before study day 85, a mixed 
effect model with repeated measurements (MMRM) using an unstructured covariance matrix 
approach will be used as the primary method.  It is assumed that the majority of the missing values 
will be one of the following:  
 
“Missing Completely at Random” (i.e., probability of an observation being missing does not 
depend on observed or unobserved measurements) or 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 61 of 114 
 
“Missing at Random” (i.e., probability of an observation being missing depends only on observed 
measurements) 
In such situations, likelihood-base methods like MMRM are appropriate17 and are already usual.16  
If a patient has a PANSS assessment recorded, but any of the 30 items are missing, the last non-
missing score for the respective item from previous assessments will be carried forward.22  If the total 
or subscale score has > 30% of the items missing at a particular visit, the respective total or subscale 
score at the visit will not be calculated and will be treated as missing data in the analysis.   
7.3.4.1 Primary Efficacy Variable Analyses 
The primary efficacy analysis is designed to show superiority of active treatment versus placebo in the 
primary efficacy variable (Section 6.7.1.1).   
Two hypotheses will be tested: 
a. 
H0,A: µRisperidone ISM   75 mg - µplacebo = 0 vs H1,A: µRisperidone ISM  75 mg - µplacebo ≠ 0 
b. H0,B: µRisperidone ISM 100 mg - µplacebo = 0 vs H0,B: µRisperidone ISM 100 mg - µplacebo ≠ 0   
with µ = PANSS total score mean change from baseline to endpoint for identified treatment group.   
An MMRM approach will be fitted for patients in the mITT population with country where enrolled, 
visit, treatment, and treatment-by-visit interaction as fixed effects and baseline PANSS total score as a 
covariate.  This model will be applied separately for patients in stage 1 and stage 2 of the study.  The 
treatment differences from the model at study day 85 will be evaluated to test the hypotheses above, 
maintaining a 2-sided type 1 error rate of 5%.  Model results from each stage will be presented. 
In order to maintain the type 1 error rate for the primary analysis, each hypothesis will be tested using 
a weighted test statistic in accordance with Cui, Hung, Wang18 (CHW) methodology which comprises 
of combining the z-statistics from the respective study day 85 treatment comparison at each stage.  
The weighting will be equal for each stage and pre-defined as sqrt (0.5). 
The nominal 2-sided p-value for each hypothesis will be calculated for the respective weighted CHW 
statistic using the cumulative normal distribution. 
To account for multiplicity of testing and to keep the type 1 error rate at 5%, the Hommel’s closed-
testing correction procedure19 as implemented in SAS software (PROC MULTTEST) will be used to 
provide adjusted p-values to assess for superiority of either dose.  
The primary efficacy analysis will be supported with sensitivity analyses.  All sensitivity analyses will 
use the CHW and Hommel adjustment to present p-values.  The MMRM (as above) and analysis of 
covariance (ANCOVA) models using both observed endpoint values and multiply imputed20 study 
day 85 values will be performed for the mITT population.  The ANCOVA models will include 
country where enrolled and treatment as fixed effects and baseline PANSS total score as a covariate.   
All analyses described above will be repeated for the ITT population. However, to account for extra 
43 patients included in Stage 1, the CHW statistic will be derived using weights of sqrt(0.55) and 
sqrt(0.45) for stage 1 and 2 respectively. 
Confirmatory findings from the Hommel adjusted CHW analyses will only remain so for a particular 
dose if p<0.05 in both the mITT and ITT analyses. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 62 of 114 
All analyses described above for the ITT and mITT population will also be repeated for the PP and 
mPP population respectively. 
The descriptive statistics summary will be presented for each country and by the baseline PANSS 
total score (< 95 v ≥ 95) for both the mITT and ITT population. In addition, the MMRM (without 
CHW or Hommel adjustments) will be repeated in the mITT and ITT population incorporating a 
treatment by country or baseline PANSS total score (< 95 v ≥ 95) interaction as a fixed effect in order 
to explore the treatment differences within each country and baseline PANSS total score (< 95 v ≥ 
95).  
The unadjusted LS means and standard errors of the change from baseline over time from the MMRM 
including all patients will be presented graphically both overall (from the primary analysis) and by the 
baseline PANSS total score (< 95 v ≥ 95) (from the interaction models). 
The effect of CYP2D6 phenotype on the primary efficacy variable will be assessed using subgroup 
analyses.  Summaries will be repeated by CYP2D6 phenotype groupings (using combined data across 
stages).  The MMRM applied to all data combined will be repeated with additional fixed effects for 
CYP2D6 phenotype and treatment-by-CYP2D6 phenotype interaction. 
7.3.4.2 Secondary Efficacy Variables Analyses 
7.3.4.2.1 
Key Secondary Efficacy Variable Analyses 
The key secondary variable will be analyzed at endpoint for the mITT and ITT population in a 
hierarchical order, taking multiplicity into account.  
If, and only if, the primary efficacy analysis shows the superiority of the Risperidone ISM treatment 
versus the IM placebo treatment for both doses will the confirmatory testing be performed 
sequentially on the mITT and ITT population with regard to the key secondary efficacy variable 
(Section 6.7.1.2.1).  Otherwise, all analyses for the key secondary efficacy variable will be deemed 
supportive/exploratory evidence.   
The CGI-S mean change will be analyzed using identical methods as described for the primary, 
sensitivity and subgroup analyses of the primary efficacy variable (Section 7.3.4.1).  The only 
exception to this will be that the baseline CGI-S will be used as a covariate in the MMRM/ANCOVA 
models instead of the baseline PANSS score.  
7.3.4.2.2 
Other Secondary Efficacy Variables Analyses 
The other secondary efficacy variables (see Section 6.7.1.2.2) will be displayed as described in 
Section 7.1, in each treatment group and at each applicable visit on the mITT, ITT and PP 
populations.  The analysis will be performed using only observed cases with both stages of the study 
combined. 
The mean scores and their changes from baseline will be displayed for PANSS, PANSS subscales, 
CGI-S and CGI-I at each applicable post-baseline visit and endpoint.  Treatments will be compared at 
each time point using a MMRM with country where enrolled, visit, treatment, and treatment-by-visit 
interaction as fixed effects and the respective baseline (PANSS will be used for CGI-I model) as a 
covariate.  Each dose level of Risperidone ISM will be compared to placebo at each study day.  
Unadjusted p-values and 95% confidence intervals will be presented. For PANSS and CGI-S, the 
models applied as part of the primary and key secondary variable sensitivity analyses (on all data 
patient data combined) will be used for these comparisons. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 63 of 114 
Overall and PANSS response rates will be shown with exact (Clopper-Pearson) 95% confidence 
intervals at each respective time point and endpoint.  Pairwise comparisons of each dose level of 
Risperidone ISM to placebo will be conducted using a Mantel-Haenzel test stratified by country 
where enrolled and baseline PANSS total score (≥ 95 or < 95). 
The time to reach the overall or the PANSS response will be displayed graphically using Kaplan-
Meier estimates.  Pairwise comparisons of each dose level of Risperidone ISM to placebo will be 
conducted using a log-rank test stratified by country where enrolled and baseline PANSS total score 
(≥ 95 or < 95). 
7.3.4.2.3 
Efficacy Variables Analyses in the Extension Segment of the Study 
The following efficacy parameters will be summarized in the extension segment of the study for the 
open-label population by treatment group and overall.  There will be no formal statistical testing. 
Durability of effect evaluations: 
 
PANSS total score 
 
Positive, negative, and general psychopathology subscale scores   
 
CGI-I score  
 
CGI-S score  
 
Overall response (as defined in 6.7.1.2.2) 
 
PANSS response (as defined in 6.7.1.2.2)  
 
Relapse, defined as 
o PANSS total score increase of ≥ 30% from baseline or  
o Re-hospitalization for psychotic symptoms or use of adjunctive antipsychotic medication 
after stabilization  
 
Remitters, defined as 
o The simultaneous attainment of a score of ≤ 3 for 6 months or  
o More on 8 main items of the PANSS  
 
Time to discontinuation  
Other evaluations include HRU, PSP, SWN-20, and concomitant antipsychotic medication use.  
7.3.4.3 Health Economics and Outcomes Research Variables Analyses 
Clinician-reported and patient-reported (or informant reported) HRU will be combined for analysis.  
When all data are missing for a time point, no imputation will take place.  Analyses will be performed 
by study phase (double-blind vs. open-label).  For analysis of each resource item and at each time 
point, non-zero missing data will be imputed using the Fully Conditional Specification procedure.  
Results for each HRU variable will be summarized by treatment group (placebo, two Risperidone 
ISM® arms, and all Risperidone ISM® combined) for the ITT and open-label populations using 
descriptive statistics, including 95% confidence limits.  For each HRU variable, an average rate of use 
per 3 months will be calculated by treatment group, and potential differences between treatment 
groups will be tested.  For analyses of the open-label population, de novo patients form a separate 
treatment group, and the rollover patients will be analyzed by their originally randomized treatment 
group in the double-blind segment. 
Country-specific unit costs will be assigned to each resource use item and costs across all items will 
be summed to yield a total direct medical cost.  Direct medical cost will be analyzed per individual 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 64 of 114 
country for each resource use category and for all resource use categories combined for the ITT and 
open-label populations.  The average cost per 3 months by treatment group will be calculated, and 
differences between treatment groups will be tested.  Indirect costs (days absent from work due to 
illness) will also be analyzed per individual country.  Parametric and nonparametric methods for cost 
analyses will be assessed.  This may include bootstrapping technique to calculate 95% confidence 
intervals.  
Details of HRU and cost analyses will be specified in the Statistical Analysis Plan. 
The PSP and SWN-20 scores will be summarized by treatment group for the ITT and PP populations 
using descriptive statistics (see Section 7.1) for data obtained during the main double-blind segment 
of the study.  The PSP and SWN-20 scores from the extension segment of the study will be similarly 
summarized for the open-label population, as applicable, for descriptive purposes. 
Analyses of PSP and SWN-20 data will be according to instrument-specific guidance, as specified in 
the Statistical Analysis Plan. 
7.3.5 
Safety 
All safety variables will be displayed as described in Section 7.1 for the safety (and modified safety 
for selected endpoints) population in the main (double-blind) part of the study and the open-label 
population in the extension segment of the study.   
Safety and tolerability will be evaluated based on the incidence of treatment-emergent AEs, incidence 
of AEs leading to discontinuation, vital sign measurements, physical examination findings, weight, 
abnormal laboratory test results, ECG findings, abnormal movement scale results (AIMS, BARS, and 
SAS), C-SSRS results, use of concomitant medications, and injection site reactions.  Additionally, 
time to early termination results will be summarized descriptively.   
Descriptive statistics will be used to summarize the changes from baseline in vital signs, body weight, 
body mass index, and safety scales (e.g., C-SSRS, SAS, AIMS, and BARS) for each treatment group 
at each visit as described in Section 7.1.   
7.3.5.1 Adverse Events 
Events that occur after a patient provides informed consent but before the time of the first dose of 
study drug will be considered pretreatment AEs.  Treatment-emergent AEs are defined as events that 
are newly occurring or worsening from the time of the first dose of IM study drug.  All AEs will be 
listed by patient but only treatment-emergent AEs will be included in summary tables.  Reported AE 
terms will be coded using Medical Dictionary for Regulatory Activities preferred terms and system 
organ classes.   
The incidence of treatment-emergent AEs will be summarized by treatment group and overall, by 
severity, and by relationship to study drug (for both safety and modified safety populations 
separately).   
The summary tables will include the number and percentage of patients with treatment-emergent AEs 
together with the number of the respective treatment-emergent AE overall, by system organ class, and 
by preferred terms within each system organ class (for both safety and modified safety populations 
separately).  Treatment-emergent AEs resulting in treatment discontinuation or modification will be 
identified and summarized by treatment group (for both safety and modified safety populations 
separately).   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 65 of 114 
7.3.5.2 Vital Signs and Physical Examinations 
Vital sign measurements (systolic and diastolic blood pressure [mmHg], pulse rate [beats/minute], 
respiration rate [breaths/minute], and body temperature [°C]) will be summarized by treatment group 
at each time point for the absolute value and for changes from baseline as described in Section 7.1.  
Orthostatic measurement data will also be summarized.  
7.3.5.3 Weight and Body Mass Index 
Weight (kg) and body mass index (kg/m2) measurements will be summarized by treatment group at 
each time point for the absolute value and for changes from baseline.   
7.3.5.4 Clinical Laboratory Tests  
Laboratory test results, including prolactin results, will be summarized by treatment group at each 
time point for the absolute value itself and for changes from baseline.  Tables showing the shift of 
clinically relevant abnormalities from baseline to endpoint will also be presented.   
7.3.5.5 Electrocardiograms  
QT, QTcB, and QTcF intervals will be calculated at each ECG assessment.  Interval data will be 
summarized by treatment group at each time point for the absolute value and for changes from 
baseline.  Additionally, QTcF values will be categorized and summarized, using the following QTcF 
value categories: increase from baseline > 30 msec, increase from baseline > 60 msec, as well as 
absolute values > 450 msec for males or > 470 msec for females.   
Other ECG variables that are collected will be listed.   
7.3.5.6 Extrapyramidal Symptoms Rating Scales 
For the SAS, AIMS, and BARS, total scores and subcategory scores, as applicable, will be 
summarized by treatment group at each time point for the absolute value and for changes from 
baseline.   
7.3.5.7 Columbia-Suicide Severity Rating Scale 
Individual items of the C-SSRS will be summarized by treatment group at each time point by the 
number and percentage of patients responding to that item.  Data will be summarized by treatment 
group.   
7.3.5.8 Concomitant Medications 
Concomitant medications will be categorized and presented using the World Health Organization 
Anatomical Therapeutic Chemical drug classification system.  The number and percentage of patients 
using concomitant medications will be summarized by treatment group.   
7.3.5.9 Injection Site Reactions 
Injection site reaction data will be summarized by treatment group.  The number and percentage of 
patients having reactions at each assessment time point will be presented.   
7.3.5.10 Time to Early Termination 
Time to early termination will be summarized by treatment group as described in Section 7.1.  
Additionally, Kaplan-Meier estimates will be displayed graphically.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 66 of 114 
7.3.5.11 Ophthalmological Examination 
Data will be summarized by treatment group.  The number and percentage of patients having changes 
from baseline will be presented. 
7.3.6 
Pharmacokinetics 
Descriptive statistics will be used to summarize plasma concentrations of risperidone, its active 
metabolite (9-OH-risperidone), and the active moiety (risperidone plus 9-OH-risperidone), whenever 
possible, at each sampling time point by injection site (gluteal and deltoid) and by study drug dose.   
Concentration values for all patients in the pharmacokinetic population will be listed.  
Pharmacokinetic parameters, including Ctrough, and accumulation index will be derived if possible, and 
results will be summarized as applicable.  Plasma concentrations will be presented graphically.   
A set of non-compartmental parameters will be estimated for a subset of patients after dose 1 (e.g., 
maximum concentration [Cmax], time to Cmax [Tmax], area under the concentration-time curve for a 
dosing interval [AUCtau], and others). 
Association of SAEs with the measured pharmacokinetic concentration either planned or outside the 
regular schedule will be evaluated. 
Comparisons of pharmacokinetic parameters between the gluteal and deltoid muscle injections will be 
performed.   
Effects of the CYP2D6 phenotype on pharmacokinetic parameters in the complete pharmacokinetic 
population and in a subset with intense pharmacokinetic sampling will be evaluated. 
A population pharmacokinetic analysis will be performed according to a separate pharmacokinetic 
analysis plan document.   
7.4 Sample Size  
The overall ratio for the random allocation of the 3 treatments to patients will be 1:1:1 (Risperidone 
ISM 75 mg: Risperidone ISM 100 mg: placebo) during the Double-blind period.  
The primary efficacy analysis will include all patients for whom the blinding was not compromised, 
who receive at least 1 dose of study drug and have both a baseline and at least 1 post-baseline PANSS 
evaluation (mITT population).  
The difference between the active treatments and placebo in the PANSS total score mean change from 
baseline to endpoint (primary efficacy variable; see Section 6.7.1.1) will be assumed as a 9-point 
decrease.   
Taking into account that each of the 2 Risperidone ISM groups (i.e., Risperidone ISM 75 mg and 
Risperidone ISM 100 mg) will be tested separately against the placebo group, a Bonferroni 
adjustment for the  level was performed.  A common standard deviation of 20 in 2-group t-tests was 
assumed.  
A sample size of 124 patients in the mITT population in each treatment group will have 90% power to 
detect a difference in means of 9 (standard deviation = 20, effect size = 0.45) with a 2.5% 2-sided 
significance level for a Risperidone ISM group versus the placebo group.  The power to show 
superiority of both Risperidone ISM doses to placebo using the above calculation would be at least 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 67 of 114 
81%.  This will be higher due to a high correlation in pharmacokinetic data between doses (see 
Section 1) and use of a less conservative multiplicity adjustment than Bonferroni (i.e., Hommel – see 
Section 7.3.4.1).   
A relatively low post-randomization dropout rate is anticipated because it is surmised that most 
patients in the inpatient setting will reach study day 4 (patients who drop out before study day 4 will 
not be included in the mITT population); therefore, a 5% dropout rate is considered reasonable.  
Assuming this 5% dropout rate, a randomized sample size of 131 patients per treatment group, or 393 
patients total (all 3 treatment groups combined) for whom the blinding was not compromised, will be 
required. This assumption will be re-assessed at the interim analysis and used in re-estimating the 
total number of randomized patients required (see Section 7.5). 
Taking into account the 43 patients for whom blinding was potentially compromised, 436 randomized 
patients in total will be required. 
Assuming a screening failure rate of 35%, approximately 671 patients will need to be screened in 
order to achieve the initially planned 436 patients randomized.  
7.5 Sample Size Re-estimation/Interim Analysis 
One unblinded interim analysis will be conducted when 196 (approximately 50%) randomized 
patients, for whom the blinding was not compromised, have either reached study day 85 or withdrawn 
from the study; to re-estimate the sample size required for the final analysis up to 558 patients (186 
patients per arm) in the mITT population. The unblinded interim statistical analysis will be conducted 
by an independent statistical center. 
Those patients included in the interim analysis (as well as those for whom the blinding was 
compromised) will constitute stage 1 patients with all subsequent patients being stage 2 patients for 
purpose of the primary and key secondary variable analyses.  There will be no overlap of patients 
between stages. Only those patients meeting the criteria for inclusion in the mITT population will be 
included in the interim analysis for purpose of sample size re-estimation. 
For stage 1 patients meeting the criteria for inclusion in the mITT population, the effect size (mean 
difference/pooled standard deviation) will be calculated for each dose compared to placebo separately 
for the primary efficacy variable (change from baseline to endpoint in total PANSS score). The mean 
difference will be repesented by the difference between LS means from the primary MMRM model at 
Day 85 (see Section 7.3.4.1) and the pooled standard deviation will be derived from the standard error 
of the difference between LS means divided by sqrt(1/nr + 1/np) where nr and np are the sample size 
included in the interim analysis for the risperidone and placebo group respectively. 
If one or both of the effect sizes are less than the expected effect size of 0.45, the lowest effect size 
will be used to derive the new sample size per group for the mITT population (M2) as suggested by 
Cui et al. (1999)18 as follows: 
M2 = 124 * (0.45/lowest effect size) up to a maximum of 186 patients per group in the mITT 
population. 
If the lowest effect size is greater than or equal to 0.45, the target sample size for the mITT population 
will be maintained at 124 patients per arm. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 68 of 114 
The dropout rate at interim (from the randomization population to the ITT population) will be used to 
re-calculate the number of patients required to be randomized in stage 2 to meet the required total 
number in the mITT. 
From an ethical point of view, there will be an early stopping for futility for a particular dose when 
the conditional power21 at interim <10%. 
8 Data and Documentation 
8.1 Data Handling and Record Keeping 
8.1.1 
Data Handling 
The data obtained during the study should be transcribed faithfully from the source documents to the 
forms of the eCRF, as these data are considered valid information for further evaluation of the 
efficacy and safety of the treatment under investigation.   
The sponsor or designee will provide the site with eCRFs.  The investigator is to provide patient data 
according to the sponsor’s instructions, in the designated data collection form, compliant with GCP 
practices.  All data collection forms and the databases from the study are the exclusive property of the 
sponsor.   
The investigator must maintain records and data during the study in compliance with all applicable 
legal and regulatory requirements.  Records of the patient’s participation in this study will be held 
confidential except as disclosure is required by law or as described in the informed consent document.  
If the results of this study are published or presented at meetings, the patients will never ever be 
identified.  Each data point must be supported by a source document at the study site.  Any records or 
documents used as the source of information (called the “patient source data”) are to be retained for 
review by authorized representatives of the sponsor or a regulatory agency.  In this study, eCRFs will 
be used.  Further details may be provided in monitoring guidelines, as applicable.   
The investigator will ensure that there are sufficient time, staff, and facilities available for the duration 
of the study to conduct and record the study as described in this protocol and according to all 
applicable guidances, laws, and regulations.   
All data collection forms, such as eCRFs, should be completed as soon as possible after the evaluation 
has occurred.  All dates appearing on the sponsor’s patient data collection forms for laboratory tests, 
cultures, and other data collected must be the dates on which the specimens were obtained or the 
procedures performed.   
Within 1 week (or other agreed timeframe) of study completion by each patient, the investigator 
should agree to have the patient’s eCRF available for inspection by the field monitor.   
8.1.2 
Data Recording 
This study will use eCRFs for recording data.  All entries, corrections, and alterations will be made by 
the investigator or other authorized study personnel, and all data entries will be verified for accuracy 
and correctness.  The electronic data capture system will maintain an audit trail.   
Source documents will remain at the study site.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 69 of 114 
8.1.3 
Inspection of Records 
The sponsor or its representative will be allowed to conduct site visits to the investigational facilities 
for the purpose of monitoring any aspect of the study.  The investigator must agree to allow the 
unblinded or blinded monitor as applicable to inspect the drug storage area, study drug stocks, drug 
accountability records, patient charts and source documents, and other records relative to study 
conduct.   
8.1.4 
Retention of Records 
Retention and storage of essential clinical study documents (e.g., worksheets, drug accountability 
forms, and other administrative documentation) will be according to the clinical study agreement as 
applicable.   
Sponsor-specific essential documents should be retained until at least 25 years after the last approval 
of a marketing application in an International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use (ICH) region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the study drug.  These documents should be retained for a 
longer period, however, if required by the applicable regulatory requirements or if needed by the 
sponsor.   
Medical files should be retained in accordance with the applicable legislation and in accordance with 
the maximum period of time permitted by the hospital, institution, or private practice.   
8.1.5 
Use of Information and Publication Policy 
Data generated in this study are proprietary information that is the sole property of the sponsor.  
Results of the study are to be held in confidence by both the investigators and the sponsor.   
The clinical study report will be issued at 2 time points: the first will have the data from the double-
blind phase of the trial, and the second will be issued after the open-label extension phase of the study 
is completed and will contain all study data (both double blind and open label).  
Please refer to the clinical study agreement for details on the procedures for publishing and presenting 
data.   
8.2 Source Materials Access 
8.2.1 
Study Monitoring 
Monitoring of the study site (including, but not limited to, reviewing eCRFs for accuracy and 
completeness) will be performed by a study monitor.   
Blinded and unblinded monitors may be involved in the study site monitoring process, and each will 
interact with blinded and unblinded study site staff in a manner that maintains the blind for all blinded 
individuals until the Data Base lock of the Double-blind period.   
8.2.2 
Institutional Review Board 
The investigator must obtain Institutional Review Board (IRB) or Independent Ethics Committee 
(IEC) approval for the investigation.  Initial IRB/IEC approval as well as all materials approved by the 
IRB/IEC for this study, including the patient informed consent form and recruitment materials, must 
be maintained by the investigator and made available for inspection.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 70 of 114 
8.2.3 
Audits and Inspections 
Authorized representatives of the sponsor, a regulatory authority, and/or an IRB/IEC may visit the site 
to perform audits or inspections, including the drug storage area, study drug stocks, drug 
accountability records, patient charts and source documents, and other records relative to study 
conduct.  The purpose of a sponsor audit or inspection is to systematically and independently examine 
study-related activities and documents (e.g., laboratory reports, radiographs, workbooks, patients’ 
medical records) to determine if these activities were conducted and if data were recorded, analyzed, 
and accurately reported according to the protocol, ICH GCP guidelines, and any applicable regulatory 
requirements.   
The investigator should contact the sponsor and/or CRO immediately if contacted by a regulatory 
agency regarding an inspection.   
9 Quality Control and Assurance 
This study will be conducted under GCP and applicable regulatory requirements.  To ensure 
compliance, the sponsor may conduct a quality assurance audit.   
9.1 Data Collection 
The eCRFs will be completed by study site staff before review by the study monitor.  All eCRFs will 
be reviewed by the investigator, as noted by his or her electronic signature, after review by the 
sponsor monitor or designated representative.  The sponsor monitor or designated representative will 
review all source records onsite and compare them with the data collected on the eCRF.   
As specified in Section 6.2.2, study site staff will retrospectively record any HRU that occurred within 
the clinical trial center into the applicable forms of the eCRF.  Study site staff will administer a paper 
survey to patients (or their informant) to report any HRU that occurred outside the clinical trial center.  
The information will subsequently be recorded into the applicable forms of the eCRF. 
Results of the clinician-administered PSP will be collected on the eCRF.  Patients will complete the 
SWN-20 on paper, and the data will be entered into the eCRF by study site staff. 
9.2 Confidentiality 
The investigator must maintain in confidence information provided to him or her by the sponsor and 
will divulge such information to his or her respective IRB/IEC under an appropriate understanding of 
confidentiality with that body.   
All data are considered the sole property of the sponsor.   
10 Ethical Considerations 
10.1 Ethics Review 
The clinical site’s IRB/IEC must meet all relevant regulatory requirements.  The study protocol and 
informed consent form will be reviewed by the IRB/IEC before enrolling patients into the study; 
written approval from the committee must be received by the sponsor before study drug will be 
released to the investigator.  The protocol must be re-approved by the IRB/IEC upon receipt of 
amendments and annually, as local regulatory requirements require.   

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 71 of 114 
The investigator is responsible for submitting all protocol changes and SAE reports to the IRB/IEC 
according to local procedures.  At a minimum, all SAEs requiring an investigational new drug safety 
report must be immediately reported.  All relevant correspondence from the IRB/IEC will be 
forwarded by the study site to the sponsor in a timely manner.   
 
10.2 Ethical Conduct of the Study 
This study must be conducted in accordance with this protocol, GCP (ICH GCP Guidelines E6), and 
applicable regulatory requirements.  The sponsor is committed to complying with GCP standards to 
protect the rights, safety, and well-being of study patients, consistent with principles having their 
origin in the Declaration of Helsinki.   
10.3 Informed Consent 
The investigator (or authorized designee) at each study site will ensure that each patient is given full 
and adequate oral and written information about the nature, purpose, and possible risk and benefit of 
the study.  Each patient will receive an informed consent form that summarizes the pertinent study 
information and will be given ample time to read and ask questions about the study.  Patients must 
also be informed of their right to withdraw consent without prejudice at any time during the study.  If 
the patient chooses to participate, he or she must sign the informed consent form before any study-
specific procedures are conducted.   
All patients will be informed of their rights to privacy and will be made aware that the study data will 
be submitted to the sponsor and to regulatory authorities for review and evaluation for the duration of 
the study and until the project has been approved for marketing or is withdrawn from investigation.  
They will also be informed that the study monitor may inspect their medical records to verify the 
accuracy and completeness of the study records and results.   
Each consent form should contain an authorization allowing the Principal Investigator(s) and 
Laboratorios Farmacéuticos ROVI, S.A. to use and disclose private health information (i.e., patient-
identifiable health information) in compliance with local laws. 
 
Significant changes to the protocol or product safety information may cause a revision of the informed 
consent form, which must be reviewed and signed by all applicable study participants.  The 
investigator must maintain the original, signed, and dated informed consent form.  A copy of the 
signed and dated informed consent form, or a second original of a signed and dated informed consent 
form, must be given to the patient. 
10.4 Patient Data Protection 
The study patients should be informed by the investigator that complete confidentiality will be 
maintained concerning their identity.  On eCRFs, patients will be identified only by the assigned trial 
number. 
Prior to any testing under this protocol, including screening tests and assessments, candidates must 
also provide all authorizations required by local law (e.g., private health information authorization in 
North America). 
A signed written informed consent signifies the explicit acceptance by the individual that data from 
the study and clinical notes will be available to the investigator and his/her staff, the representatives of 
the sponsor and, if required, by the IRB/IEC and regulatory authorities.  However, all data contained 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 72 of 114 
in the patients’ clinical notes will be considered as confidential. Laboratorios Farmacéuticos ROVI, 
S.A. will also treat data according to European Union Data Privacy Directive 95/46/EC. 
11 Indemnification 
The sponsor will contract a clinical study insurance policy in compliance with all applicable laws, 
rules, and regulations.   
12 Further Requirements and General Information 
12.1 External Service Organizations 
12.1.1 Interactive Voice Response System 
An external vendor will be selected to provide interactive voice or web response system support for 
this study.  Each site will be provided with appropriate training and a user manual before patients are 
screened or enrolled. 
12.1.2 Contract Research Organization 
A CRO will be responsible for all administrative aspects of the study including, but not limited to, 
regulatory submissions, study initiation, monitoring, data management and submissions of AE/SAE 
reporting.  Prior to enrollment of the first patient at each site, the CRO will review study 
responsibilities with the investigators and other site personnel, as appropriate.  The roles and 
responsibilities of all parties involved (CRO), third-party vendors, and the sponsor will be described 
in the Study Project Management Plan.  
12.1.3 Central Laboratories for Laboratory Assessments 
A central laboratory will be selected to analyze all hematology, blood chemistry, and urinalysis 
samples collected for this study.  Pharmacokinetic determinations will be done by another laboratory 
selected by Laboratorios Farmacéuticos ROVI, S.A.  Detailed procedures and instructions are 
included in the Laboratory Reference Guide. 
12.1.4 Central Facility for Other Assessments 
12.1.4.1 Electrocardiogram Reading Center 
An external vendor will be selected to evaluate all ECGs collected for this study.  Detailed procedures 
and instructions are included in an ECG Study Reference Guide. 
12.1.4.2 Central Training  
An external vendor will be selected to train the study raters before they perform any study 
assessments to ensure they understand and use the study scales consistency.  All raters will be 
required to pass an assessment on the use of the PANSS before to perform any efficacy assessments.  
Patients should be rated as much as possible by the same rater across the study.  
12.2 Study Committees 
12.2.1 Data Monitoring Committee 
A Data Monitoring Committee (DMC) will be formed to monitor patient accrual and to monitor 
compliance with the protocol at individual investigational sites, review any safety data (including 
individual AEs and SAEs), and alert and/or make recommendations to the sponsor about any existing 
or potential problems.  The DMC will be composed of a minimum of 3 voting members; they will not 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 73 of 114 
be allowed to participate as investigators in this study and will not be affiliated in any way with 
Laboratorios Farmacéuticos ROVI, S.A.  Findings and conclusions will be reported to the 
Laboratorios Farmacéuticos ROVI, S.A. Medical Director.  Investigational sites will be notified of 
any relevant safety findings that may jeopardize patient safety.  The DMC will meet approximately 
twice a year.  A charter will be established between Laboratorios Farmacéuticos ROVI, S.A. and the 
DMC to outline the DMC’s responsibilities and procedures.  In one of their regular meetings, the 
DMC will receive from the unblinded statistician the results of outcome of the interim analysis for 
sample size re-estimation (blinded outcome only) performed as described in Section 7.5.  The DMC 
will communicate to the sponsor the blinded outcome from the interim analysis together with the 
conclusions from any other data review performed.  
12.3 Changes to Final Study Protocol 
All protocol amendments must be submitted to the IRB/IEC.  Protocol modifications that affect 
patient safety, the scope of the investigation, or the scientific quality of the study must be approved by 
the IRB/IEC before implementation of such modifications to the conduct of the study.  If required by 
local law, such modifications must also be approved by the appropriate regulatory agency prior to 
implementation.  However, Laboratorios Farmacéuticos ROVI, S.A., at any time, can amend this 
protocol to eliminate an apparent immediate hazard to a patient.  In this case, the appropriate 
regulatory authorities will be notified subsequent to the modification.  In the event of a protocol 
modification, the patient consent form may require similar modifications (see Sections 10.1 and 10.3). 
12.4 Ethics Committee Notification of Study Completion or Termination 
The Health Authority and the IRB/IEC in each country must be notified within 90 days of the 
completion of the study or within 15 days if the study is terminated early, unless any more restrictive 
period of time is specified by local applicable laws and regulations. 
12.5 Retention of Study Data 
The Principal Investigator(s) must maintain all essential documents (as listed in the ICH GCP 
Guidelines E6) until notified by Laboratorios Farmacéuticos ROVI, S.A. and in accordance with all 
local laws regarding retention of records. 
12.6 Study Report Signatory 
Laboratorios Farmacéuticos ROVI, S.A. will designate 1 of the participating study investigators as a 
signatory for the study report.  This determination will be made by several factors, including, but not 
limited to, the investigator’s experience and reputation in the studied indication; the investigator’s 
contribution to the study in terms of design, management, and/or patient enrollment; or other factors 
determined to be relevant by Laboratorios Farmacéuticos ROVI, S.A. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 74 of 114 
References 
1. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients 
can do better. J Clin Psychiatry. 2003;64(11):1308-15. 
2. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence 
and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin 
Psychiatry. 2006;67(3):453-60. 
3. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-
acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry. 2003;64(Suppl 16):34-
40. 
4. Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and 
cost-effectiveness. Expert Rev Neurother. 2009;9(1):9-31. 
5. Hargarter L, Cherubin P, Bergmans P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, 
Vidailhet P, Schreiner A. Intramuscular long-acting paliperidone palmitate in acute patients with 
schizophrenia unsuccessfully treated with oral antipsychotics. Prog Neuropsychopharmacol Biol 
Psychiatry. 2015;58:1-7. 
6. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, 
randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients 
with schizophrenia. J Clin Psychiatry. 2008;69(5):790-9. 
7. Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching 
strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical 
trial data. CNS Drugs. 2011;25(10):829-45. 
8. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38.  
9. Nakajima S, Uchida H, Bies RR, Caravaggio F, Suzuki T, Plitman E, Mar W, Gerretsen P, 
Pollock BG, Mulsant BH, Mamo DC, Graff-Guerrero A. Dopamine D2/3 receptor occupancy 
following dose reduction is predictable with minimal plasma antipsychotic concentrations: an 
open-label clinical trial. Schizophr Bull. 2016;42(1):212-9. 
10. Catafau AM, Penengo MM, Nucci G, Bullich S, Corripio I, Parellada E, García-Ribera C, 
Gomeni R, Merlo-Pich E; Barcelona Clinical Imaging in Psychiatry Group. Pharmacokinetics and 
time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized 
schizophrenic patients. J Psychopharmacol. 2008;22(8):882-94. 
11. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to 
objective psychopathology, quality of life, compliance and other clinical variables. Int Clin 
Psychopharmacol. 1995;10(Suppl 3):133-8. 
12. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B. Improvement of 
schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 
2001;50(1-2):79-88. 
13. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and 
acceptability of a new version of the DSM-IV Social and Occupational Functioning Scale 
(SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323-9. 
14. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, and Leeder JS. The CYP2D6 
Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype. 
Clinical Pharmacology and Therapeutics. 2008; 83(2):234-42. 
15. Nasser AF, Henderson DC, Fava M, Fudala PJ, Twumasi-Ankrah P, Kouassi A, Heidbreder C. 
Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute 
schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 
study. J Clin Psychopharmacol. 2016;36(2):130-40. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 75 of 114 
 
16. Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, Perry PP, Gara M, McQuade 
RD, Carson WH, Sanchez R.  Aripiprazole once-monthly in the acute treatment of schizophrenia: 
findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 
2014;75(11):1254-60. 
17. European Medicines Agency (EMA); Committee for Medicinal Products for Human Use 
(CHMP). Guideline on missing data in confirmatory clinical trials. EMA/CPMP/EWP/1776/99 
Rev. 1. 2 July 2010. 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC5000
96793.pdf. Accessed 12 May 2016 
18. Cui L, Hung HMJ, Wang SJ. Modification of sample-size in group sequential trials. Biometrics. 
1999;55:853-7. 
19. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test.  
Biometrika. 1988;75(2):383-6. 
20. Ratitch B, O’Kelly M. Implementation of pattern-mixture models using standard SAS/STAT 
procedures. SUGI 2011. 
21. Chang M. Adaptive Design Theory and Implementation Using SAS and R. 2008: p144. 
22. NDA/Serial Number 200603 / S 000 Drug Name: Lurasidone Hydrochloride Indication: 
Schizophrenia   
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000StatR.pdf. Accessed 
2 January 2018 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 76 of 114 
 
Appendix A: Study Assessments and Procedures by Study Visit 
The by-visit descriptive list of study assessments and procedures in this appendix reflects information 
in in the main body text of the protocol (Section 3.1) for the main (double-blind) part of the study, the 
optional open-label extension segment and the extension segment for de novo patients (Table 1, Table 
2 and Table 3, respectively). 
In order to ensure consistency and minimize inter-rater variability, all efforts should be made to have 
efficacy and safety scales assessments at all visits performed by the same investigator/rater. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 77 of 114 
Double-Blind Study 
Allowable study visit time windows for treatment period study visits occurring after study visit 3 
(study day 4) are as follows:  
 
± 1 day for study visit 5,  
 
± 2 days for study visit 14 
 
± 3 days for each of the other treatment period study visits (i.e., study visits 6 through 13, 
inclusive) 
The follow-up telephone visitis to occur 14 (± 3) days after the end-of-treatment visit (i.e., the week 
12 time point or earlier in the case of an early termination).  This visit is not applicable for patients 
who enter into a long-term extension study. 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 78 of 114 
Study Visit 1: Screening Visit 
Study Day -8 to -1 
Obtain informed consent from the patient. 
 
Informed consent form must be signed and dated by the patient before any study-related 
procedures are performed (see protocol Section 6.1.1) 
Obtain the following information (see protocol Section 6.1.2): 
 
Demographic data 
 
Medical and psychiatric history data 
Diagnostic interview will be performed, including the following: 
 
MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders studies 
will be completed (see protocol Section 6.1.4) 
Complete the following efficacy scales: 
 
PANSS (see protocol Section 6.2.1) 
 
CGI-S (see protocol Section 6.2.1.) 
Complete the following safety assessments: 
 
Physical examination (see protocol Section 6.4.1) 
 
Ophthalmological examination (see protocol Section 6.4.2) 
 
Height 
 
Weight and body mass index 
 
Vital signs (see protocol Section 6.4.3 for details) 
 
ECG (see protocol Section 6.4.4) 
 
Assess for AEs (see protocol Section 6.4.9) 
 
Review concomitant medications (see protocol Section 6.1.3) 
Complete the following safety scales: 
 
AIMS, BARS, SAS (see protocol Section 6.4.7) 
 
C-SSRS (see protocol Section 6.4.8) 
Blood samples for the following will be obtained: 
 
Hematology panel (see protocol Section 6.4.5.1) 
 
Chemistry panel (see protocol Section 6.4.5.2) 
 
Prolactin (see protocol Section 6.4.5.2) 
 
Serology panel (see protocol Section 6.4.5.4.1) 
 
Pregnancy test, serum (see protocol Section 6.4.5.4.2) 
Urine samples for the following will be obtained: 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 79 of 114 
 
Urinalysis (see protocol Section 6.4.5.3) 
 
Urine drug screen (see protocol Section 6.4.5.4.3) 
Inclusion/exclusion criteria will be reviewed for patient eligibility. 
Patients who, after completion of all scheduled assessments on the screening visit day, are considered 
provisionally eligible will be admitted directly to the inpatient study that day.   
 
Patients will subsequently remain on the inpatient study unit for the remainder of the screening 
period (i.e., through study day -1, inclusive).     
Patients who have never taken risperidone must take oral risperidone 2 mg/day for 3 days sometime 
during the screening period, to ensure a lack of clinically significant hypersensitivity before the first 
IM dose of study drug is administered; this oral risperidone trial is not required for patients who have 
previously taken any formulation of risperidone. 
If there is a valid reason for a given potential patient to extend the screening period duration beyond 
the designated 8 days, the investigator may contact the medical monitor to request an extension of up 
to 14 days; such an extension may be implemented only after medical monitor approval has been 
obtained. 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 80 of 114 
Study Visit 2: Baseline Evaluations and Administration of First Dose of Study Drug 
Study Day 1 
Patients must be already admitted to the inpatient study unit for study day 1; confirmed eligible 
patients will remain inpatient on study day 1 to complete the study day 1 assessments and procedures 
and to receive the first injection of IM study drug. 
The following baseline evaluations are to be completed before randomization occurs (and before the 
first dose of study drug is administered), with the exception of vital signs and ECG that should be 
checked within one hour before study drug administration: 
 
PANSS 
 
CGI-S 
Complete the following health economics and outcome research evaluations: 
 
Socio-demographic information 
 
PSP 
 
SWN-20 
Complete the following safety assessments: 
 
Weight and body mass index 
 
Vital signs  
 
ECG  
 
Assess for AEs 
 
Review concomitant medications 
Complete the following safety scales: 
 
AIMS, BARS, SAS 
 
C-SSRS 
Blood samples for the following will be obtained: 
 
Hematology panel 
 
Chemistry panel 
 
Prolactin 
 
Pharmacokinetic sample 
Urine samples for the following will be obtained: 
 
Urinalysis 
 
Pregnancy test, urine 
 
Urine drug screen 
Inclusion/exclusion criteria will be reviewed for patient eligibility. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 81 of 114 
 
Confirmation patient eligibility for continued participation in the study 
Randomization will be performed (for patients confirmed to be eligible) after all of the above baseline 
evaluations have been performed. 
 
Obtain assigned unique randomization number via interactive voice or web response system 
The following will be performed after randomization: 
 
First dose of IM study drug (i.e., double-blind Risperidone ISM 75 mg, Risperidone ISM 100 mg, 
or placebo) will be administered by IM injection 
o A designated unblinded individual at the study site will prepare and administer IM study drug 
in a manner that maintains the blind for investigators, other study site personnel, and the 
patient  
A blood sample for genotype sample may be collected at any point after randomization during a 
patient’s participation in the study (for patients who have given specific informed consent for 
genotyping). 
The following will be performed after administration of IM study drug 
 
Complete the following safety assessments: 
o Vital signs 
o ECG 
o Injection site evaluation by investigator approximately 1 hour after injection 
o Injection site pain VAS by study patient approximately 1 hour after injection 
All patients will remain on the inpatient study unit through the entire day of study day 1 and into 
study day 2. 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 82 of 114 
Study Visit 3, Study Visit 9 and Study Visit 12 
Treatment Week 1, Treatment Week 4, and Treatment Week 8 (Study Day 3, Study Day 31 and Study 
Day 59) 
Complete the following safety assessments: 
 
Vital signs 
 
ECG 
 
Assess for AEs 
 
Review concomitant medications 
Blood sample for the following will be obtained: 
 
Pharmacokinetic testing  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 83 of 114 
Study Visit 4 
Study Day 4 
Complete the following efficacy scales: 
 
PANSS  
 
CGI-S and CGI-I 
Complete the following safety assessments: 
 
Vital signs 
 
ECG 
 
Assess for AEs  
 
Review concomitant medications 
Complete the following safety scales: 
 
AIMS, BARS, SAS 
No patient should be discharged from the inpatient study unit before study day 2, and it is anticipated 
that most patients will remain on the inpatient unit through study day 8, and that thereafter patients 
will be discharged from the inpatient unit when the investigator has assessed the patient and 
determines that he or she is appropriately clinically stable and otherwise ready for safe discharge.   
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 84 of 114 
Study Visit 5 and Study Visit 6 
Treatment Week 1 (Study Day 8) and Treatment Week 2 (Study Day 15) 
Complete the following efficacy scales: 
 
PANSS 
 
CGI-S and CGI-I 
Complete the following safety assessments: 
 
Physical examination 
 
Weight and body mass index 
 
Vital signs 
 
ECG 
 
Assess for AEs 
 
Review concomitant medications 
Complete the following safety scales: 
 
AIMS, BARS, SAS 
 
C-SSRS 
Blood samples for the following will be obtained: 
 
Hematology panel 
 
Chemistry panel  
 
Prolactin (visit 5 [study day 8] only) 
 
Pharmacokinetic sample (a subgroup of 75 study participants only) 
Urine samples for the following will be obtained: 
 
Urinalysis 
 
Optional: urine drug screen 
It is anticipated that most patients will remain on the inpatient unit through study day 8, and that 
thereafter patients will be discharged from the inpatient unit when the investigator has assessed the 
patient and determines that he or she is appropriately clinically stable and otherwise ready for safe 
discharge.   
After study day 8, continuation of a patient on the inpatient unit from study day 9 through study day 
15, inclusive, is an allowable option, as deemed clinically indicated.   
If the investigator believes that a given patient should remain inpatient beyond study day 15, the 
investigator should contact the medical monitor to discuss the proposed inpatient duration extension.

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 85 of 114 
Study Visit 7 (a subgroup of 75 study participants only) 
Treatment Week 3 (Study Day 22)  
Complete the following safety assessments: 
 
Vital signs 
 
ECG 
 
Assess for AEs 
 
Review concomitant medications 
Blood samples for the following will be obtained: 
 
Pharmacokinetic sample  
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 86 of 114 
 
Study Visit 8 and Study Visit 11: Study Drug Administration Visits 
Treatment Week 4 and Treatment Week 8 (Study Day 29 and Study Day 57) 
Complete the following efficacy scales: 
 
PANSS 
 
CGI-S and CGI-I 
Complete the following health economics and outcome research evaluations: 
 
Socio-demographic information 
 
HRU data collection – patient (or informant) 
 
PSP 
 
SWN-20 
Complete the following safety assessments: 
 
Weight and body mass index 
 
Vital signs 
 
ECG 
 
Assess for AEs 
 
Review concomitant medications 
Complete the following safety scales: 
 
AIMS, BARS, SAS 
 
C-SSRS 
Blood samples for the following will be obtained: 
 
Hematology panel 
 
Chemistry panel 
 
Prolactin 
 
Pharmacokinetic sample  
Urine samples for the following will be obtained: 
 
Pregnancy test, urine 
 
Urinalysis 
 
Optional: urine drug screen 
Study drug (i.e., double-blind Risperidone ISM or placebo) will be administered by IM injection 
 
Study drug doses 3 and 4 at study visit 8 and study visit 11, respectively 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 87 of 114 
The following will be performed after administration of IM study drug: 
 
Complete the following safety assessments: 
o Vital signs  
o ECG  
o Injection site evaluation by investigator approximately one hour after injection 
o Injection site pain VAS by study patient approximately 1 hour after injection 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 88 of 114 
 
Study Visit 10 and Study Visit 13 
Treatment Week 6 and Treatment Week 10 (Study Day 43 and Study Day 71) 
Complete the following efficacy scales: 
 
CGI-I 
Complete the following safety scales: 
 
AIMS, BARS, SAS 
Complete the following safety assessments: 
 
Vital signs 
 
ECG 
 
Assess for AEs 
 
Review concomitant medications 
Urine samples for the following will be obtained: 
 
Optional: urine drug screen 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 89 of 114 
 
Study Visit 14: End-of-Treatment Visit 
Treatment Week 12 (Study Day 85) 
Complete the following efficacy scales: 
 
PANSS 
 
CGI-S and CGI-I 
Complete the following health economics and outcomes research evaluations: 
 
Socio-demographic information 
 
HRU data collection - center 
 
HRU data collection - patient (or informant) 
 
PSP 
 
SWN-20 
 Complete the following safety assessments: 
 
Physical examination 
 
Ophthalmological examination 
 
Weight and body mass index 
 
Vital signs 
 
ECG 
 
Assess for AEs 
 
Review concomitant medications 
Complete the following safety scales: 
 
AIMS, BARS, SAS 
 
C-SSRS 
Blood samples for the following will be obtained: 
 
Hematology panel 
 
Chemistry panel  
 
Prolactin 
 
Pharmacokinetic sample  
Urine samples for the following will be obtained: 
 
Pregnancy test, urine 
 
Urinalysis  
 
Optional: urine drug screen 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 90 of 114 
Study Visit 15: Safety Follow-up Contact (Via Telephone) 
Study Day 99  
Complete the following safety assessments: 
 
Assess for AEs 
 
Review concomitant medications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 91 of 114 
 
Optional Open-Label Extension Segment of the Study 
The allowable study visit time window for each of the extension baseline visit is within 3 days after 
visit 14 of the main part of the study occurs; however, it is generally preferable to conduct the 
extension baseline visit assessments and procedures later in the day (i.e., after completion of all 
assessments and procedures scheduled for the end-of-treatment visit for the double-blind treatment 
period of the main part of the study) on the same day on which the main study visit 14 occurs.  The 
allowable study visit time window for each of the subsequent extension visits is ± 3 days (i.e., 
extension visits 2 through 15, inclusive).   
The follow-up telephone visit is to occur 28 (± 3) days after the end-of-extension visit (i.e. the week 
52 time point, or earlier in the case of an early termination).   
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 92 of 114 
 
Extension Visit 0: Screening Visit (de novo patients only) 
Study Day -8 to -1 
Obtain informed consent from the patient. 
 
Informed consent form must be signed and dated by the patient before any study-related 
procedures are performed (see protocol Section 6.1.1) 
Obtain the following information (see protocol Section 6.1.2): 
 
Demographic data 
 
Medical and psychiatric history data 
Diagnostic interview will be performed, including the following: 
 
MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders studies 
will be completed (see protocol Section 6.1.4) 
Complete the following efficacy scales: 
 
PANSS (see protocol Section 6.2.1) 
 
CGI-S (see protocol Section 6.2.1) 
Complete the following safety assessments: 
 
Physical examination (see protocol Section 6.4.1) 
 
Height 
 
Weight and body mass index 
 
Vital signs (see protocol Section 6.4.3 for details) 
 
ECG (see protocol Section 6.4.4) 
 
Assess for AEs (see protocol Section 6.4.9) 
 
Review concomitant medications (see protocol Section 6.1.3) 
Complete the following safety scales: 
 
AIMS, BARS, SAS (see protocol Section 6.4.7) 
 
C-SSRS (see protocol Section 6.4.8) 
Blood samples for the following will be obtained: 
 
Hematology panel (see protocol Section 6.4.5.1) 
 
Chemistry panel (see protocol Section 6.4.5.2) 
 
Prolactin (see protocol Section 6.4.5.2) 
 
Serology panel (see protocol Section 6.4.5.4.1) 
 
Pregnancy test, serum (see protocol Section 6.4.5.4.2) 
Urine samples for the following will be obtained: 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 93 of 114 
 
Urinalysis (see protocol Section 6.4.5.3) 
 
Urine drug screen (see protocol Section 6.4.5.4.3) 
Inclusion/exclusion criteria will be reviewed for patient eligibility. 
Patients who, after completion of all scheduled assessments on the screening visit day, are considered 
provisionally eligible will be admitted directly to the study that day.   
If there is a valid reason for a given potential patient to extend the screening period duration beyond 
the designated 8 days, the investigator may contact the medical monitor to request an extension of up 
to 14 days; such an extension may be implemented only after medical monitor approval has been 
obtained. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 94 of 114 
Extension Visit 1: Baseline 
Extension Study Day 1 
Obtain informed consent from the prospective patient (rollover patients only) 
 
A separate informed consent form for participation in the optional extension segment of the study 
must be signed before any assessments or procedures for the extension segment are performed for 
a given patient, and before any dose of open-label Risperidone ISM is administered to that 
patient. 
Inclusion/exclusion criteria for extension segment will be reviewed for patient eligibility. 
Treatment arm assignment (de novo patients only) 
 
Patients on 4 mg of oral risperidone will be assigned to 75 mg (Risperidone ISM) every 28 days. 
Patients on more than 4 mg to a maximum of 6 mg of oral risperidone will be assigned to 100 mg 
(Risperidone ISM) every 28 days. 
ECG and vital signs assessments will be performed within one hour before study drug administration. 
A dose of IM study drug (Risperidone ISM 75 mg or Risperidone ISM 100 mg) will be administered 
by IM injection. Patients who had been receiving placebo in the double-blind segment of the study 
will be randomly assigned to receive either 75 or 100 mg of Risperidone ISM during the extension 
segment” 
The following will be performed after administration of IM study drug 
Complete the following safety assessments: 
 
Vital signs 
 
ECG 
 
Injection site evaluation by investigator approximately 1 hour after injection 
 
Injection site pain VAS by study patient approximately 1 hour after injection 
Collect socio-demographic information.  Complete the following health economics and outcome 
research evaluations (de novo patients only): 
 
HRU data collection – center  
 
HRU data collection – patient  
 
SWN-20 - patient reported  
 
PSP - clinician-administered  
For rollover patients, for assessments listed below results obtained as part of the main study 
visit 14 may be used as the extension baseline values and do not need to be repeated for the 
extension baseline visit time point if and only if the extension baseline visit occurs on the same 
day and date as the main study visit 14/week 12/end-of-treatment visit (rollover patients only).     
If the extension baseline visit instead occurs on a day 1 to 3 days after the main study visit 14/study 
week 12/study day 85/end-of-treatment visit, and for all de novo patients, all of the following 
assessments must be performed on the day of the extension baseline visit: 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 95 of 114 
Complete the following efficacy scales: 
 
PANSS  
 
CGI-S  
Complete the following safety assessments: 
 
Physical examination  
 
Weight and body mass index  
 
Vital signs  
 
ECG  
 
Assess for AEs  
 
Review concomitant medications  
Complete the following safety scales: 
 
AIMS, BARS, SAS  
 
C-SSRS  
Blood samples for the following will be obtained: 
 
Hematology panel  
 
Chemistry panel  
 
Prolactin 
 
Pregnancy test, serum - optional 
Urine samples for the following will be obtained: 
 
Pregnancy testing  
 
Urinalysis  
 
Urine drug screen – optional for rollover patients, mandatory for de novo patients 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 96 of 114 
Extension Visit 2, Extension Visit 6, and Extension Visit 11 
Extension Week 4, Extension Week 20, and Extension Week 40 
(Extension Day 29, Extension Day 141, and Extension Day 281)  
Complete the following efficacy scales: 
 
PANSS  
 
CGI-S  
 
CGI-I  
Complete the following health economics and outcome research evaluation: 
 
HRU data collection – patient  
Complete the following safety assessments: 
 
Physical examination 
 
Vital signs  
 
ECG  
 
Assess for AEs  
 
Review concomitant medications  
Complete the following safety scales: 
 
AIMS, BARS, SAS  
 
C-SSRS  
Blood samples for the following will be obtained: 
 
Pregnancy test, serum - optional 
Urine samples for the following will be obtained: 
 
Pregnancy testing  
 
Urine drug screen - optional 
A dose of IM study drug (Risperidone ISM 75 mg or Risperidone ISM 100 mg) will be administered 
by IM injection. 
The following will be performed after administration of IM study drug 
 
Complete the following safety assessments: 
o Vital signs  
o ECG  
o Injection site evaluation 
o 
Injection site pain VAS 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 97 of 114 
Extension Visit 3, Extension Visit 5, Extension Visit 8, Extension Visit 9, and Extension Visit 12 
Extension Week 8, Extension Week 16, Extension week 28, Extension Week 32, and Extension Week 
44 
(Extension Day 57, Extension Day 113, Extension Day 197, Extension Day 225, and Extension Day 
309)  
Complete the following efficacy scales: 
 
PANSS  
 
CGI-S  
 
CGI-I  
Complete the following health economics and outcome research evaluation: 
 
HRU data collection – patient  
Complete the following safety assessments: 
 
Physical examination  
 
Vital signs  
 
ECG (at Extension Visit 8 only) 
 
Assess for AEs  
 
Review concomitant medications  
 Complete the following safety scales: 
 
AIMS, BARS, SAS  
 
C-SSRS  
Blood samples for the following will be obtained: 
 
Pregnancy test, serum - optional 
Urine samples for the following will be obtained: 
 
Pregnancy testing 
 
Urine drug screen - optional 
A dose of IM study drug (Risperidone ISM 75 mg or Risperidone ISM 100 mg) will be administered 
by IM injection. 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 98 of 114 
The following will be performed after administration of IM study drug 
Complete the following safety assessments: 
 
Vital signs 
 
Injection site evaluation 
 
Injection site pain VAS 
 
ECG (at Extension Visit 8/Extension Day 197 only) 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 99 of 114 
Extension Visit 4 
Extension Week 12 (Extension Day 85) 
Complete the following efficacy scales: 
 
PANSS  
 
CGI-S  
 
CGI-I  
Collect socio-demographic information. 
Complete the following health economics and outcome research evaluations: 
 
HRU data collection – patient  
 
SWN-20 - patient reported  
 
PSP - clinician-administered  
Complete the following safety assessments: 
 
Physical examination  
 
Weight and body mass index  
 
Vital signs  
 
ECG  
 
Assess for AEs  
 
Review concomitant medications  
Complete the following safety scales: 
 
AIMS, BARS, SAS  
 
C-SSRS  
Blood samples for the following will be obtained: 
 
Hematology panel  
 
Chemistry panel  
 
Prolactin 
 
Pregnancy test, serum - optional 
Urine samples for the following will be obtained: 
 
Pregnancy testing  
 
Urinalysis  
 
Urine drug screen - optional 
A dose of IM study drug (Risperidone ISM 75 mg or Risperidone ISM 100 mg) will be administered 
by IM injection. 
The following will be performed after administration of IM study drug 
Complete the following safety assessments: 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 100 of 114 
 
Vital signs  
 
ECG  
 
Injection site evaluation 
 
Injection site pain VAS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 101 of 114 
Extension Visit 7 
Extension Week 24 (Extension Day 169) 
Complete the following efficacy scales: 
 
PANSS  
 
CGI-S  
 
CGI-I  
Collect socio-demographic information.Complete the following health economics and outcome 
research evaluations: 
 
HRU data collection – center  
 
HRU data collection – patient  
 
SWN-20 - patient reported  
 
PSP - clinician-administered  
Complete the following safety assessments: 
 
Physical examination  
 
Weight and body mass index  
 
Vital signs  
 
Assess for AEs  
 
Review concomitant medications  
Complete the following safety scales: 
 
AIMS, BARS, SAS  
 
C-SSRS  
Blood samples for the following will be obtained: 
 
Hematology panel  
 
Chemistry panel  
 
Prolactin 
 
Pregnancy test, serum - optional 
Urine samples for the following will be obtained: 
 
Pregnancy testing  
 
Urinalysis  
 
Urine drug screen - optional 
A dose of IM study drug (Risperidone ISM 75 mg or Risperidone ISM 100 mg) will be administered 
by IM injection. 
The following will be performed after administration of IM study drug 
Complete the following safety assessments: 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 102 of 114 
 
Vital signs  
 
Injection site evaluation 
 
Injection site pain VAS 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 103 of 114 
Extension Visit 10 
Extension Week 36 (Extension Day 253) 
Complete the following efficacy scales: 
 
PANSS  
 
CGI-S  
 
CGI-I  
Collect socio-demographic information. 
Complete the following health economics and outcome research evaluations: 
 
HRU data collection – patient  
Complete the following safety assessments: 
 
Physical examination  
 
Weight and body mass index  
 
Vital signs  
 
Assess for AEs  
 
Review concomitant medications  
 Complete the following safety scales: 
 
AIMS, BARS, SAS  
 
C-SSRS  
Blood samples for the following will be obtained: 
 
Hematology panel  
 
Chemistry panel  
 
Prolactin 
 
Pregnancy test, serum - optional 
Urine samples for the following will be obtained: 
 
Pregnancy testing  
 
Urinalysis  
 
Urine drug screen - optional 
A dose of IM study drug (Risperidone ISM 75 mg or Risperidone ISM 100 mg) will be administered 
by IM injection. 
The following will be performed after administration of IM study drug 
Complete the following safety assessments: 
 
Vital signs  
 
Injection site evaluation 
 
Injection site pain VAS 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 104 of 114 
Extension Visit 13 
Extension Week 48 (Extension Day 337) 
Complete the following efficacy scales: 
 
PANSS  
 
CGI-S  
 
CGI-I  
Complete the following health economics and outcome research evaluation: 
 
Collect socio-demographic information. 
 
HRU data collection – center  
 
HRU data collection – patient  
Complete the following safety assessments: 
 
Physical examination  
 
Vital signs  
 
Assess for AEs  
 
Review concomitant medications  
 Complete the following safety scales: 
 
AIMS, BARS, SAS  
 
C-SSRS  
Blood samples for the following will be obtained: 
 
Pregnancy test, serum - optional 
Urine samples for the following will be obtained: 
 
Pregnancy testing  
 
Urine drug screen - optional 
A dose of IM study drug (Risperidone ISM 75 mg or Risperidone ISM 100 mg) will be administered 
by IM injection. 
The following will be performed after administration of IM study drug 
Complete the following safety assessments: 
 
Vital signs  
 
Injection site evaluation 
 
Injection site pain VAS 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 105 of 114 
Extension Visit 14 
Extension Week 52 (Extension Day 365) 
Complete the following efficacy scales: 
 
PANSS  
 
CGI-S  
 
CGI-I  
Complete the following health economics and outcome scales: 
 
SWN-20 - patient reported  
 
PSP - clinician-administered  
Complete the following safety assessments: 
 
Physical examination  
 
Weight and body mass index  
 
Vital signs  
 
ECG  
 
Assess for AEs  
 
Review concomitant medications  
 Complete the following safety scales: 
 
AIMS, BARS, SAS  
 
C-SSRS  
Blood samples for the following will be obtained: 
 
Hematology panel  
 
Chemistry panel  
 
Prolactin 
 
Pregnancy test, serum - optional 
Urine samples for the following will be obtained: 
 
Pregnancy testing  
 
Urinalysis  
 
Urine drug screen - optional 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 106 of 114 
Extension Visit 15: Extension Follow-up Visit (Conducted by Telephone) 
Extension Week 56 (Extension Day 393) 
Complete the following safety assessments: 
 
Assess for AEs  
 
Review concomitant medications  

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 107 of 114 
 
Appendix B: Prohibited Medications 
 
Cytochrome P450 3A4 Inducers and Inhibitors and 2D6 Inhibitors 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm2923
62.pdf 
Also see the following SAMPLE TABLE: 
Prohibited Medications Affecting Cytochrome P450 3A4 (Inducers and Inhibitors) or 2D6 
(Inhibitors) 
3A4 Inducers 
3A4 Inhibitors 
2D6 Inhibitors 
 Carbamazepine 
 Barbiturates  
(e.g., phenobarbital) 
 Phenytoin 
 Rifampin 
 Hyperforin  
(e.g., St. John’s Wort) 
 Modafinil 
 Cyproterone (e.g., antiandrogen, 
progestin, Diane-35) 
 Non-nucleotide reverse 
transcriptase inhibitors (e.g., 
efavirenz, nevirapine, etravirine) 
 Ketoconazole 
 Itraconazole 
 Fluconazole 
 Clarithromycin 
 Erythromycin 
 Telithromycin 
 Nefazodone 
 Fluvoxamine 
 Protease inhibitors  
(ritonavir, indinavir, nelfinavir) 
 Verapamil 
 Grapefruit juice 
 Bergamottin  
 Quercetin 
 Quinidine 
 Selective serotonin reuptake 
inhibitors  
(e.g., fluoxetine, paroxetine, 
citalopram) 
 Duloxetine Bupropion MDMA  
(3,4-methylenedioxymeth-
amphetamine; ecstasy) 
 Terbinafine 
 Goldenseal  
(Hydrastis canadensis) 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 108 of 114 
 
Appendix C : Rating Scale and Interview Descriptions 
 
MINI  
The MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders 
Studies is a short, structured diagnostic interview that was developed for DSM-V and ICD-10 
psychiatric disorders that has been validated against the Structured Clinical Interview for DSM 
diagnoses (SCID).  It will be used to assess for excluded psychiatric conditions outlined in the study 
entry criteria. 
PANSS 
The Positive and Negative Syndrome Scale (PANSS), is a 30-item clinician-rated instrument for 
assessing the symptoms of schizophrenia and will be used as the primary efficacy endpoint measure. 
The positive scale consists of 7 items which measure delusions, conceptual disorganization, 
hallucinations, grandiosity, and suspiciousness/persecution.  The negative subscale consists of items 
which measure blunted affect, emotional withdrawal, poor rapport, passive/apathetic social 
withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and 
stereotyped thinking.  The general psychopathology scale consists of 16 items which measure somatic 
concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, 
uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and 
insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. The 
change from baseline in the PANSS total score at 12 weeks is the primary efficacy endpoint. 
CGI-S 
The Clinical Global Impression Severity of Illness (CGI-S) is a 7-point clinician-rated scale for 
assessing the global severity of the illness. The change in CGI-S score from baseline to 12 weeks will 
be used as a secondary efficacy endpoint. Also the change in PANSS positive subscale response 
change from baseline to 12 weeks will be included as a secondary endpoint. The PANSS positive 
subscale assesses features such as delusions and hallucinations. 
CGI-I 
The CGI-I consists of a single 7-point rating score total improvement, regardless of whether or not the 
change it is due entirely to drug treatment. Raters select one response based on the following question, 
“Compared to your patient’s condition at the beginning of treatment, how much has your patient 
changed?” Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No 
change; 5, Minimally worse; 6, Much worse; or 7, Very much worse.  For the CGI-I Scale, the 
patient’s condition at the Day 1 (baseline) visit will be the criterion for judging improvement at 
subsequent visits. 
AIMS 
The Abnormal Involuntary Movement Scale (AIMS) will be used to document occurrences of 
dyskinesias in patients, specifically tardive dyskinesia. The scale incorporates observation and brief 
examination of the patient and consists of 12 items. Items 1-4 assess the severity of orofacial 
movements.  Items 5-7 assess extremity and truncal dyskinesias. Items 8-10 rate global severity of 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 109 of 114 
movements as indicated by the examiner’s judgment of the severity of abnormal movements (item 8), 
the examiner’s judgment of the patient’s incapacitation due to the movements (item 9), and the 
patient’s awareness of the movements and associated distress (item 10).  Items 11 12 concern the 
patient’s dental status 
BARS 
The Barnes Akathisia Rating Scale (BARS) will be administered to assess akathisia. The scale is 
designed to rate akathisia through observation of restless behavior and questioning of the patient to 
determine the degree of subjective restlessness and distress associated with restlessness. A global 
clinical rating completes the assessment. The first 3 items of the BARS (Objective, Subjective, and 
Distress related to restlessness) are rated on a 4 point scale (0-3). The fourth item, the global clinical 
assessment of akathisia, uses a 6 point scale (0-5). Only the global clinical assessment measure from 
this scale will be analyzed.  Higher scores indicate increased severity. All ratings are anchored. The 
BARS takes approximately 10 minutes to administer 
SAS 
The Simpson Angus Scale (SARS) will be administered to assess parkinsonian symptoms and related 
extrapyramidal side effects through observation of the patient. The scale contains 10 items, including 
gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, glabellar tap, 
tremor, and salivation.  The head rotation item (from the modified SAS) will be substituted for the 
original #7 item, head dropping. Seven of the 10 items measure parkinsonian rigidity. Each item is 
rated on an anchored 5-point scale, with 0 = the absence of the condition or normal and 4 = the most 
extreme form of the condition. A total score is obtained by adding all of the scores of the individual 
items. The SAS takes approximately 10 minutes to administer. 
C-SSRS 
The Columbia Suicide Severity Rating Scale (C-SSRS) is an interview-based rating scale to 
systematically assess suicidal ideation and suicidal behavior. Versions are available for screening 
/baseline and follow-up visits. 
PSP 
This operationalized, 100-point scale consists of 4 main areas: socially useful activities, personal and 
social relationships, self-care, and disturbing and aggressive behavior. Each of the 4 domains is rated 
in 6 degrees of severity (absent, mild, manifest, marked, severe, very severe).  A difference of 8 points 
can be classified as a clinically highly relevant difference.  
SWN-20 
The Subjective Well-being Under Neuroleptic Treatment Scale (SWN) is used to assess well-being in 
patients with schizophrenia undergoing antipsychotic treatment. The 20-item version of the SWN 
scale consists of 20 items referring to the last 7 days.  The total score ranges from a minimum of 20 
(poor) to a maximum of 120 (excellent). 10 items are formulated positively and 10 items are 
formulated negatively, describing each complaint in a positive and negative phrase. The SWN-20 
measures subjective experience in 5 subscales: emotional regulation, self-control, mental functioning, 
social integration and physical functioning.   
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 110 of 114 
 
Appendix D: Visual Analog Scale (VAS) 
 
 VISUAL ANALOG SCALE  
 
 
On the scale of zero to ten, where zero means no pain and ten equals the worst possible pain, 
what is the level of the pain right now at the injection site? Please circle the number that 
corresponds to it.  
 
 
 
 
10
Worst 
possible 
pain
9
No pain
6
7
8
0
1
2
3
4
5
 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 111 of 114 
 
Appendix E: Risperidone ISM Investigator Brochure 
 
Due to the size of the document, the most updated version of the Investigator’s Brochure for 
Risperidone ISM® is available as a separate document.  
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 112 of 114 
 
Appendix F: Contact Information 
 
ROVI Pharmacovigilance Department 
Phone: +34 917617561/+34 911863678 
Fax: +34 912444421 
Email: farmacovigilancia@rovi.es 
Laboratorios Farmacéuticos ROVI S.A. (SAEs) 
ROVI Pharmacovigilance Department 
Fax number: +34 912444421 
E-mail: farmacovigilancia@rovi.es 
Phone number: +34 917617561/+34 911863678 
 
INC Research – (SUSARs only) 
Milan Matković MD, Senior Project Manager 
Fax number: +381 11 240 25 70 
E-mail: milan.matkovic@syneoshealth.com 
Phone number: +381 11 715 8058 
Enrique Comesaña MD, MBA 
Executive Medical Director - Medical Affairs 
E-mail: enrique.comesana@syneoshealth.com 
Moble Phone number: +1 (512) 367 0592 
 
 
 
 
 
 
 
 

Laboratorios Farmacéuticos ROVI, S.A. 
 
Protocol ROV-RISP-2016-01 
PRISMA-3 
VERSION 7.0 
22 Mar 2018 
CONFIDENTIAL 
Page 114 of 114 
 
Appendix H : Investigator Agreement  
 
Laboratorios Farmacéuticos ROVI, S.A. 
Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and 
Safety of Intramuscular Injections of Risperidone ISM® in Patients with Acute Exacerbation of 
Schizophrenia (PRISMA-3) 
Protocol No. ROV-RISP-2016-01, Version No. 7.0  
Date: 22 March 2018 
Amendment No.: 4.0 
PRINCIPAL INVESTIGATOR COMMITMENT: 
I will provide copies of the protocol, any subsequent protocol amendments and access to all information 
provided by the Sponsor to the study personnel under my supervision.  I will discuss this material with 
them to ensure that they are fully informed about the investigational drug and the study protocol. 
I agree to conduct this clinical trial according to the attached protocol, except when mutually agreed to 
in writing.  I also agree to conduct this study in compliance with all federal, state and local regulations, 
Good Clinical Practices (GCP), as well as with the requirements of the appropriate Institutional Review 
Board(s) (IRB)/Independent Ethics Committee(s) (IEC) and any other institutional requirements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Printed Name of Principal Investigator 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Principal Investigator 
 
 
 
 
 
 
 
 
Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institution